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ABSTRACT 
It has been well established that both insulin and muscle contraction 
increase total blood flow to skeletal muscle. A number of studies have also 
demonstrated that insulin and muscle contraction increase muscle 
microvascular perfusion in vivo in both humans and animals. The 
haemodynamic responses to insulin have been thought to promote delivery of 
glucose and hormones to the myocyte to enhance glucose disposal. In models 
of insulin resistance, insulin mediated increases in blood flow (total and 
microvascular) and glucose uptake are impaired. In contrast contraction 
stimulated increases in blood flow and glucose uptake are generally not 
impaired in insulin resistant rodents and humans. Although increases in total 
blood flow, microvascular perfusion and glucose uptake in skeletal muscle 
can be stimulated by either insulin or muscle contraction these processes use 
different signalling pathways. The main focus of this thesis was to explore 
mechanisms involved in insulin- and contraction-stimulated haemodynamics 
in skeletal muscle and their impact on insulin-mediated glucose uptake. 
The in vivo techniques employed in this thesis include 
hyperinsulinemic euglycaemic clamps performed in anesthetised rats, arterial 
blood flow measurements by Transonic® flow probes, microvascular 
perfusion measurements by either metabolism of exogenously infused 1- 
methylxanthine (1-MX) or contrast enhanced ultrasound (CEU). Test agents 
were administered either systemically or locally into one hindlimb via the 
epigastric artery. Isolated resistance arteries were used in one study to 
compliment the in vivo studies. 
The hypothesis that a PI3K dependant signalling pathway, leading to 
activation of eNOS and the production of NO, is involved in the 
hemodynamic actions of insulin in muscle was examined. Wortmannin, a 
PI3K inhibitor, was infused systemically during an insulin clamp in vivo. 
Wortmannin administration resulted in inhibition of the haemodynamic 
effects of insulin including total flow and microvascular perfusion as well as 
ii 
glucose uptake. The relationship between insulin mediated NOS activation 
and microvascular perfusion was also studied. A NOS inhibitor, L-NAME, 
was infused locally in one leg and attenuated insulin action in skeletal muscle 
by inhibiting microvascular perfusion and blunting glucose uptake. 
AMPK is a potential mediator of metabolic changes in muscle during 
contraction and can be artificially activated by the compound AICAR. Acute 
activation of AMPK in vivo by low dose AICAR resulted in increased 
microvascular blood volume without effects on blood pressure, femoral blood 
flow or hindleg glucose uptake. In addition, in isolated resistance arteries, 
AICAR induced vasodilatation, which was abolished by the NO synthase 
inhibitor L-NA or the AMPK inhibitor compound C. Activation of AMPK by 
AICAR also sensitised smooth muscle cells to sodium nitroprusside (SNP) 
mediated vasodilatation and induced vasodilatation of resistance arteries. 
AMPK activation by AICAR resulted in marked enhancement of insulin-
mediated microvascular perfusion and glucose uptake. 
Collectively the findings in this thesis highlight the important role of 
microvascular perfusion for facilitating skeletal muscle glucose metabolism 
and explore some of the mechanisms which are involved. Insulin mediated 
microvascular perfusion occurs via a PI3K dependant pathway and is strongly 
associated with NOS activation. Activation of AMPK increases microvascular 
perfusion which is also associated with NOS activation. The combination of 
AMPK activation and insulin resulted in marked enhancement of insulin-
mediated microvascular perfusion and glucose uptake. Improvement of 
microvascular perfusion through targeting AMPK activation may provide a 
potential therapeutic avenue for enhancing glucose metabolism. 
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CHAPTER 1- Introduction. 
The ability of insulin to maintain glucose homeostasis in healthy 
individuals is well known, following a meal insulin acts to stimulate glucose 
disposal and inhibit hepatic glucose production [1]. More recently it has been 
demonstrated that insulin increases microvascular flow by increasing the 
number of perfused capillaries in skeletal muscle vascular beds [2]. The 
physiological effect of insulin to increase blood flow to peripheral tissues may 
promote cellular glucose uptake by increasing hormone and nutrient access to 
muscle. In insulin resistance, the precursor to type 2 diabetes, the increases in 
capillary blood flow and glucose uptake become unresponsive to stimulation 
via insulin [2]. Physical activity which has been shown to be protective 
against the development of insulin resistance also stimulates capillary 
recruitment. A greater understanding of the vascular mechanisms used by 
insulin and muscle contraction will provide targets for future drug therapies 
for type 2 diabetes. 
1.1 	Insulin 
Insulin is a peptide hormone, produced in the pancreas by the 13 cells of 
the islets of Langerhans. Insulin acts as a regulator during periods of glucose 
surplus, by promoting peripheral glucose uptake and hepatic glucose storage 
following a meal. Following ingestion of a carbohydrate containing meal, a 
rise in plasma glucose concentration initiates insulin release into the 
bloodstream which stimulates glucose transport in insulin responsive tissues 
(skeletal muscle and adipose tissue) by causing GLUT4 translocation to the 
plasma membrane. Skeletal muscle accounts for up to 75% of insulin-
dependant glucose disposal, whereas adipose tissue accounts for a small 
portion [3]. In the liver, insulin acts to suppress glucose production by 
inhibiting gluconeogenesis and glycogenolysis and stimulates glycogen 
storage. The additional longer term cellular effects of insulin include growth 
promotion, protein synthesis and gene regulation. 
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1.2 Effects of Insulin on Total Flow in Skeletal 
Muscle 
In addition to insulin's direct metabolic effects on glucose 
homeostasis, interest in insulin's vasodilatory activity in skeletal muscle has 
increased in recent years. It has been proposed that the vasodilatory actions of 
insulin to increase blood flow to skeletal muscle improve delivery of glucose 
and nutrients as well as its own access [2]. In 1990, Baron and colleagues first 
reported the concept that insulin may function to increase blood flow and 
improve substrate delivery to skeletal muscle. Baron's group demonstrated 
that high physiological concentrations of insulin, in lean human subjects, 
increased total flow to skeletal muscle [4] during hyperinsulinemic 
euglycaemic clamps. In support of these findings, increased total 
blood flow due to insulin was also observed following intravenous glucose, 
oral glucose and a carbohydrate meal [5]. In addition Baron et al. 
demonstrated that insulin sensitivity was decreased in obese humans, 
measured by both lower glucose extraction and lower total blood flow to 
insulin sensitive tissues, compared to lean subjects [4]. Subsequent 
experiments have confirmed that insulin mediated increases in total flow and 
decreases in vascular resistance are impaired in obese and type 2 diabetic 
subjects compared with lean controls [6-9]. 
Insulin-mediated increases in total blood flow have been 
demonstrated by others in humans [6, 7] as well as in animals [8] however 
there was considerable variation in the extent of this vascular response to 
insulin. In contrast, other studies observed no changes in flow with insulin [9-
13]. Studies by Sjostrand etal. [14] on type 2 diabetic subjects suggested that 
decreased insulin-mediated glucose uptake is caused by insulin resistance at 
the cellular level rather than impaired access of insulin and glucose to the 
myocyte. The physiological relevance of decreased total blood flow was 
challenged by investigators who have found that blood flow had a minor 
influence on insulin stimulated glucose uptake [15], skeletal muscle interstitial 
glucose [16] and insulin levels [17]. Some researchers have shown the direct 
effect of local hyperinsulinemia in humans had no effect [13, 18, 19] or only 
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slight vasodilation [20, 21] in large vessels. Cardillo et a/. [22] demonstrated 
that in humans systemic but not local hyperinsulinemia induced large vessel 
vasodilation in the forearm. The total flow effects observed during systemic 
infusion suggests that centrally mediated sympathetic changes may play a 
role. In contrast, Hermann et al. [23] demonstrated that four hours of local 
hyperinsulinemia caused a sustained increase in vasodilation in resistance 
vessels of healthy humans. The type of administration may have been 
important as vasodilation was greater with systemic rather than local infusion. 
Methodological differences including insulin dose and technique of flow 
measurement as well as individual heterogeneity in vascular response to 
insulin may account for some of the differences noted. 
The effect of insulin on total flow was most pronounced when 
circulating concentrations of insulin during systemic hyperinsulinemia are 
supra-physiological or when insulin was administered over extended time 
periods [24]. Thus, some have questioned the physiological relevance of these 
observations since high levels of insulin are not normally sustained following 
a meal. 
1.3 Insulin Stimulated Microvascular Perfusion in 
Skeletal Muscle 
Earlier studies on the vascular actions of insulin had focused on the 
effect of insulin to increase total blood flow to skeletal muscle however more 
recent studies have highlighted the importance of insulin upon the 
microcirculation to increase capillary surface area for enhanced delivery of 
insulin and glucose to the myocytes. It was demonstrated that insulin has 
direct vasodilatory action on peripheral vessels, mainly in skeletal muscle 
vascular beds to increase microvascular flow to ensure adequate supply of 
glucose and nutrients [2, 24-26]. A study from Vincent etal. [27] indicated 
that insulin mediated vasodilation occurred rapidly in muscle 
microvasculature and was then followed by relaxation of larger vessels 
leading to increased total flow in muscle. 
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1.3.1 Anatomy of Skeletal Muscle Microvasculature 
The microvasculature is widely taken to include vessels less than 
150[tm in diameter and includes arterioles, capillaries and venules. The 
anatomical arrangement of muscle microvasculature has been mapped using 
muscles such as the cremaster, hamster retractor, tenuissimus or the 
spinotrapezius since the anatomical properties of these muscles allows 
relatively easy access for visualization. Many similarities exist between the 
microvasculature of these muscle types however consideration must be given 
to the specialized nature of these muscles compared with load bearing skeletal 
muscle. Sweeney et al. [28] classified the arrangement of arterioles in the 
hamster cremaster as follows; blood flows to a skeletal muscle from a feed 
artery, which is external to the muscle. Within the muscle the first branch of 
the arteries are classified as a first order arteriole. Subsequent branches are 
numbered in increasing order, with transverse arterioles being third order and 
fifth-order arterioles lead to the capillaries [29]. Flow to muscles is controlled 
by the first to third-order arterioles and flow to individual capillary networks 
is controlled by third to fifth-order arterioles [30]. A study by Borgstron [31] 
schematically illustrates (Figure 1, pg. 6) the vasculature in the rabbit 
tenuissimus muscle, the transverse arteriole supplies capillaries, muscle tissue 
and adjacent connective tissue. During the basal state, muscle is minimally 
perfused [29, 32, 33] and undergoes vasomotion [34], a rhythmic fluctuation 
of microvascular blood flow, which is thought to be a protective mechanism 
against hypoxia. 
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Figure 1: Blood flow in the rabbit tenuissimus muscle (adapted from 
Borgstrom et al., 1988 [31] to show connective tissue adipocytes) 
The principal function of the microcirculation is to optimize nutrient 
and oxygen supply to tissues in response to various physical stimuli. At the 
microvascular level insulin mediated vasodilation begins when insulin acts at 
the terminal arterioles thus increasing the number of perfused capillaries. As 
noted by Vincent et al. this action occurs within a few minutes [27]. This is 
followed by relaxation of larger resistance vessels which increase the total 
blood flow [35]. Dilation of terminal arterioles can result in maximal 
recruitment of downstream capillaries without initially altering the total blood 
flow [36]. This may occur due to the redistribution of blood flow between two 
vascular routes within the muscle, termed nutritive and non-nutritive 
(described further in section 1.3.2). 
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1.3.1.1 	The Endothelial Barrier 
The endothelium is a single layer of cells that lines the lumen of all 
blood vessels including; conduit vessels, resistance vessels, pre-capillary 
arterioles and capillaries. The endothelial layer is in direct contact with the 
circulating blood and vessel wall and plays an important role in maintaining 
vascular function. The vessel wall endothelium adjusts vascular tone and 
permeability by secreting vasoactive substances such as NO, endothelin, 
prostacyclin and endothelium-derived hyperpolarising factors. It has been 
demonstrated that endothelial cells have insulin receptors and that insulin 
stimulates phosphorylation and activation of Akt which can phosphorylate and 
activate eNOS to induce NO production and vasorelaxation [37, 38]. 
Endothelial dysfunction has been linked to the initiation and 
development of atherosclerotic vascular diseases [39, 40] and is associated 
with an imbalance between vasodilator and vasoconstrictor activity due to 
reduced NO activity. Insulin is reported to increase blood flow and 
microvascular perfusion via production of NO [41] (see section 1.6) thus 
endothelial dysfunction may contribute to impaired vascular actions of insulin 
in insulin resistance. 
1.3.2 Evidence for Macrovascular and Microvascular flow 
Routes in Muscle 
Evidence for different flow routes in muscle came from experiments 
using the pump-perfused rat hindlimb. These early studies indicated the 
existence of separate total blood flow and microvascular blood flow routes in 
skeletal muscle. These two flow routes have been termed nutritive and non-
nutritive, a concept which has been extensively researched in our laboratory 
(reviewed in [2]). The nutritive route is thus named as it is thought to consist 
of long tortuous capillaries which are in direct contact with muscle cells. The 
non-nutritive flow route is thought to consist of shorter and possibly larger 
capillaries of lower resistance which supply the muscle connective tissue 
(septa and tendon) [42] as well as associated adipocytes [43] (Figure 1). It has 
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been proposed that the non-nutritive route can act as a flow reserve which can 
rapidly redistribute flow to the nutritive route during periods of high 
metabolic demand such as exercise [44] and insulin. It is thought that the 
balance between these two flow routes is controlled by vasomodulators and 
neural input [45]. 
The agents which control metabolism in constant-flow pump perfused 
skeletal muscle by vasoconstriction have been classified as either type A or 
type B vasoconstrictors [46]. Type A vasoconstrictors include low-dose 
norepinephrine (NE), angiotensin II, vasopressin and low frequency 
sympathetic nerve stimulation (SNS). Type A vasoconstrictors are thought to 
constrict non-nutritive feed arterioles and thus re-direct flow to the nutritive 
route increasing oxygen consumption. Type B vasoconstrictors including 
serotonin, high-dose NE and high frequency SNS activation result in reduced 
oxygen consumption and metabolism by decreasing perfusion to the nutritive 
route [46]. During type B vasoconstriction the sites for constriction are likely 
to be large vessels which can sustain constriction by anaerobic metabolism. 
The changes in flow distribution from type A and B vasoconstrictors have 
been suggested from the patterns of red blood cell washout and visualisation 
using vascular casts [47]. 
The pump perfused hindlimb studies enabled important initial 
observations for the presence of two flow routes in skeletal muscle. These 
early findings may explain previous observations of the ability of many 
systemic vasodilators to markedly increase limb blood flow without affecting 
insulin-mediated glucose uptake [15, 48]. Studies on microvascular flow 
routes in intact animals were lacking and so what followed was the 
development of specific techniques for measuring changes in microvascular 
perfusion in vivo. 
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1.3.3 Techniques for Measuring Microvascular Blood Flow 
Direct evidence for insulin-mediated microvascular flow in vivo first 
appeared in 1997 when Rattigan, Clark and colleagues developed the 1- 
methylxanthine (1-MX) method in rats [49]. This technique is based on the 
metabolism of infused 1-MX which is an exogenous substrate for xanthine 
oxidase (XO). Xanthine oxidase exists in many tissues, however 
immunohistochemical evidence had shown that in rodent muscle X0 is 
concentrated in the capillary endothelium with much less in the endothelium 
of large arteries, vascular smooth muscle and skeletal muscle [50, 51]. The 
substrate 1-MX was selected because it does not alter haemodynamics, is 
converted to a single product 1-methylurate (1-MU), is not further 
metabolized, the metabolism of 1-MX is solely due to X0 and both 1-MX and 
1-MU are easily detectible using HPLC [52]. The extent of the metabolism of 
infused 1-MX reflects the availability of capillary surface area and provides a 
measurement of microvascular perfusion. 
The newly developed 1-MX method was initially validated in the 
pump-perfused rat hindlimb by altering the flow distribution using specific 
vasoconstrictors to enable predominantly nutritive or non-nutritive flow 
patterns [53, 54]. It was demonstrated that the change in 1-MX metabolism 
correlated positively with various nutritive or non nutritive states. For 
example in the constant flow perfused hindlimb, it was demonstrated using a 
vasoconstrictor serotonin which reduces nutritive flow, that there was reduced 
conversion of 1-MX to 1-MU [52]. Additionally, under conditions which were 
positive for microvascular perfusion such as muscle contraction, there was an 
increased conversion of 1-MX to 1-MU in the constant flow pump per -fused 
hindlimb [54]. 
After initial testing in the perfused hindlimb, the 1-MX method was 
subsequently applied to the anaesthetized rat in vivo. It was demonstrated that 
physiological doses (3mU.min-l .kg-I ) and high doses (10mU.min. -I kg-1 ) of 
insulin increased 1-MX metabolism by approximately 80% [49] and it was 
observed that this increase was associated with increases in muscle glucose 
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uptake. Epinephrine administration in vivo increased total blood flow to the 
same extent as high dose insulin but did not alter microvascular perfusion 
[49]. This observation indicated that microvascular perfusion does not depend 
on total flow in vivo [55]. 
A second more recent method employed to measure microvascular 
perfusion is contrast enhanced ultrasound (CEU) imaging. An advantage of 
the CEU imaging technique over 1-MX is that is can be used in humans as 
well as animals, is less invasive and allows continuous real-time assessment 
of microvascular perfusion under various stimuli [56-58]. The technique is 
based on that described by Wei et al. [59] for the myocardium. The method 
involves systemic infusion of gas filled albumin or phospholipid microbubbles 
as a contrast agent which is detected by the ultrasound probe positioned over 
the area of interest (methodological details in section 2.1.8.2). The acoustic 
signal generated from the microbubbles when exposed to ultrasound produces 
tissue opacification which is proportional to the number of microbubbles 
within the imaged area. In animals, physiological doses of insulin lead to 
increases in microvascular volume [58, 60]. Comparisons of measures of 
microvascular perfusion using CEU and 1-MX methods in animals treated 
with insulin and contraction have demonstrated excellent correlation [60-62]. 
1.4 Physiological Relevance of Blood Flow on 
Glucose Uptake 
As previously discussed, initial studies in the pump perfused rat 
hindlimb gave recognition to the presence of a non-nutritive route in muscle 
which may explain the ability of many systemic vasodilators to markedly 
increase limb blood flow without affecting insulin-mediated glucose uptake or 
ameliorating insulin resistance. The development of 1-MX and CEU 
techniques allowed further insights into the relationship between total blood 
flow, microvascular perfusion and glucose uptake. It was demonstrated by 
Vincent et al. [27] using the CEU technique, that insulin-stimulated increases 
in microvascular flow occur within minutes, prior to increases in total flow. In 
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that same study a tight and positive correlation between microvascular 
perfusion and glucose uptake in the same muscle bed indicated that 
microvascular perfusion contributes to insulin-mediated increases in glucose 
uptake in vivo. Zhang et al., using CEU and 1-MX techniques also 
demonstrated that microvascular perfusion precedes increases in total blood 
flow [63]. In that study; microvascular perfusion was fully stimulated by 
physiological doses of insulin below the threshold for stimulation of glucose 
uptake or total blood flow. From these studies it became apparent that 
precapillary arterioles that regulate microvascular perfusion are more sensitive 
to insulin than resistance arterioles that regulate total blood flow. Together 
these observations may provide an explanation for reports which questioned 
the relevance of total blood flow where insulin mediated glucose uptake had 
been observed in the absence of increases in total blood flow [64, 65]. 
1.5 Mechanisms for the Vascular Actions of 
Insulin 
There are a number of possible mechanisms by which insulin can 
cause vasodilation. In order to better understand these mechanisms it is useful 
to examine the action of insulin on cultured cells and isolated vessels. The 
results of in vitro studies must be viewed with caution since the conditions, 
which often use supraphysiological concentrations of insulin, do not 
necessarily reflect conditions in vivo. Insulin at high concentrations may 
interact with the insulin-like growth factor (IGF-1) receptor rather than the 
insulin receptor [66]. 
Insulin may mediate vasodilation directly by acting on the vascular 
smooth muscle cell (VSMC) or indirectly via metabolic stimulation within the 
myocytes. Studies by Chen and Messina et al. [67] and Schroeder et al. [68] 
suggest that insulin acts directly on blood vessels to induce dilation. 
Schroeder et al. [68] examined 1 St order arterioles isolated from red and white 
gastrocnemius muscle. In that study it was demonstrated that physiological 
insulin (60 and 600pM) increased vessel diameter. Removal of the 
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endothelium or incubation with the nitric oxide synthase inhibitor N G-nitro-L-
arginine (L-NNA) abolished these effects. 
Metabolic activation, similar to exercise, is where blood flow to 
muscle increases to facilitate supply of oxygen and nutrients to the working 
muscle via release of metabolic vasodilators such as adenosine, potassium, 
NO or lactate [69]. It has been suggested that lactate may induce skeletal 
muscle arteriolar dilation which is dependant on VSMC cGMP [70]. McKay 
and Hester [71] demonstrated that insulin mediated dilation of second and 
fourth-order arterioles was blocked by an adenosine receptor agonist, 
suggesting a role for adenosine in response to insulin. 
While insulin may act directly on endothelial cells, it has been 
demonstrated that human VSMC express NOS [38] which is activated by 
insulin to increase cGMP. Increases in cGMP in human VSMCs following 
incubation with insulin (240-960pM) have been reported by Trovati et al. [72, 
73]. Treatment with the NOS inhibitor N°-monomethyl- L-arginine (L-
NMMA) or the guanylate cyclase inhibitor methylene blue blocked this effect, 
indicating that insulin stimulates NOS in VSMCs. 
In addition, insulin is known to activate the Na±/K+ ATPase in VSMC 
resulting in hyperpolarisation of the cell, blocking of voltage-dependant 
calcium channels and relaxation [74]. Insulin also decreases intracellular 
calcium by stimulating calcium efflux and inhibiting calcium influx by 
receptor-operated calcium channels leading to VSMC relaxation. 
1.6 Role of Nitric Oxide during Insulin 
Nitric oxide (NO) is a key signalling molecule that causes vascular 
relaxation. In endothelial cells, endothelial NO synthase (eNOS) catalyzes the 
conversion of the substrate L-arginine to the products NO and L-citrulline [75, 
76]. The reaction requires co-factors such as Ca2+/calmodulin, flavin adenine, 
dinucleotide, flavin mononucleotide and tetrahydrobiopterin (BH4) [77, 78]. 
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The nNOS isoform, reported to be present in vascular smooth muscle [79], 
has an uncertain role in vascular function. 
Vascular NO has a variety of functions and one of those is to dilate 
blood vessels and maintain vascular homeostasis. Vascular smooth muscle 
relaxation occurs when NO or NO donors diffuse to neighbouring VSMC and 
activate soluble guanylate cyclase which catalyses the production of 
guanosine 3':5'-cyclic monophosphate (cGMP) [80, 81]. Cyclic GMP is 
known to be involved in vasodilation by reducing intracellular Ca 2+ in VSMC 
[82]. A number of compounds infused in vivo have demonstrated local 
vasodilation via endothelial NO, including acetylcholine, methacholine and 
bradykinin [83]. 
There is significant evidence available from in vitro studies which 
demonstrate that insulin's vasodilatory action in muscle is NO-dependant. 
Studies using cultured human umbilical vein endothelial cells (HUVEC) 
demonstrate that insulin stimulates the production of NO [37]. This process 
was shown to involve phosphoinositide 3-kinase (PI3K) and Akt [37, 38, 84]. 
Insulin has been shown to directly activate a signalling cascade leading to 
eNOS phosphorylation on cultured endothelial cells via IRS-1, PI3K and Akt 
[85]. Insulin induced (60-600pM) dilation of first-order arterioles was 
abolished with endothelial cell removal or L-NNA treatment [68], suggesting 
the involvement of endothelial cell derived NO. 
Evidence from in vivo studies indicates that insulin's vasodilatory 
action in muscle is NO-dependant in support of in vitro findings. Steinberg et 
al. [41] demonstrated that local L-NMMA (16mg.min -1 ) following a 3 hour 
euglycaemic hyperinsulinemic clamp (120mU.m -2 .min-1 ) in humans inhibited 
insulin-mediated vasodilation and blunted insulin-mediated leg glucose uptake 
by 25%. Baron et al. [86] reported that acute systemic administration of high 
doses of L-NMMA (30 and 15 mg.kg1 ) in healthy male rats resulted in 
development of insulin resistance. Roy et al. [87] demonstrated in rats that 
systemic L-NAME (30mg.min-l .kg 1 ) during an insulin clamp (64mU.min-
1 .kg-1 ) significantly blunted muscle 2-DG uptake in soleus, red and white 
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gastrocnemius and tibialis muscles. Vincent et al. [88] reported that acute 
systemic infusion of L-NAME (50gg.min -l .kg-1 ) in rats completely inhibited 
insulin-mediated microvascular perfusion and blunted insulin-mediated 
glucose uptake (insulin clamp 10mU.min-l .kg-1 ). Together with in vitro 
studies [68], this evidence indicates that insulin has a direct interaction with 
insulin receptors on the vascular endothelium for increased production of NO 
[37], which suggests an NO dependant mechanism by which insulin controls 
total blood flow and microvascular perfusion. Scherrer et al. [89] 
demonstrated that NOS inhibition by L-NMMA (1-81.tmol.min -1 ) infused 
locally during a 2 hour hyperinsulinemic euglycaemic clamp (6pmol.min -l .kg-
1 ) in humans blocked insulin mediated increases in total blood flow however 
glucose uptake was unchanged. 
A study by Shankar et al. [90] examined the effects of acute central 
intracerebroventricular (ICV) administration of L-NMMA which resulted 
hyperglycaemia, hypertension and reduced glucose disposal rates by 22% 
during an insulin clamp (12mU.min-l .kg-1 ). Similarly, Bradley etal. [91] 
demonstrated that systemic insulin-mediated (10mU.min -l .kg-1 ) increases in 
limb blood flow, muscle microvascular perfusion and glucose uptake were 
significantly blocked by central L-NMMA (500gg ICV). Together these data 
suggest that a central pathway that is NO-dependant may regulate peripheral 
insulin action. Thus central NO-dependant pathways may be involved in the 
pathogenesis of insulin resistance. 
The aforementioned studies demonstrate that the haemodynamic 
actions of insulin are NO-dependant. One of the aims of the present thesis is 
to determine whether local infusion of the NOS inhibitor L-NAME during 
systemic insulin affects insulin's haemodynamic and metabolic actions in 
muscle. 
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1.7 Mechanisms for Insulin-mediated Increases in 
Microvascular Perfusion 
The mechanism of insulin-mediated microvascular perfusion has not 
been fully resolved. Microvascular perfusion is likely to be mediated by third 
to fifth order arterioles whereas total flow is likely to be mediated by first to 
third order arterioles. It is now accepted that insulin has a direct vasodilator 
action on larger peripheral arterioles in vitro but it is not known whether a 
similar mechanism occurs in small arterioles. 
Insulin signalling leading from the receptor to the activation of eNOS 
has been demonstrated using vascular endothelial cells. Small arterioles of the 
rat cremaster muscle respond to subcutaneously injected insulin (835pM 
insulin in serum) viewed by intravital microscopy [92]. Insulin receptors are 
present on endothelial, vascular smooth muscle and skeletal muscle cells so it 
is feasible that insulin has a direct effect on these cell types resulting in the 
formation of a vasodilator. It is likely that the vasodilator acts locally, 
diffusing from the site of formation to the VSMC of the terminal arterioles. 
Current data from Vincent et al. [27] and Zhang et al. [63] suggest that 
insulin mediated microvascular perfusion occurs before increases in total 
flow. Clark et al. [2] suggests that flow is redistributed from the non-nutritive 
vessels to nutritive capillaries. A direct dilatory action of insulin on muscle 
micro-vessel endothelial cells is supported by evidence from euglycaemic 
hyperinsulinemic clamp studies where it was demonstrated that the NOS 
inhibitor, L-NAME, blunted microvascular perfusion [88]. In addition, 
methacholine, a NO producer, increases insulin-mediated microvascular 
perfusion and glucose uptake [93]. 
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1.8 Insulin Signalling Pathways 
The cellular effects of insulin begin when it binds to the cell surface 
insulin receptor (IR) [94, 95] and initiates activation signal transduction 
pathways that regulate diverse cellular functions [96]. There are two major 
signalling branches; the phosphoinositide 3-kinase (PI3K) branch of the 
cascade and mitogen activated protein kinase (MAPK) dependant pathway. 
The PI3K branch is involved in glucose metabolism and stimulation of NO 
production in the vascular endothelium. The MAPK branch mediates the non-
metabolic mitogenic and growth effect of insulin and controls secretion of 
endothelin 1 (ET-1) in the vascular endothelium. 
The insulin receptor (IR) is a large heterotetrameric glycoprotein 
containing two a-subunits (M r 140kDa) and two 3-subunits (M r 95kDa) linked 
by disulfide bonds [97]. Insulin binding to the a-subunit leads to a 
conformational change [98] resulting in auto-phosphorylation of tyrosine 
residues of the transmembrane 13-subunit which initiates intracellular 
signalling [99]. The first down stream targets of the I3-subunit are the insulin 
receptor substrate (IRS) [100, 101] and Shc that serve as docking proteins for 
downstream signalling molecules [102]. Once phosphorylated the IRS 
proteins are able to bind to She homology (SH2) domain binding for effectors 
such as the PI3K complex [103] and Grb-2 leading to MAPK 
phosphorylation. 
The actions of insulin that have been shown to depend on PI3K 
activity include stimulatory effects on glucose transport, glycogen synthesis, 
protein synthesis and inhibitory effects on lipolysis [104]. PI3K is a tightly 
associated heterodimeric enzyme consisting of a M r 85,000 regulatory subunit 
and a M r 110,000 catalytic subunit [105-108]. PI3K is activated by the 
binding of tyrosyl phosphorylated IRS-1 through the SH2 domain of the p85 
subunit of PI3K [109]. Figure 2 illustrates a simplified representation of the 
insulin signalling, involving the PI3K cascade, leading to glucose uptake. 
PI3K catalyses the phosphorylation of the lipid product phosphatidylinositol 
4,5-bisphosphate (PIP-2 ) on the D3 position of inositol [105] to PI 3,4,5- 
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triphosphate (PIP-3)[110]. PIP-3 binds and activates the signalling protein 
pleckstrin homology domain in 3-phosphoinositide-dependant protein kinase-
1 (PDK-1). PDK-1 activates downstream effectors such as Akt and protein 
kinase C (PKC) [111-113]. The glucose transporter GLUT4 is then stimulated 
to migrate from the intracellular compartment to the plasma membrane [1, 
114, 115] resulting in glucose transport into the cell. Akt has been implicated 
as a key signalling protein for several of the actions of insulin, including 
activation of glycogen synthesis, protein synthesis and GLUT4 translocation 
[111, 116, 117]. 
Figure 2: A simplified schematic diagram of the insulin signalling cascade in 
skeletal muscle leading to glucose uptake. 
1.8.1 Mitogen-activated Protein Kinase Cascade 
The MAPK-dependant branch of insulin-signalling pathway generally 
regulates biological actions such as growth, mitogenesis and differentiation. 
MAPK responds to extracellular stimuli and have been found to play a role in 
variety of cellular processes including inflammation, cell growth and 
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differentiation, cell cycle and cell death [118-121]. There are four subgroups 
within the MAPK family which include extracellular signal-regulated kinases 
(ERK), c-jun N-terminal or stress-activated protein kinases (JNK/SAPK), 
ERK5 or big MAP kinase 1(BMK1) and the p38 group of protein kinases 
[120, 122, 123]. The p38 MAPK mitogen-activated protein kinases (p38 
MAPKs) are activated by ischemia, exercise, muscle contraction, oxidative 
stress, heat shock and inflammation [124]. Studies using mouse skeletal 
muscle and L6 myotubes have indicated that p38 MAPK pathway may be 
involved in regulation of glucose transport [125]. Skeletal muscle contraction, 
which has been demonstrated to increase GLUT4- mediated glucose transport, 
has been shown to activate p38 MAPK [126]. Ischemia pre-conditioning in rat 
hearts increases glucose transport which been shown to is mediated by p38 
MAPK [127]. Metabolic stress conditions such as contraction and hypoxia 
increase glucose uptake and AMPK activity in skeletal muscle which is also 
associated with p38 MAPK activation [128]. AICAR, an AMPK activator, 
increases phosphorylation and activity of both p38 and MAPKa and p38 
MAPKfl in EDL muscle [129]. It has been demonstrated by Xi etal. [130] in 
clone 9 cells, that p38 MAPK is a downstream component of AMPK 
signalling pathway in AICAR-stimulated glucose transport. This finding 
suggests that there are interactions between AMPK and the MAPK signalling 
pathway in the regulation of glucose transport. 
1.8.2 Wortmannin 
Studies of the role of PI3K have been facilitated by the availability of 
relatively specific inhibitors such as wortmannin and LY294002. Wortmannin 
is toxic to fungi and was originally isolated from the soil bacteria culture broth 
of Penicillium wortmannii [131]. The low molecular weight (MW = 428.4) 
cell permeable compound which has a sterol-like structure is shown in Figure 
3 [132, 133] and is soluble in methanol and DMSO. Wortmannin has been 
extensively applied to cell cultures and is one of the major tools used to 
elucidate the biological functions of PI3K activation at a cellular level [134]. 
Studies using wortmannin have deduced that PI3K is essential for the 
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stimulation of glucose transport in adipocytes [105, 135] and skeletal muscle 
[136]. 
Figure 3: The chemical structure of wortmannin [134]. 
Activation of PI3K appears to be necessary for insulin-induced 
stimulation of glucose transport [127] and is involved in insulin-mediated 
signalling mechanisms leading to Akt activation and subsequent NO 
production. One of the aims of the present thesis is to determine whether 
administration of wortmannin during an insulin clamp blocks the 
haemodynamic and metabolic processes involved in insulin action. 
1.9 Insulin Resistance 
Insulin resistance is typically defined as a decreased responsiveness to 
the metabolic actions of insulin to promote glucose disposal [137-139]. 
Impaired insulin action in diabetes is coupled with elevated blood glucose 
concentration due to decreased muscle glucose uptake and reduced ability of 
insulin to suppress hepatic glucose output. This is compensated for by 
increased secretion of insulin by the pancreas resulting in hyperinsulinemia. 
Type 2 diabetes results when the pancreas can no longer maintain insulin 
hyper-secretion which results in chronic hyperglycaemia [137, 140]. The 
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incidence of type 2 diabetes is rapidly increasing in developed and developing 
countries and it is now considered an epidemic [139, 141-144]. 
At the cellular level many proteins are involved in insulin signalling 
and disruption of any of these proteins can lead to impaired insulin action. In 
vivo studies in humans have demonstrated multiple defects in muscle cells in 
insulin resistant subjects, including disturbances of the insulin receptor signal 
[145], glucose transporter proteins [146] and glycogen synthase activity [147]. 
Mutations in genes responsible for insulin signalling leading to insulin 
resistance occur in a small number of human subjects however in most cases 
the disease is an acquired condition which is strongly associated with a 
sedentary life style and obesity [139]. It has also been demonstrated that 
muscle obtained from the obese Zucker rat, a commonly used animal model 
for insulin resistance which carries a recessive mutation in the gene for the 
leptin receptor, is insulin resistant when isolated and incubated [148]. In 
addition, studies have shown decreased PI3K activity in insulin resistant 
humans [149]. 
Insulin resistance is a metabolic disorder however vascular effects may 
contribute to the pathogenesis of the disease. Later stage complications of type 
2 diabetes include microvascular abnormalities resulting in damage to the 
retina, nephrons of the kidney and the blood supply and cells of the peripheral 
nervous system. Macrovascular complications include altered blood flow in 
the cardiovascular system which may contribute to heart attack and stoke 
[150]. Pathological changes in skeletal muscle include diminished 
capillarisation which may reduce the capacity for exchange of glucose and 
insulin to muscle cells, contributing to insulin resistance. 
There are a number of studies using human and animal models of 
insulin resistance which have demonstrated impaired vascular function which 
may contribute to insulin resistance. The vascular actions of insulin to 
stimulate production of nitric oxide from the endothelial cell lead to 
vasodilation and increased blood flow and microvascular perfusion which 
enhances glucose uptake in skeletal muscle [151]. Since micro vascular 
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perfusion contributes to glucose uptake in normal individuals the question 
remains whether blood flow is altered in states of insulin resistance, 
contributing to diminished insulin-mediated glucose uptake. Resistance to 
these vascular actions of insulin, characterized by reduced nitric oxide 
dependant vascular activity, is a consistent feature in obesity and diabetes 
[152]. A number of studies have also demonstrated that the vasodilatory 
action of insulin is blunted in peripheral tissues such as skeletal muscle in 
insulin resistant subjects [153-155]. 
1.9.1 Impaired Total Flow Response in Insulin Resistance 
Baron and colleagues [156] first reported on the decreased ability of 
insulin to stimulate total blood flow in insulin resistant humans. In this study 
dose response curves were shifted to the right in the obese and type 2 diabetic 
subjects compared with lean controls. In insulin resistant subjects, basal limb 
blood flow is generally not impaired [4, 26, 157-162], although it has been 
demonstrated that insulin's ability to increase total flow and glucose uptake is 
impaired in states of insulin resistance [156]. Conversely a number of studies 
have found no impairment of insulin stimulated blood flow in type 2 diabetes 
as previously discussed in section 1.2 and reviewed in Clark et. al. [163]. 
1.9.2 Impaired Microvascular Flow in Insulin Resistance 
Several studies have demonstrated that during states of insulin 
resistance, microvascular perfusion measured using the 1-MX method, is 
impaired thus restricting the availability of glucose and insulin available to 
muscle cells. It has been shown, that insulin mediated microvascular 
perfusion is abolished in the insulin resistant Zucker rat [164] which is 
coupled with impaired glucose uptake in hind limb muscle during 
supraphysiological insulin. Studies involving obese human subjects have 
demonstrated, using contrast enhanced ultrasound, that systemic physiological 
insulin failed to increase forearm microvascular perfusion, glucose uptake or 
brachial artery flow compared with lean controls [165]. 
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A number of interventions can induce acute insulin resistance. Firstly 
infusion of the vasoconstrictor a-methylserotonin has been shown to decrease 
microvascular flow and glucose uptake in perfused rat hindlimb studies [47]. 
In vivo, a-methylserotonin abolished the ability of insulin to increase total 
flow and microvascular perfusion was blunted [55]. In incubated muscles it 
was demonstrated that a-methylserotonin had no effect on glucose uptake, 
compared with the perfused hindlimb studies, suggesting a role of the vascular 
system in insulin resistance [166]. Secondly, it was demonstrated by Youd et 
al. [167] that insulin resistance can be induced by acute administration of 
TNF-a, a cytokine which is elevated in various states of insulin resistance and 
obesity. TNF-a infusion during an insulin clamp decreased glucose infusion 
rate (GIR) and muscle glucose uptake as well as decreasing total blood flow 
and microvascular perfusion. In aortic endothelial cells TNF-a inhibits IRS-1, 
PI3K and phosphorylation of eNOS [85], suggesting TNF-a can inhibit the 
haemodynamic actions of insulin directly. Thirdly, Clerk et al. [168] 
demonstrated that microvascular perfusion and glucose disposal is impaired in 
rats following acute elevation of free fatty acid (FFA) by administration of 
Intralipid® heparin. In that study it was noted that insulin-mediated 
microvascular perfusion and increased limb blood flow was completely 
blocked, which was coupled with a 50% reduction in glucose uptake. Taken 
together, these studies demonstrate that impaired microvascular recruitment is 
associated with a decline in skeletal muscle insulin-mediated glucose disposal 
and that muscle metabolism is dependant on the extent of microvascular 
perfusion. 
1.10 Exercise and Insulin Sensitivity 
1.10.1 Exercise Increases Glucose Uptake 
Exercise or muscle contraction stimulates glucose uptake into skeletal 
muscle in the absence of insulin [169, 170]. The contracting muscle has 
increased demand for energy during exercise and requires an adequate supply 
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of oxygen and glucose. Muscle contraction stimulates the translocation of 
GLUT4 to the plasma membrane and glucose uptake is promoted [171, 172]. 
There is evidence that exercise and insulin use different signalling pathways 
for glucose uptake since the two stimuli act synergistically [172-175]. 
Exercise-mediated glucose uptake, unlike insulin-mediated glucose uptake 
which involves PI3K signalling, is not inhibited by wortmannin [176]. Part of 
the signal that generates an increase in exercise mediated glucose uptake may 
be the activation of the enzyme AMP-activated protein kinase (AMPK) [177] 
(section 1.11). 
1.10.2 Exercise Increases Insulin Sensitivity 
Evidence from several studies demonstrates that physical activity is 
beneficial for the prevention of insulin resistance [178-180] through 
increasing insulin sensitivity [181, 182]. The signalling mechanisms involved 
in exercise mediated glucose uptake may provide important targets for drug 
therapies for insulin resistance [183]. 
Acute exercise induces GLUT4 translocation in skeletal muscle of 
normal and insulin resistant subjects [184]. A number of researchers have 
shown that a single bout of light exercise by human subjects improves whole 
body insulin sensitivity measured during a hyperinsulinemic euglycaemic 
clamp [185-188]. This beneficial effect of the single bout of exercise can be 
observed for up to 16 hours [189, 190]. The improved insulin sensitivity after 
exercise is mainly observed in muscles recruited during exercise [191] [192]. 
Exercise training, which is a repetition of several exercise bouts, has 
been shown to increase insulin sensitivity and maximal insulin responsiveness 
[193, 194] [195, 196] in healthy and insulin resistant individuals. In insulin 
resistant type 2 diabetic subjects one-legged physical training has been shown 
to increase insulin action in skeletal muscle compared with control subjects 
[197]. During a hyperinsulinemic euglycaemic clamp in individuals which 
23 
CHAPTER 1- Introduction. 
had undergone six weeks of exercise training resulted in a 30% increase in 
glucose uptake compared with no prior exercise training [198]. 
During exercise, perfusion of the muscle is dramatically increased. It 
has been demonstrated that muscle contraction increases total flow to muscle 
[199] and microvascular perfusion [200]. It is possible that haemodynamic 
factors contribute to improved insulin sensitivity following exercise [201] 
since the delivery and surface area available for insulin is markedly enhanced. 
It has been demonstrated that exercise training increases capillary density in 
skeletal muscle in humans [202, 203] and in rats [204] which may contribute 
to enhanced glucose uptake. Rattigan etal. [205] demonstrated in rats that 14 
days of voluntary exercise training increased insulin-mediated whole body 
glucose infusion rate (by 24%) and hind leg glucose uptake (by 93%) as well 
as improvements in microvascular perfusion compared with sedentary 
controls [205]. 
1.11 AMP-Activated Protein Kinase 
An enzyme now known as AMP-activated protein kinase (AMPK) was 
first reported in two independent articles published in 1973. These studies 
demonstrated that the enzyme inactivated 2 key metabolic enzymes involved 
in lipid synthesis; acetyl-CoA carboxylase (ACC) (involved in FA synthesis) 
and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (involved in 
isoprenoid/cholesterol synthesis). The report from Carlson and Kim [206] 
described regulation of ACC by reversible phosphorylation, using rat 
hepatocytes. Beg et. al. [207] described modulation of HMG-CoA reductase 
using protein fractions of rat liver. The ability of the kinase to phosphorylate 
the ACC kinase (1980) [208] and the HMG-CoA reductase kinase (1985) 
[209] were dependant on the presence of AMP. It was reported by David 
Carling and Grahame Hardie et a/. [210] in 1987, that inactivation of ACC 
and HMG-CoA was performed by the same protein kinase. The enzyme was 
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subsequently named AMP-activated protein kinase (AMPK) by the same 
group the following year [211]. 
Further investigations and cloning of AMPK revealed that the kinase is 
related to a family of metabolic stress-sensing protein kinases of the yeast 
SNF-1 protein kinase sub-family which is found in fungi, plants and 
nematodes [212-217]. The kinase is highly conserved through evolution and is 
present in mammalian tissues. 
Recent research has established that AMPK is an energy sensing 
enzyme which is regulated in mammalian tissue by physiological stimuli such 
as nutrients and changes in ATP consumption [218]. AMPK has been 
proposed to function as a 'metabolic master switch' which co-ordinates 
cellular energy metabolism by regulating catabolic pathways that produce 
ATP and anabolic pathways that consume ATP [219] (see section 1.11.2). 
1.11.1 Structure of AMPK 
AMPK is a serine/threonine protein kinase consisting of a catalytic a-
subunit (63 kDa) and regulatory J3- (38 kDa) and y-subunits (35 kDa) [217, 
220-222] which associate to form a heterotrimer [223, 224]. The 13-  and y-
subunits are important for maintaining the stability of the heterotrimer 
complex [225]. All three subunits are encoded by distinct genes (al, a2, 131, 
132, y 1, y2, y3) which gives rise to at least 12 different heterotrimic 
combinations of the isoform which have alternative transcription sites [226]. 
The genes encoding the a -, p- and y-subunits are highly conserved in all 
eukaryote species [220]. Co-expression of all three subunits is required for 
kinase activity [225, 227, 228]. The expression pattern for the isoforms 
appears to vary among tissues [229] suggesting that there are different 
physiological roles depending on the complex formation. 
25 
CHAPTER 1- Introduction. 
1.11.1.1 AMPK Subunits 
The a subunit contains the serine/threonine protein kinase catalytic 
domain including a phosphorylation residue at Thr 172 . Phosphorylation of this 
site is essential for enzyme activity [221]. Expression of AMPK complexes 
containing a2 (the first catalytic subunit to be cloned [230]) are predominantly 
found in skeletal and heart muscle [231], whereas adipocytes express the al 
isoform [232]. Approximately equal proportions of al and a2 are found in 
liver [233]. AMPK a 1 and a2 isoforms are expressed in arterial smooth 
muscle cells in different proportions between different arteries [234]. In 
endothelial cells al and a2 isoforms are expressed [235] with a higher 
proportion of al expression [236]. 
The f3 subunit is thought to act as a scaffolding protein for binding of 
the a and 7 subunits [223]. It has been proposed that binding of the 13 and 7 
subunits stabilizes the subunit [217, 222, 237]. Both a- and 0-subunits are 
phosphorylated by AMPK kinases(s) and by auto-phosphorylation. It has also 
been suggested that the 0-subunit is involved in phosphorylating glycogen 
synthase [238] and that high glycogen in muscle may regulate AMPK [239- 
241]. The 131-subunit is widely expressed, whereas the [32-subunit is 
predominantly expressed in skeletal [242] and heart muscle [229]. 
The y isoform contains 4 cystathionine43-synthase (CBS) domains 
[221]. The function of the CBS domain is not known but it has been suggested 
that the y subunit binds to the adenosine portion of AMP [228]. The yl 
subunit is widely expressed and is the predominant isoform contributing to 
kinase activity in skeletal muscle [228]. The 71- and y2-subunits are widely 
expressed [228, 231, 243] and the 73-subunit has been shown to display a high 
degree of specificity for skeletal muscle [228] and in particular white skeletal 
muscle [244]. 
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1.11.2 Regulation of AMPK 
AMPK acts as a metabolic sensor to the energy status of a cell [230] 
and plays a critical role in many metabolic processes, including glucose 
uptake and fatty acid oxidation in muscle, fatty acid synthesis and 
gluconeogenesis in the liver [245]. Once activated, AMPK phosphorylates 
several downstream substrates to switch off ATP-consuming pathways (e.g. 
fatty acid synthesis and cholesterol synthesis) and to switch on ATP-
generating pathways (e.g. fatty acid oxidation and glycolysis) [217, 220, 230]. 
AMPK can be activated allosterically by increases in the AMP to ATP 
ratio or by covalent modification by AMP dependant AMPK kinase 
(AMPKK) which phosphorylates the a-subunit on Thr 172 [246]. Woods et al. 
[247] and Carlson et al. [248] demonstrated that AMP binds to AMPK which 
enables the complex to be more susceptible to phosphorylation by AMPKK. 
Protein kinases which may phosphorylate AMPK include LKB1 [248] and the 
Ca217calmodulin-dependant protein kinase kinase (CaMKK) [249]. It has 
recently been reported that LKB1 is sufficient to activate AMPK in vitro and 
is genetically required for AMPK activation by energy stress in a number of 
mammalian cell lines [248]. Studies using cell extracts have demonstrated that 
LKB1 acts by directly phosphorylating AMPK rather than promoting auto 
phosphorylation of AMPK [247]. 
1.11.3 Activators of AMPK 
The activity of AMPK increases in response to stressors such as 
muscle exercise, nutrient starvation, hypoxia and oxidant stress [230]. AMPK 
can also be activated by pharmacological agents such as AICAR and some 
anti-diabetic drugs such as metformin and thiozolidinediones as well as 
hormones that act through Gq receptors [250], leptin [251], adiponectin [252, 
253], a- and P-adrenoreceptor agonists [232, 254]. 
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1.11.3.1 Exercise 
Muscle contraction is associated with an increase in energy turnover in 
the muscle cell as it depletes ATP and generates AMP resulting in AMPK 
activation (reviewed in [255]). The first report of AMPK involvement in 
exercise signalling was by Winder and Hardie in 1996 [256] who 
demonstrated that AMPK activity increases in rats by 2 to 3 fold within 5 
minutes of commencing treadmill running exercise. A number of subsequent 
studies have demonstrated that AMPK is activated during muscle contraction. 
For example; the activity of AMPK increases in sciatic nerve-stimulated rat 
muscle ex vivo [257, 258] and by motor nerve stimulation in vivo and perfiised 
rat hindlimb in situ [177, 259-261]. In vivo studies have revealed that AMPK 
is activated in rat muscle during treadmill running [260, 262]. In humans, 
exercise significantly increases AMPK activity during cycling exercise at 70% 
of V02 max [263] and 75% of V02 max [264]. 
In general, in rodent muscle both al and a2 associated AMPK 
complexes are activated during contraction/exercise. In human muscle, 
AMPK a2 is activated during moderate and high intensity exercise whereas 
the al isoform is only activated during high intensity exercise such as sprint 
cycling [264, 265]. 
There are beneficial effects of regular physical activity for prevention 
of pathological conditions such as obesity and diabetes. It has been 
demonstrated that individuals with type 2 diabetes subjected to exercise 
activate AMPK a2 to a similar extent as controls [266]. This finding indicates 
that individuals with diabetes have normally functioning AMPK, which has 
implications for targeting AMPK for drug development. 
1.11.3.2 AICAR 
AMPK can be activated artificially by the compound 5- 
aminoimidazole-4-carboxamide-1-13-D-ribofuranoside (AICAR) [267-272] 
which has featured as a major tool for research on AMPK. AICAR, an 
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analogue of adenosine, can be transported across the plasma membrane. After 
AICAR enters the cell, it is phosphorylated by adenosine kinase [273] to its 
monophosphorylated form called 5-aminoimidazole-4-carboxamide-1-13-D-
ribofuranotide (ZMP) [270] (Figure 4). ZMP (Z-base compound) is a normal 
intermediate in the pathway of synthesis of purine nucleotides and may be 
metabolised to form inosine monophosphate (IMP), AMP, ZDP or ZTP [267, 
270, 273]. The monophosphate ZMP mimics the effect of AMP which 
activates AMPK both by direct allosteric activation [274] and via promoting 
increased phosphorylation by AMPKK [255, 267, 268]. 
OH OH 
Figure 4: ZMP and AMP. The chemical structure of AICAR monophosphate 
(ZMP) and adenosine monophosphate (AMP). 
Early reports of AICAR to be a specific pharmacological activator of 
AMPK were made by Sullivan et. al. [271] in 1994 and Corton et. al. [267] in 
1995, which proved to be a major development in AMPK research. It was 
demonstrated that AICAR markedly activated cellular AMPK in a time and 
dose dependant manner in rat adipocytes [271]. Similarly, it was demonstrated 
that incubation of rat hepatocytes with AICAR activates AMPK due to 
phosphorylation and inactivation of a known target for AMPK (3-hydroxy-3- 
methylglutaryl-CoA reductase) [267]. The overall effect was that ZMP 
mimicked the effect of AMP on allosteric activation of AMPK [267]. In these 
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experiments, using rat hepatocytes, it was also noted that AICAR was a 
specific method for activating AMPK since the cellular contents of ATP, ADP 
or AMP were not altered which avoided non-specific side effects. 
1.11.3.3 Antidiabetic Drugs 
Oral medication as a treatment of diabetes began with the use of 
Gallega officinalis (goat's-rue or French lilac) in medieval Europe [275, 276]. 
Guanidine, the active component of Galega, was used to synthesise anti-
diabetic compounds which lead to the production of two main biguanides; 
metformin and phenformin in the 1950s [277, 278]. Biguanides and 
Thiazolidinedions (TZDs) are two currently prescribed drug treatments for 
type 2 diabetes. 
Metformin is currently the most prescribed oral antidiabetic agent. 
Metformin suppresses hepatic glucose production [279], increases skeletal 
muscle glucose disposal and reduces circulating free fatty acids [276, 280]. 
Unlike other prescribed antidiabetic agents metformin is not associated with 
weight gain. The mechanism of action of metformin has not been fully 
determined however Zhou et al. demonstrated that metformin activates 
AMPK in isolated rat hepatocytes [278]. In isolated rat muscle metformin 
activates AMPK together with stimulation of glucose uptake [278]. In type 2 
diabetic humans, after 4 weeks of metformin treatment, a significant increase 
in AMPK a2 activity and glucose disposal was observed [281]. 
Thiazolidinedions are a class of drugs to which pioglitazone and 
rosiglitazone belong. Fryer et al. demonstrated that rosiglitazone is able to 
activate AMPK in muscle cell cultures, which was associated with an increase 
in the ratio of AMP:ATP [282]. In addition pioglitazone has been shown to 
activate AMPK [283, 284]. 
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1.11.3.4 Other AMPK Activators 
It has been demonstrated by a number of studies that hypoxia 
stimulates glucose uptake and AMPK activity in skeletal muscle [285]. The 
increase in hypoxia stimulated glucose uptake has been shown to be additive 
to insulin but not muscle contraction. In muscle which is dominant negative 
for AMPK, AICAR and hypoxia mediated glucose uptake is blocked [286]. In 
heart muscle, hypoxia [287] or ischemia [288] have been shown to activate 
AMPK. During ischemic reperfusions in the heart it was demonstrated that 
glucose transport was increased [289], which was independent of PI3K [127]. 
Leptin and adiponectin are adipokine hormones secreted by 
adipocytes. AMPK can be activated by leptin in skeletal muscle [290] and 
adiponectin in skeletal muscle and liver [291, 292]. 
The traditional activators of AMPK have included exercise or muscle 
contraction, anti-diabetic drugs such as metformin, TZDs and AICAR. More 
recently other AMPK activators such as polyphenols, estrogen, lipoic acid and 
rimonabant have emerged potential targets for diabetes treatments. 
Polyphenols, such as resveratrol (a major polyphenol in red wine), 
apigenin and S17834 increase phosphorylation of AMPK and the down 
stream target, acetyl-CoA carboxylase (ACC) and they increase the activity of 
AMPK with 200 times the potency of metformin in HepG2 hepatocytes [293]. 
Epigallocatechin-3-gallate (EGCG) a poly phenol found in green tea, has been 
shown to be an effective treatment of type 2 diabetes in rodents [294], 
possibly through its reported ability to activate AMPK [295-297]. 
Additionally, EGCG treatment of spontaneously hypertensive rats (SHR) 
improved insulin sensitivity and dose dependently increased vasodilation of 
isolated mesenteric beds (MVB) by increasing NO production [298], 
suggesting a role of the vasculature for improving the action of insulin. 
Studies by Watt et al. [299] have shown that ciliary neurotrophic 
factor (CNTF) which signals through the CNTF a-IL-6R-gpl3013 receptor 
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complex, acts to increase fatty-acid oxidation and reduce insulin resistance by 
activating AMPK in isolated mouse skeletal muscle. There is also some 
evidence to suggest that estrogen plays a role in AMPK activation since 
ovaectomised mice exhibited promoted visceral fat accumulation by inhibiting 
AMPK activation and stimulating lipogenesis [300]. 
More recently, Cool etal. [301] identified A-769662 as the first small 
molecule direct pharmacological activator of AMPK. In vivo administration of 
the compound to oh/oh mice lowered plasma glucose by 40% and reduced 
body weight gain and plasma and liver triglycerides [301]. Studies in mouse 
embryonic fibroblasts or hepatocytes determined that A-769662 is a direct and 
specific activator of AMPK which is independent of upstream kinases [302]. 
In addition, it has been demonstrated that the compound activates AMPK both 
allosterically and by inhibiting dephosphorylation of AMPK on Thr 172 via an 
AMP independent mechanism [303]. More recently evidence has suggested 
that this action is dependant on the 13 sub-unit carbohydrate-binding molecule 
and the y sub-unit [304], which is a novel function of AMPK. 
The traditional Chinese medicine berberine activates AMPK and 
improves insulin sensitivity [305]. Recently a berberine derivative, 
dihydroberberine (dhBBR) has been demonstrated to improve in vivo efficacy 
by counteracting increased adiposity, tissue triglyceride accumulation and 
insulin resistance in HFF rodents [306]. 
1.12 Role of AMPK in the Vasculature 
It has been reported that AMPK phosphorylates and activates the 
endothelial NO synthase (eNOS). Chen et al. [307], using ischemic rat hearts, 
demonstrated that AMPK phosphorylates eNOS at Ser 1177 . Morrow et al. 
[308], using human aorta endothelial cells, have also demonstrated that 
AMPK causes increased phosphorylation of eNOS at Ser 1r77 and increased 
NO production. Studies using cultured endothelial cells have demonstrated 
that AMPK phosphorylates and activates eNOS [309]. AMPK is also 
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activated by hypoxia in HUVEC cells and it was demonstrated that adenoviral 
expression of a dominant negative AMPK mutant in those cells blocked 
increased eNOS phosphorylation at Ser 1177 [310]. It has also been 
demonstrated that fenofibrate activates AMPK and increases eNOS 
phosphorylation and NO production in HUVEC cells [311]. Taken together 
these findings indicate that AMPK, through increased NO production, could 
have a positive effect to increase blood flow to tissues possibly through 
increasing microvascular blood flow [312]. It has been demonstrated that 
AICAR activates AMPK (section 1.11.3.2), therefore one of the aims of the 
present thesis it to determine whether AICAR increases vasodilation through 
AMPK activation and enhances microvascular perfusion in vivo. 
1.13 AICAR Stimulated Glucose Uptake 
Numerous studies have demonstrated that AICAR increases glucose 
transport in rat skeletal muscle [313], perfused muscle [269] and isolated 
muscles [177]. In 1997, Merrill et al. [269], using perfused rat hindlimb was 
the first to describe AMPK involvement in glucose uptake when it was 
demonstrated that AICAR simultaneously enhanced fatty acid oxidation and 
increased insulin stimulated glucose uptake. It was then demonstrated by 
Hayashi etal. [177] in 1998 and Bergeron etal. [313] in 1999 that AICAR 
can increase glucose uptake in isolated rat muscle in the absence of insulin. 
Studies performed in vitro have determined that AICAR is effective in 
causing enhanced uptake of glucose into isolated perfused muscle [177, 269]. 
Similarly, in vivo studies have demonstrated that AICAR causes enhanced 
muscle glucose uptake [313]. The increases in glucose uptake correspond with 
increased glucose transporter 4 (GLUT4) fusion with the plasma membrane 
[314] and activation of AMPK [286]. These AICAR induced increases in 
glucose transport resemble the acute effects of muscle contraction. 
It has been demonstrated that the over expression of a dominant-
negative AMPK in H-21( 1) skeletal muscle cells blocked the stimulation of 
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glucose uptake by AICAR and osmotic stress, but did not alter insulin 
mediated glucose uptake [315]. Sakoda et al. [316] demonstrated that over 
expression of a dominant-negative AMPK in rat soleus muscle blocked 
AICAR mediated glucose uptake. In addition, AICAR mediated glucose 
uptake in mice over expressing a kinase inactive AMPK mutant in skeletal 
muscle was completely blocked [286], however contraction-stimulated 
glucose uptake was only partially blocked, suggesting that AMPK is not the 
only mechanism involved in contraction. It appears that AMPK activation is 
essential for AICAR-induced glucose uptake in skeletal muscle. In contrast, 
Sakoda et al. demonstrated that over expression of a dominant-negative 
AMPK in 3T3-L1 adipocytes had no effect on AICAR induced 2-DG uptake, 
suggesting that AICAR mediated glucose uptake in these cells is AMPK-
independent [316]. 
Similar to exercise, AICAR mediated increases in muscle glucose 
uptake are not inhibited by the PI3K inhibitor wortmannin [177, 313]. These 
studies demonstrated that AICAR and insulin have additive effects on glucose 
uptake in contrast to AICAR and contraction which do not have additive 
effects on glucose uptake. 
AICAR increases glucose uptake in the insulin resistant rat model. For 
example, Bergeron et al. [317] have examined the acute effects of AICAR in 
the obese insulin resistant rat in vivo. A constant AICAR infusion 
(10mg.kg-l .min-1 ) to Zucker obese and lean rats increased glucose transport in 
red gastrocnemius muscle. In addition, insulin clamps (4mU.min -l .kg-1 ) 
combined with AICAR increased glucose transport activity in gastrocnemius 
muscle of lean but not obese rats [317]. In another study using insulin-
resistant high fat fed rats in vivo, Iglesias et al. [318] examined the effect of 
subcutaneous injection of AICAR (250mg.kg -1 ) one day prior to 
commencing a hyperinsulinemic insulin clamp. In this study [318] AICAR 
was found to enhance glucose infusion rate during the clamp and improve 
insulin stimulated glucose uptake in white quadriceps. 
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The first reported study in human subjects was by Cuthbertson et al. in 
2007 [319], which demonstrated that AICAR infusion (10mg.kg -I for 3 hours) 
acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men, 
which occurred in the absence of AMPK al or a2 activity. Similarly a study 
by Boon et al. [320] in 2008, revealed that AICAR infusion 
(0.75 mg.min --I kg-1 ) in humans increased blood glucose disposal without 
increasing phosphorylation of AMPK. The absence of AMPK activation in 
human subjects highlights the difference between humans and rodents 
subjects in terms of AMPK activation due to AICAR. 
Several studies have reported that when administered in vivo, AICAR 
induced glucose uptake shows a preference for white, glycolytic skeletal 
muscle. As mentioned previously, Iglesias et al. demonstrated that AICAR 
enhanced insulin stimulated glucose uptake in white quadriceps but not red 
quadriceps [318]. A study by Winder et al. [321] also demonstrated that after 
sub-cutaneous injections of AICAR in rats, AMPK activity increased in the 
white region of the quadriceps but not in the deep red region of the quadriceps 
muscles. Similar to AICAR mediated glucose uptake, contraction mediated 
glucose uptake differs between muscles with different fiber-type compositions 
[322]. 
In isolated rat soleus muscle, Ai et al. [323] demonstrated that AICAR 
increased 2-deoxyglucose transport and total AMPK activity approximately 
two fold in epitrochlearis (EPI), less in flexor digitorum brevis and not at all 
in the soleus muscle. In the per-fused hind-limb, muscle 2-deoxyglucose 
uptake increased with AICAR, especially in the white gastrocnemius which 
corresponded with a larger stable activation of the a2 AMPK subunit 
compared to the soleus muscle [239]. 
1.13.1 Limitations of AICAR 
A number of investigators have noted that caution should be taken 
when interpreting the results from experiments using AICAR. 
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Pharmacological activators of AMPK, such as AICAR, could act through non-
AMPK mediated mechanisms [267, 324-326]. For example, AICAR does not 
have strict specificity to AMPK, activating all enzymes directly activated by 
AMP [325], such as glycogen phosphorylase [327, 328] and glycogen 
synthase [239]. In rat muscle and L6 myotubes, AICAR activates the 
extracellular signal-regulated kinase (ERK) / atypical protein kinase C (aPKC) 
pathway, resulting in increased glucose uptake [329]. A study in cultured 
hepatocytes has also demonstrated inhibition of fructose-1,6-bisphosphatase 
[330] and 6-phosphofructo-2-kinase (PFK-2) by AICAR, raising the 
possibility of non-AMPK mediated effects. 
AICAR may also act via adenosine receptors [331] or adenosine 
transporters [324]. This raises the possibility that AICAR may compete with 
released adenosine for re-uptake into the cells, therefore increasing adenosine 
accumulation and exert effects via adenosine receptors [332]. Han et al. [333] 
provided evidence that extracellular adenosine plays a role in mediating 
increased glucose uptake into skeletal muscle. The effect of adenosine on 
contraction or insulin stimulated glucose uptake is controversial. A study by 
Merrill et al. [269] has demonstrated that skeletal muscle perfused with 
AICAR show no change in ATP, ADP or AMP. In isolated epitrochlearis 
muscles 10p.M 8-(p-sulfopheny1)-theophylline, an adenosine receptor agonist, 
did not block AICAR stimulated 2-deoxyglucose uptake [313]. 
ACIAR can also have systemic effects when administered in vivo 
[334]. Daily subcutaneous injections of high dose AICAR (1mg.g -1 body 
weight) for 4 weeks in rats results in liver hypertrophy [335]. In a similar 
study, acute subcutaneous AICAR injection (1mg.g -1 body weight) resulted in 
increased lactate production [336]. Due to these side effects it is unlikely that 
AICAR will be a drug of choice for pharmacological treatment of diabetes. 
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1.14 The Present Study: Summary and Aims 
The work presented in this thesis was designed to investigate 
mechanisms involved in microvascular perfusion and glucose metabolism in 
skeletal muscle. Insulin and muscle contraction modulate haemodynamic 
actions in muscle; increase blood flow, microvascular perfusion and stimulate 
glucose uptake [49, 337]. In models of insulin resistance the action of insulin 
to increase blood distribution within the muscle is impaired [338] and this 
may contribute, in part, to the state of insulin resistance. The mechanisms 
involved in muscle contraction induced glucose uptake and vasodilation are 
generally not impaired in insulin resistance and thus provide an attractive 
therapeutic target for type 2 diabetes. 
Acute Effects of Wortmannin on Haemodynamic and Metabolic Actions of 
Insulin In Vivo. 
The mechanisms of insulin leading to glucose uptake are dependant on 
P13 K, which can lead to downstream phosphorylation and activation of eNOS 
resulting in vascular relaxation [38, 84]. Wortmannin is an effective inhibitor 
of PI3K and it's downstream effects [132]. Wortmannin was infused in vivo 
during a hyperinsulinemic euglycaemic clamp to determine if the 
microvascular effects of insulin are dependant on PI3K. 
Effects of Nitric Oxide Synthase Inhibition on the Actions of Insulin in 
Skeletal Muscle. 
The actions of insulin to increase total blood flow and microvascular 
perfusion have been linked to the activation of eNOS and the production of 
the potent vasodilator NO. Local NOS inhibition during a hyperinsulinemic 
euglycaemic clamp by L-NAME was utilised to determine if the action of 
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insulin to increase glucose uptake in muscle in vivo is dependant on insulin 
mediated microvascular perfusion. 
Acute Effects of AMPK Activation by AICAR on Muscle Microvascular 
Perfusion In Vivo and Isolated Muscle Resistance Arteries In Vitro. 
Skeletal muscle contraction leads to AMPK activation, increased blood 
flow and microvascular perfusion. AMPK has been shown to enhance 
endothelium-dependant vasodilation [235] and increase eNOS 
phosphorylation at Ser lm [308]. The AMPK activator AICAR was used to 
investigate the role of AMPK activation in microvascular perfusion in vivo in 
the rat and in vitro using muscle resistance arteries and isolated endothelial 
cells. 
Acute Effects of AICAR on Haemodynamic and Metabolic Actions of 
Insulin In Vivo. 
Skeletal muscle contraction can lead to glucose uptake, which is not 
inhibited by Wortmannin and is therefore independent of insulin. Muscle 
contraction and direct activation of AMPK by AICAR have been shown to 
enhance insulin-mediated muscle glucose uptake and ameliorate insulin 
resistance [339]. Infusion of AICAR during the hyperinsulinemic euglycaemic 
clamp was used to determine if increased microvascular perfusion, due to 
AMPK activation, contributes to enhancement of insulin-mediated glucose 
uptake. 
The overall aim of this study was to directly explore the mechanisms in 
muscle microvasculature leading to microvascular perfusion and glucose 
uptake. Mechanisms involved in microvascular perfusion may contribute to 
new targets for the treatment of insulin resistance. 
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2.1 In Vivo Experiments 
2.1.1 Animal Care 
The Animal Ethics Committee (University of Tasmania, Hobart, 
Tasmania, Australia) in accordance with the National Health and Medical 
Research Council of Australia (NHMRC) guidelines on animal experimentation 
approved all experimental protocols and procedures. 
Male Hooded Wistar rats, obtained from the University Animal House 
(Hobart, Tasmania, Australia), were housed at a constant temperature of 
21 ± 1 °C with a 12:12 hour light:dark cycle (lights on at 0600 hours). All rats 
were allowed access to a commercial rat chow (Pivot, Launceston, Australia) 
together with water ad libitum. The rat chow contained 21.4% protein, 4.6% lipid, 
68% carbohydrate and 6% crude fiber with added vitamins and minerals. Food 
and water was freely available (unless otherwise stated in individual chapters ie: 
fasted) until the animals were administered anaesthetic. 
2.1.2 Surgical Procedures 
The rats were anesthetized using a bolus intra-peritoneal (IP) injection of 
pentobarbital sodium (50 mg.kg-1 body weight). The surgical procedure began 
with a tracheotomy to avoid respiratory problems during anesthesia. Polyethylene 
cannulas (PE-60, Intramedice) were then surgically implanted into the carotid 
artery for arterial sampling and measurement of blood pressure (pressure 
transducer Transpac IV, Abbott Critical Systems) and into both jugular veins for 
continuous infusion of anesthetic and other intravenous infusions. 
For rats undergoing venous blood sampling and femoral blood flow 
monitoring, small incisions (1.5cm) were made in the right and left sides of the 
skin overlaying the femoral vein and artery of both legs. A section of the femoral 
artery (I cm) on the right side was separated from the saphenous nerve and the 
femoral vein. A small animal flow probe (Transonic Systems, VB series 0.5 mm) 
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was positioned around the artery just distal to the rectus abdominus muscle of the 
right leg. The cavity in the leg surrounding the probe was filled with conductive 
gel (Medical Equipment Services, Melbourne, Australia) to provide acoustic 
coupling to the probe. The probe was connected to the flow meter (Model T206 
small animal blood flow meter, Transonic Systems). This was connected with a 
computer which acquired the data (at a sampling frequency of 100Hz) for femoral 
blood flow, heart rate and blood pressure using WINDAQ data acquisition 
software (DATAQ Instruments). The femoral vein of the left leg was exposed and 
used for venous sampling, using an insulin syringe fitted with a 29G needle 
(Becton Dickinson). 
The surgical procedure was conducted over approximately 30 minutes. 
Rats were then maintained under anesthesia for the duration of the experiment 
using a continual infusion of pentobarbital sodium (0.6mg.min -l .kg-1 ) via the left 
jugular cannula. The body temperature was maintained at 37 °C using a water-
jacketed platform and a heating lamp positioned above the rat with the ambient 
room temperature controlled at 20°C. At the completion of the experiment the rat 
was euthanased by a bolus injection of pentobarbital sodium via the carotid artery 
cannulation before tissues were excised and stored for later analysis. 
2.1.2.1 	Contrast Enhanced Ultrasound (CEU) 
Rats receiving microbubbles (Chapter 5 and 6) had the left leg shaved, 
keeping the skin intact. Ultrasound transmission gel (Aqua Sonic 100) was 
applied to the surface of the leg for acoustic coupling to the ultrasound probe. A 
linear-array transducer (L7-4) interfaced with an ultrasound system (HDI-500; 
Philips Ultrasound, Santa Ana, CA, USA) was positioned over the left hindlimb 
of the rat to image the proximal adductor muscle group and the transducer was 
secured with a clamp for the duration of the experiment. A schematic diagram of 
the position of the ultrasound probe for experiments using the CEU technique is 
shown in Figure 5. Details of the technique are described in section 2.1.8.2. 
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Figure 5: A schematic diagram of the in vivo set up for experiments using the 
CEU technique. 
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2.1.2.2 	The Epigastric Artery Technique 
Cannulation of the epigastric artery is a technique first developed by 
Hema Mahajan in our laboratory in 2004, for the infusion of test substances 
locally into one leg (see Chapter 4). The epigastric artery is a branch of the 
femoral artery, in the middle part of the thigh. A schematic diagram of the in vivo 
set-up for experiments employing the epigastric technique is shown in Figure 6. 
The epigastric artery of the test leg was tied off and had a polyethylene cannula 
(PE-20, Intramedic® tubing attached to a blunt 29G syringe needle) surgically 
implanted at the junction immediately at the femoral artery. Retrograde infusion 
of the epigastric artery resulted in delivery of substances to the leg via the 
femoral artery. 
A transonic flow probe was placed around the femoral artery of both legs 
to measure the femoral blood flow simultaneously; the contra-lateral leg served as 
a control. At the end of the experiment, after taking the arterial sample (100[iL 
plasma) from the carotid cannula, the venous samples (100RL plasma) were taken 
from the femoral veins of control and test legs in rapid succession and used for 
subsequent analysis. 
Cannulation of the epigastric artery is a technique which was developed 
for administration of vasoactive substances such as L-NAME which, when 
administered systemically, have a profound effect on the blood pressure thus 
activating counter-regulatory reflex mechanisms. Infusion via the epigastric 
artery avoids unwanted systemic effects of the test substance. The cannula was 
used to infuse the test substance L-NAME (Chapter 4). An advantage of this 
technique is that the opposite leg can be used as control. Substances must be 
readily metabolized in the test leg to use this technique. Since L-NAME is 
vasoactive, any effect on blood pressure and heart rate were taken as an 
indication that the substance had appeared in systemic circulation. An effect on 
femoral blood flow in the test leg was taken as a definitive indicator of the 
substance being infused. The infusion of the test substance was regularly adjusted 
according to the measure of femoral blood flow in the test leg so that a constant 
and optimal dose could be maintained in the test leg. 
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Figure 6: A schematic diagram of the in vivo set up for experiments using the 
epigastric technique for local infusion of test agents in the rat. 
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2.1.3 In Vivo Experimental Procedures 
Once the surgical procedures were completed a 30 to 60 minute 
equilibration period was allowed so that the leg blood flow and pressure could 
become constant and stable before commencement of the experimental protocol. 
Detailed experimental protocols are given in each of the experimental chapters. 
2.1.3.1 	Blood Sampling 
An arterial blood sample (approximately 25gL) was taken 2 minutes prior 
to the commencement and at regular intervals throughout the experiment in order 
to monitor blood glucose and lactate concentrations. At the conclusion of the 
experiment arterial blood and venous blood (300-500gL) samples were collected 
after other measurements of blood flow had been completed. The total blood 
volume withdrawn from the animals before the final arterial and venous blood 
samples did not exceed 1.5mL and was compensated by the volume of fluid 
infused. 
2.1.3.1.1 Glucose and Lactate Assay 
Blood and plasma glucose and lactate was determined with a glucose 
analyser (Yellow Springs Instruments, Model 2300 Stat Plus, USA) at regular 
intervals throughout the experiments. A sample volume of 251.11., of whole blood 
or blood plasma was required for each glucose and lactate determination. The 
blood glucose assay was performed immediately after collection of the arterial 
sample. Plasma glucose was determined immediately after spinning down whole 
blood and separating the plasma into a fresh vial. 
2.1.3.1.2 Plasma Insulin Assay (ELISA) 
Plasma insulin concentration was determined from arterial plasma 
samples (kept frozen at -20 °C) using a commercial rat insulin enzyme 
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immunoassay kit (ELISA, Mercodia AB, Sweden). The detection range of the 
assay was between 0.15-5.5tig.L -I and if necessary samples were diluted to fall 
into this range. A correction factor calculation was performed on samples 
containing exogenously infused human insulin, which had 120% or 167% cross-
reactivity (depending on the kit batch) within the assay compared with rat insulin. 
Plasma insulin was determined immediately before the commencement of the 
experiment and at the conclusion of the experimental protocols. 
2.1.4 Euglycaemic Hyperinsulinemic Clamp Technique 
The euglycaemic hyperinsulinemic clamp is a method used for 
quantifying whole body insulin sensitivity in vivo and was first established by R. 
DeFronzo in humans in 1979 [340]. Soon after the clamp technique was adapted 
for use in the laboratory rat [341-343] and has since been widely used. The clamp 
consists of a continuous intravenous infusion of exogenous insulin to achieve 
elevated insulin levels which stimulates glucose removal from the plasma into the 
insulin responsive tissues such as skeletal muscle. This action is compensated by 
simultaneous infusion of exogenous glucose which is adjusted to maintain blood 
glucose at a stable basal value (euglycaemia) and represents the net effect of 
insulin on glucose metabolism. After repeated adjustments of the glucose infusion 
rate (GIR), a steady state is achieved where the glucose infusion remains constant 
and reflects the animals insulin sensitivity [341]. In the presence of insulin, in an 
insulin responsive individual, the liver responds by suppressing glucose output 
and stimulating glucose uptake. In states of insulin resistance or pharmacological 
interventions the hepatic glucose output may not be completely suppressed and 
the glucose secreted by the liver may contribute to glucose taken up by tissues in 
response to insulin. Insulin sensitivity or resistance is estimated by comparison to 
a normal control group. The clamp technique can be combined with several other 
techniques as required in order to measure various aspects of metabolism due to 
insulin [344]. The clamp can be combined with administration of glucose isotope 
tracers to estimate the glucose dynamics for whole body rates of appearance and 
disappearance of glucose and in individual muscles (section 2.1.5). During 
assessment of whole body rates of appearance (Ra) and disappearance of glucose 
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(Rd), it should be ensured that the animal is fasted which eliminates contributions 
by absorption of glucose. 
The clamp was performed on anaethetised rats as follows; a basal arterial 
blood sample was taken (200[0 and analyzed for glucose concentration (section 
2.1.3.1.1) and the remaining blood plasma was stored at -20°C for subsequent 
plasma insulin assay (section 2.1.3.1.2). The clamp commenced at the onset of a 
pre-determined fixed level of continuous insulin infusion 
(3, 10 or 20mU.min-1 .4-1 ) resulting in an elevated steady state concentration. 
Blood samples (501.IL) were taken at regular intervals from the arterial cannula to 
monitor blood glucose. The initial basal blood glucose concentration 
(euglycaemia) of each rat was kept constant by a variable infusion of glucose 
(30% w/v solution). The glucose infusion rate (GIR) was adjusted to maintain the 
basal glucose level until a steady state was achieved for glucose delivery. The 
value obtained for the GIR gave a measure of the insulin sensitivity of the rat. In 
the control experiments a saline infusion was given which matched the volumes 
of insulin and glucose administered. 
2.1.4.1 	Glucose Homeostasis 
The GIR gives a measure of insulin sensitivity and reflects the animals' 
need for glucose in the presence of exogenous insulin. The formula for the GIR 
calculated for rat weight is given as follows: 
GIR = (Si x 0.3) / Wt. 
Where Si is the setting on the infusion pump (.11—min -1 ) at time i; 0.3 is based on 
the use of a 30% glucose solution and Wt. is the rat weight in kg. The units for 
GIR are expressed as mg.min-l .kg-1 . 
The exogenously infused glucose as well as glucose secreted from the 
liver contributes to the glucose taken up by the insulin sensitive tissues. Once 
GIR has obtained a steady state, which usually takes approximately 75 minutes, 
47 
CHAPTER 2— Methods. 
the clamp technique can be combined with the administration of radio-labelled 
glucose tracers to measure the glucose homeostasis specifically in the liver and 
muscles [345, 346]. The use of radio-labelled glucose tracers for estimates of 
whole body rate of glucose disposal and muscle specific glucose uptake is 
explained in more detail in section 2.1.5.1 and section 2.1.5.2 respectively. 
2.1.5 Glucose Tracers 
Analysis of the metabolic fate of infused glucose tracers at conclusion of 
the clamp has allowed assessment to be made of insulin action at both the whole 
body and individual tissue level. Three different radio-labelled glucose tracers 
were used throughout this thesis and are listed in Table 1. Where two tracers have 
been used in the same animal a combination of 3H and 14C radiolabels was 
selected and activity was determined using a dual label counting protocol on a 
liquid scintillation counter (Perkin Elmer Inc., Tri-Carb 2800TR, IL, USA). 
Table 1: Radio-labelled glucose tracers. 
COMPOUND 
	
ABBREVIATION 	DETERMINATION 
2-Deoxy-D-[2,6-3 H] 
	
[ 3H] 2-DG 	 muscle glucose uptake 
glucose 
2-Deoxy-D-[1- 14C] glucose 	[ 14C] 2-DG 	 muscle glucose uptake 
D-[3-3H] glucose 	 [ 3 H] glucose 	whole body rate of glucose disposal 
2.1.5.1 	Whole Body Rate of Glucose Disposal 
The whole body rate of glucose disposal can be calculated from the rate of 
glucose disappearance from plasma (Rd). With it, Ra (rate of glucose appearance) 
can be calculated according to the formula Ra = Rd — GIR, giving an estimation 
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of the liver insulin sensitivity [345]. During this procedure the animal should be 
fasted so that glucose contributions arising from the gut are eliminated. 
In experiments measuring glucose turnover, a primed (2pCi bolus in 
0.2mL saline), continuous (0.1p.Ci.min-1 ) dose of [ 3H] glucose (specific activity = 
16.6 Ci.mmo1 -1 , Amersham Pharmacia Biotech) was infused during the final 60 
minutes of the experiment when glucose homeostasis had attained steady state. 
Arterial plasma samples were taken at 105 and 120 minutes and were 
de-protenated. A 25uL sample of the supernatant was evaporated to dryness using 
a freeze dryer (iLshin Lab Co. Ltd. Netherlands) to remove 3H20 and re-
suspended in 100[EL of distilled H 20. Biodegradable counting scintillate BSC 
(Amersham, Arlington Heights, IL) was added to each sample and [ 3 H] glucose 
radioactivity was determined using a liquid scintillation analyser (Perkin Elmer 
Inc., Tri-Carb 2800TR, IL, USA). The rate of appearance (Ra) and rate of 
disappearance (Rd) of glucose was calculated using the isotope dilution equation 
Ra = Rd = F/SA, 
where F is the rate of tracer infusion and SA is the specific activity of glucose 
[342]. SA was calculated from the plasma radioactivity divided by the glucose 
concentration. 
2.1.5.2 	Muscle Specific Glucose Uptake (R'g) 
The muscle specific glucose uptake assay relies on the principle that 
2-Deoxy-D-[2,6-3H]glucose (2-DG) is taken up by the cell, via the normal 
transport process and is phosphorylated to 2-Deoxy-D-[2,6- 3H]glucose 
phosphate. This compound cannot be metabolized any further and accumulates in 
the tissue. The rate of glucose uptake for muscle tissues can be calculated 
according to the amount of tracer accumulation of 2-DG phosphate in muscle and 
the amount of 2-DG disappearance from the plasma [347, 348]. 
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In experiments measuring glucose uptake into individual muscles, a 
501tCi bolus (in 0.2mL saline) of 2-Deoxy-D-[2,6- 3 H] glucose ([ 3H] 2-DG) 
(specific activity = 44.0 Ci.mmo1 -1 , Amersham Life Science, Castle Hill, NSW, 
Australia) was administered 45 minutes before the end of the experiment via the 
venous cannula. The tracer bolus was flushed into the animal with a bolus of 
saline (1004) to ensure complete delivery of the tracer. In experiments where 
Ra and Rd were determined using the [ 3H] glucose tracer, a 40i.iCi bolus of 2- 
Deoxy-D-[1- 14C] glucose ([ 14C] 2-DG) (specific activity = 56.0 mCi.mmor l , 
Amersham Life Science, Castle Hill, NSW, Australia) was used in order to 
individually quantify the tracers. Blood samples were taken at 5, 10, 15, 30 and 
45 minutes following the injection (45 minute sampling protocol) and the plasma 
was separated. The plasma (254) was added to 3mL of biodegradable counting 
scintillant-BCA (Amersham, USA) and the rate of clearance of [ 3 I-1] 2-DG or 
[ I4C] 2 -DG was determined over the 45 minute time course. After the final blood 
sample the animal was euthanised at the end of the experiment before immediate 
removal of the muscle samples. Soleus, plantaris, red and white gastrocnemius, 
extensor digitorum longus (EDL) and tibialis muscles were excised and freeze 
clamped using liquid nitrogen cooled tongs and stored at -20 °C until assayed for 
[ 3 H] or ([ 14C] 2-DG uptake. 
Individual frozen muscles from the clamps were ground under liquid 
nitrogen. Approximately 100mg of ground tissue was homogenized in 1.5mL of 
distilled water using a Silent Crusher M (Heildorf, Germany). The homogenate 
was centrifuged at 13,000 rpm at 4°C to eliminate debris. A sample of the 
supernatant (1004) was placed in a scintillation vial and 3mL of scintillation 
liquid was added, mixed and counted in a scintillation counter. A lmL sample of 
the supernatant was loaded into prepared resin columns containing approximately 
lmL of ion exchange resin (AG1-X8, Bio-Rad, USA). Free and phosphylorated 
[ 3 
 
H] or [ 14C] 2-DG were separated and collected from the column using distilled 
water and 2M HC1 washes. Biodegradable Counting Scintillant-BCA, 
(Amersham, USA) was added to each radioactive sample and radioactivity 
determined using a liquid scintillation counter (Perkin Elmer Inc., Tri-Carb 
2800TR, IL, USA). From this measurement and knowledge of plasma glucose, 
the time course of plasma [ 3H] 2-DG disappearance, which reflects glucose 
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uptake into the muscle, was calculated as previously described by others [345, 
346, 348]. The measurement for R'g is expressed as [tmol.min -1 .100g-I or [tg.g - 
1 	• 	- .mm I  ) 
2.1.6 Experimental Protocols 
Experimental groups were generally allocated into either control group 
(saline), hyperinsulinemic euglycaemic insulin clamp (insulin alone or insulin 
plus test substance) or test substance alone control group. 
2.1.6.1 	Wortmannin Protocol 
After placement of all cannulae, Transonic flow probe and a 60 minute 
equilibration, rats were infused for 3 hours with either 0.5% (v/v) 
dimethysulfoxide (DMSO) or wortmannin (111g.min -l .ke , Sigma Chemical Co., 
St. Louis, MO) in 0.5% DMSO as shown in (Chapter 3, Figure 10, page 71). 
Wortmannin infusions were initiated by a bolus injection of 2.51g in 0.20mL 
saline at t = -60 minutes. One hour later (t = 0 minutes) saline or insulin 
(10mU.miri l .kg-I , Humulin R Eli Lilly, Indianapolis, IN) infusion was 
commenced (Chapter 3, Figure 10, page: 71). 
2.1.6.2 	Local L-NAME Protocol 
Once the surgery was completed, a 60 minute equilibration period was 
allowed, rats then entered a protocol where they received either local saline or 
local L-NAME (10[tM final concentration calculated from the femoral blood 
flow) in the test leg (Details are given in Chapter 4, Figure 18). At 15 minutes 
after the commencement of the local infusion rats underwent a euglycaemic 
insulin clamp (3mU.kg-l .miri l , Humalin R, Eli Lilly & Co., Indianapolis) or 
received saline alone. 
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2.1.6.3 AICAR Protocols 
Once the surgery was completed a 60 minute equilibration period was 
allowed, rats then entered a protocol (Chapter 5, Figure 25, page122 and Chapter 
6, Figure 35, page 147) where they underwent a euglycaemic insulin clamp 
(3mU.kg-i .min-1 , Humalin R, Eli Lilly & Co., Indianapolis) or received saline 
alone. Animals receiving AICAR were administered a bolus of 5mg in 0.20mL 
saline, followed by a continuous intravenous infusion of 3.75mg.kg-i .min-1 for 60 
minutes. 
2.1.7 Infusate Preparation 
	
2.1.7.1 	Insulin 
Insulin (Humalin R, Eli Lilly & Co., Indianapolis) was diluted 1:10 with 
2% bovine serum albumin (BSA, `Bovostar', Bovogen Biologicals, VIC, 
Australia) in order to prevent adhesion of insulin to glass ware and plastic 
surfaces. The insulin infusate is then prepared in heparinised saline to a desired 
concentration calculated according to rat weight and infused at a constant rate of 
101.11-min-1 for 1 to 2 hours (see individual chapters). 
2.1.7.2 	Glucose 
Glucose (30% w/v solution, glucose monohydrate, Merck, Darmstadt, 
Germany) was dissolved in heparinised saline using heating to 50 °C and then 
filtered using a 0.45tim syringe filter. 
2.1.7.3 	1-MX and Allopurinol 
The 1-methylxanthine (1-MX, Sigma-Aldrich, Inc., St. Louis, MO, USA) 
infusion solution was made to a final concentration of 30mM by dissolving in 
30mM NaOH heparinised saline solution with heating to 50 °C. Allopurinol ( 
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Sigma-Aldrich, Inc., St. Loius, MO, USA) was made to a final concentration of 
12.5 mM by dissolved in 20mM NaOH heparinised saline solution. 
	
2.1.7.4 	Microbubbles 
Commercially available albumin microbubbles (OptisonTM,  Molecular 
Biosystems Inc., San Diego, CA, USA), composed of an albumin shell and a 
perfluropropane gas core, were used as a contrast agent to image the vasculature. 
Microbubbles were diluted 1:50 in saline gassed with perfluropropane and 
infused at 40p.L.min -I via a dedicated venous cannula (PE-20 tubing). 
2.1.8 Techniques for Measuring Microvascular Perfusion 
Two techniques employed for measurement of microvascular perfusion 
are contained within this thesis which include the 1-MX method and contrast 
enhanced ultrasound (CEU). The 1-MX method is a biochemical technique which 
is an end-point determination made at steady state. In contrast, using the CEU 
technique, it possible to make end point determinations as well as continually 
measure changes in microvascular perfusion during a time course. A study by 
Vincent et al. [60] has demonstrated that the two techniques are comparable for 
assessing microvascular perfusion in the rat hindlimb. 
The 1-MX method was used for studies involving wortmannin and L-
NAME. The CEU technique was utilised in the AICAR studies as it was not 
possible to use the 1-MX technique with AICAR due to interference with the 
measurements. 
2.1.8.1 	1-MX Metabolism Measurements 
The technique for the measurement of in vivo insulin-mediated 
haemodynamic changes in skeletal muscle microvascular perfusion, by 
metabolism of exogenously added 1-methylxanthine (1-MX, Sigma Aldrich Inc., 
St. Louis, MO, USA) was developed and by Rattigan and Clark et al. [49] in 
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1997. Microvascular perfusion was determined by measuring the metabolism of 
infused 1-MX, a substrate metabolized by xanthine oxidase (XO) which converts 
I-MX to a single product 1-methylurate (1-MU) [49, 349]. Both 1-MX and 1-MU 
are non-vasoactive [49]. In the hindleg muscle xanthine oxidase is predominately 
located in the endothelial cells of the capillaries [50, 350]. Thus 1-MX 
metabolism across the hindleg corresponds to hindleg capillary surface area. 
I-MX was infused at a constant rate (0.4mg.min -l .kg-1 ) for 60 minutes 
prior to the conclusion of the experiment. 1-MX clearance from plasma is very 
rapid and it was necessary to partially inhibit the xanthine oxidase activity [49] 
thus lowering the K m of the enzyme, in order to maintain a constant arterial 1- 
MX concentration. To do this an injection of a specific xanthine oxidase 
inhibitor, allopurinol (Sigma-Aldrich Inc. St. Louis, MU, USA) [351] was 
administered as a bolus dose (10grnol.kg -1 ) 5 minutes prior to commencing the 
1-MX infusion. Allopurinol was rapidly converted to oxypurinol which could be 
detected until the completion of the experiment [49]. This allowed constant 
arterial concentrations of 1-MX to be maintained at a steady arterial state of 
approximately 201.IM throughout the infusion period while the arterial 
concentration of allopurinol remained at approximately 81iM. 
At the conclusion of the experiment duplicate arterial (A) and venous (V) 
samples (300 to 500gL) were collected in clean eppendorf tubes which had been 
coated in heparin and dried by evaporation at room temperature then placed on 
ice. Immediately after collection, the blood plasma was separated by 
centrifugation for 60 seconds at 13,000 rpm in a biofuge pico (Heraeus) at room 
temperature. A 100p,L sample of the plasma was added to 20p,L 2M perchloric 
acid (PCA, for protein precipitation) followed by vortexing to ensure complete 
mixing. The PCA treated samples were stored at -20 °C until assayed for 1-MX 
concentration. When required, samples were thawed on ice, centrifuged at 13,000 
rpm for 10 minutes and the supernatant used to determine 1-MX, 1-MU and 
oxypurinol concentrations by reverse-phase HPLC. The 1-MX metabolism in 
nmol.min-I was calculated from the following equation: 
1-MX metabolism (MXD) = (Art[1-MX] - Ven[1-MX]) x 0.871 x FBF 
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Where; Art[1-MX] and Ven[1-MX] are the plasma 1-MX concentrations 
(i.nnol.L-1 ) obtained from arterial and venous blood samples respectively, 0.871 is 
the factor to convert the 1-MX concentration measured in plasma to that in whole 
blood and FBF is the femoral blood flow rate (mL.min -1 ) measured immediately 
before the blood samples are withdrawn. 
For separation and quantification of 1-MX, 1-MU and oxypurinol a 
Gemini C18 5j..tm reverse phase column (4.6 x 150mm) was used (Phenomenex, 
NSW, Australia) under isocratic conditions at 1.0mUmin -1 . The buffer contained 
0.3M KH2PO4, 0.5% methanol, 0.5% acetonitrile and 0.2% tetrahydrofuran at pH 
4.0. Detection was conducted with a Varian instrument fitted with a Varian 
Polychron Model 9065 diode array detector equipped with LC Star Workstation 
reading simultaneously at wavelengths of 254 (oxypurinol), 268 (1-MX) and 
282nm (1-MU). The peaks obtained were identified by retention time and 
absorbance spectra (measured against 10011M standards) and then quantified 
using a commercial software package (Star Chromatography Workstation, 
version 6.41). 
2.1.8.2 	Contrast Enhanced Ultrasound (CEU) 
Contrast enhanced ultrasound (CEU) was used to measure microvascular 
blood volume. The OptisonTM albumin shell perfluoropropane gas filled 
microbubbles have a mean diameter of 41.tm and share a similar flow pattern to 
red blood cells through the vasculature [352]. The CEU probe can be positioned 
to allow imaging of specific regions within skeletal muscle and is not influenced 
by contributions from non-muscle tissue (skin, adipose and bone, Figure 7). The 
acoustic signal which is generated from the microbubbles exposed to ultrasound 
is proportional to the concentration of microbubbles within the volume of tissue 
being imaged. Each high energy pulse generated by the ultrasound destroys the 
microbubbles within the ultrasound beam at that time. The time between each 
successive pulse is prolonged and the area being sampled becomes progressively 
filled with microbubbles until all perfused vessels are filled, so that further 
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increases in the time between each pulse will not affect the microbubble signal in 
tissue. The rate at which the microbubbles re-appear within the ultrasound beam 
provides an indication of microvascular flow velocity and the plateau video 
intensity reached at long pulsing intervals provides a measurement of 
microvascular volume or a measure of microvascular perfusion. Once the images 
are collected, the signal from the tissue as well as larger rapid filling vessels was 
eliminated using a background subtraction (pulsing interval of 0.5 seconds, 
Figure 9), so that only the microvascular volume is observed. A linear-array 
transducer interfaced with an ultrasound system (HDI-5000, Philips Ultrasound) 
was positioned over the left proximal adductor muscle (aductor magnus and 
semimembranosus, Figure 7). Pulse imaging was performed using a L7-4 MHz 
probe with a transmission frequency of 3.3MHz and the mechanical index (a 
measure of acoustic power), set at 0.8. Gain setting were optimized and set at the 
same values for each experiment. Albumin microbubbles (OptisonTM, GE Health 
Care, USA), the contrast-enhancement agent, were diluted 1:50 with 
perfluoropropanegassed saline and infused via the left jugular vein cannula (PE-
20, Intramedice) at 40uLmin-1 for the duration of data acquisition. A 
microbubble infusion rate of 4011L.min -1 was chosen because this rate resulted in 
video intensity measurements that were well within the linear range of the 
microbubble concentration and video intensity. Images were acquired during 
continuous imaging and at pulsing intervals of 0.5, 1, 2, 3, 5, 8, 12 and 15 
seconds. The pulsing intervals chosen allowed for incremental microvascular 
(capillary) replenishment with microbubbles between each pulse until the volume 
within the beam was completely refilled [353]. Approximately 3 frames were 
acquired at each PI. Data was analysed using QLABTM  software (Version 2.0, 
Philips Ultrasound, Bothwell). The ultrasound intensity in decibels (dB) within 
the region of interest (ROT) was converted to acoustic intensity (Al). Images 
acquired at 0.5 seconds were considered to be the large rapid flow vessels 
(velocity > 0.1cm.s -1 , larger than —1001.tm [354]) and these values were 
background subtracted from images obtained at subsequent pulsing intervals, 
which represented the microvascular compartment . The background-subtracted 
video intensity at each pulsing interval (seconds) was measured from the region 
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of interest in muscle and pulsing interval versus acoustic-intensity curve was 
plotted (Figure 8 and typical trace Figure 33). 
Acoustic-intensity curves, were constructed using the following equation: 
y = A (1-e -0(t-05)) 
where; y is the acoustic intensity at a given pulsing interval, 
A is the plateau AT representing the total vascular volume being 
perfused at the current state of the muscle bed [355], 
p is the rate of Al rise and reflects the velocity of microbubbles 
[353]. 
The values of A and 0 represent the values for the microcirculation and the 
product of A and p (A x p) represent the filling velocity [59, 353]. 
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Figure 7: A section of rat thigh muscle showing video intensity (VI) image and 
region of interest (ROT) used for analysis. Perspective is essentially transverse. 
Connective tissue (used to help orientate the image) and skin are also shown. 
0 	4 	8 12 	16 20 
Pulsing Interval (seconds) 
Figure 8: A typical relation between pulsing interval and acoustic signal, 
measured as video intensity. As the pulsing interval is prolonged, the number of 
microbubbles within the capillaries increases, resulting in a higher video 
intensity. Eventually a plateau is reached where an increase in the time between 
each pulsing interval does not cause a further increase in video intensity due to 
complete replenishment of the vessels in the beam. The asymptote that intercepts 
the y-axis is the maximal video intensity signal and a measurement of 
microvascular volume (microvascular perfusion). The x-intercept of the y-axis 
A 
0 
0 
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asymptote and the tangent to the upward sloping intensity rise (p), is an indicator 
of microvascular flow velocity. Reproduced from Vincent [60]. 
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Continuous imaging 0.5 second 
2 seconds 
	
20 seconds 
I • Microbubbles absent • Microbubbles present 
Figure 9: A schematic depiction of the replenishment of microbubbles in 
capillaries and larger vessels after a pulses of high-energy ultrasound. As time 
between each ultrasound pulse is prolonged more microbubbles reappear. A 
pulsing interval of 0.5 seconds allows replenishment of large blood vessels and is 
used for background subtraction. 
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2.1.9 Muscle ZMP and AICAR Assay 
High performance liquid chromatography (HPLC) was used to determine 
ZMP and AICAR content in skeletal muscle and AICAR content in plasma, based 
on methods described by Rattigan etal. [52] and Wynants et al. [356]. 
For muscle determination; a sample of pulverized gastrocnemius muscle 
(100-200mg) was de-proteinised using perchloric acid (PCA, 0.42M) and then 
centrifuged (IEC centrifuge) at 3,000 rpm at 4 °C for 5 minutes. The supernatant 
(1mL) was transferred to a clean eppendorf tube and neutralized with K2CO3 
(230pL, 1M). The extract remained on ice for at least 10 minutes to allow 
precipitation of potassium perchlorate. The salt precipitate was removed by 
centrifugation at 13,000 rpm in a Biofuge pico (Heraes) for 5 minutes at 4°C and 
the samples were then stored at -80°C for subsequent AICAR and ZMP analysis 
using HPLC. For the plasma samples; 100p L of arterial plasma was de-
proteinised using 20pL of PCA (2M) and then centrifuged at 13,000 rpm in a 
Biofuge pico (Heraes) for 5 minutes at room temperature. The supernatant was 
stored at -20°C for subsequent AICAR analysis by HPLC. 
For separation and quantification of AICAR and ZMP a Gemini C 1 8 5pm 
reverse phase column (4.6 x150mm) was used (Phenomenex, NSW, Australia) 
using a gradient buffer system. Buffer A was composed of 174mM ammonium 
dihydrogen phosphate (NH4H2PO4) and 1.77mM tetrabutyl-ammonium hydrogen 
sulfate (TBAHS) (pH 6.0) and ran from 0 to 10 minutes while buffer B contained 
174mM NH4H2PO4, 1.77mM TBAHS and 10% acetonitrile (pH 6.0) and ran 
from 10 to 20 minutes. Detection was conducted with a Varian instrument fitted 
with a Varian Polychron (Model 9065) diode array detector equipped with LC 
Star Workstation reading at 254nm. Solutions of known amounts of the pure 
compounds AICAR (Toronto Research Chemicals, Canada) and ZMP (Sigma-
Aldrich Inc., St. Louis, MO, USA) were used as standards. The peaks obtained in 
the plasma samples were then identified by retention times and absorbance 
spectra and then quantified using a commercial software package (Star 
Chromatography Workstation, version 6.41). 
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2.1.10 Western Blots 
Tissue homogenates were subject to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) for the separation of proteins 
and further identification was determined by immunoblotting. 
The tissues for the homogenates were obtained at the end of the 
experiment. The thoracic aorta, a portion of the liver and the lower leg muscles 
(gastrocnemius group) were removed and freeze-clamped (muscles and liver in 
situ; aorta as quickly as possible after removal) using liquid nitrogen-cooled tongs 
and stored at -80°C until assayed. The frozen tissue samples were ground into a 
fine powder under liquid nitrogen and homogenized in (1/60 w/v) ice cold 
solubilizing buffer with a Silent Crusher S (Heidolph). The solubilizing buffer 
was composed of 25mM Tris (pH 7.5), 2.6M potassium fluoride and 250mM 
EDTA. The insoluble material was removed by centrifugation at 13,000 rpm in a 
Biofuge pico (Heraeus) for 10 minutes at 4°C. The protein concentration of the 
supernatants was determined using Bio-Rad Protein Assay (Bio-Rad Protein 
Assay, Bio-Rad Laboratories, Hercules, CA, USA). Aliquots of the resulting 
supernatant containing 101..tg of protein were then heated treated with 70mM Tris 
buffered (pH 6.8) sodium dodecylsulphate (2% SDS) for 5 minutes in a dry block 
heater (Ratek) for 5 minutes at 90 to 100°C. Heat treated aliquots were subjected 
to SDS gel electrophoresis run at 200V for 1 hour at room temperature using a 
pre-cast 10% Bis-Tris Gel (Invitrogen). The BenchMarkTm Pre-Stained Protein 
Ladder (Invitrogen) was used for molecular weight comparison. 
Electrotransfer of proteins from the gel to nitrocellulose membranes was 
performed at 30V (constant voltage) at 4°C over night. After transfer membranes 
were blocked with Tris Buffered Saline (TBS), 0.1% Tween-20 with 5% w/v 
nonfat dry milk for lhour. The membranes were then incubated with the primary 
antibody Phospho-Akt (Ser473) diluted at 1:2000 or Akt Antibody (Cell 
Signalling) diluted at 1:2000 in buffer containing Tris Buffered Saline (TBS), 
0.1% Tween-20 with 5% BSA overnight at 4°C. Membranes were then washed 
and incubated with the secondary horse radish linked antibody (Cell Signaling) 
diluted at 1:2000 Tris Buffered Saline (TBS), 0.1% Tween-20 with 5% w/v non- 
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fat dry milk, for 1 hour at room temperature. The membranes were developed 
using an enhanced chemiluminescence system (ECL, Progen Biosciences). 
Bound antibodies were detected by exposure to x-ray Hyper film (Amersham 
Biosciences). The protein band intensities were quantified by optical density 
using a commercial software package (DScan EX software version 3.1). 
2.2 In Vitro Experiments 
2.2.1 Animal Care 
All experimental protocols and procedures were approved by the Animal 
Ethics Committee of the Vrije University Medical Center, Amsterdam, 
Netherlands under the guidelines for Institutional Animal Care and Use. 
Male Harlan Wistar rats weighing 324 ± 9 g were obtained from the 
University Animal House (Amsterdam) and were kept at a constant temperature 
of 21 ± 0.6°C on a 12:12 hour light:dark cycle (lights on at 0600 hours). All rats 
were allowed free access to standard laboratory rat chow and water ad libitum. 
2.2.2 Preparation and Set-up for the Isolated Vessels 
Male wistar rats were anethetised with pentobarbital sodium (Nembutal; 
70mg.kg-I i.p) and ketamine (25mg.kg -I i.m). The right cremaster muscle was 
exposed by a ventral incision of the scrotal sac and cleared from connective 
tissue. The muscle was opened by an incision and the testes were removed. The 
cremaster was excised and pinned in a dissecting dish containing cold MOPS 
buffer (approximately 5 °C). The buffer consisted of 145mM NaCl, 5mM KC1, 
2mM CaC12, 1mM MgSO4, 1mM NaH2PO4, 5mM dextrose, 2mM pyruvate, 
0.02mM EDTA and 3mM 3-(N-morpholino) propanesulfonic acid. 
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A first-order arteriole (passive inner diameter 150-200 p.m) was dissected 
from the surrounding muscle and a 1-2 mm long segment was transferred to a 
pressure monograph. A video camera mounted on a microscope was connected to 
an electronic measurement system to continuously monitor inner arteriolar 
diameters. The vessel chamber contained two glass cannulas (outer diameter of 
tip —1001.tm), a circular heating coil and a thermistor. The vessel chamber was 
filled with MOPS buffer and sealed with a glass cover. The arteriolar segment 
was cannulated at one end and secured with a 20gm suture. The vessel 
preparation was pressurized to 5 mmHg and flushed to remove blood cells. The 
other end of the vessel was then cannulated and secured with a suture. The second 
cannula was then connected to a column filled with MOPS buffer. Pressure inside 
the vessel was set at 65 mmHg, which has been the reported to be in the normal 
range for first-order arterioles in the cremaster muscle of anesthetized rats [357]. 
The temperature was raised gradually to 34 °C, the in vivo temperature of a 
cremaster muscle. Experiments were performed under low flow conditions and 
vessels were exposed to vasoactive substances by adding them directly to the 
vessel chamber. 
Prior to experiments, vessel segments were super-fused with MOPS 
buffer for at least 15 minutes. Segments were then equilibrated for at least 15 
minutes. Segments were equilibrated for at least 30 minutes after the end of the 
washout period. Arterioles included in this study had to full-fill three criteria. 
First, arterioles that showed signs of leakage were excluded from the study. 
Second, the arterioles had to develop a level of spontaneous tone corresponding 
to a reduction in diameter of 40-60% of the passive diameter. Finally the 
arterioles had to dilate for a long period of time (>6 minutes) in response to the 
endothelium-dependent vasodilator acetylcholine (ACh, 0.111M) before and after 
the experiment as a measure of the endothelial integrity and stability. At the end 
of each experiment the passive (maximally dilated) diameter was assessed by 
adding papaverine (0.111M). One or more segments were obtained from one 
animal. If multiple segments from the same rat were used, each segment was 
included in a different group (e.g.; insulin and control). 
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All vasoactive substances were applied to the vessel by adding them to the 
superfusate. The Krebs buffer consisted of 110mM NaC1, 5mM KC1, 2.5mM 
CaC12, 1mM MgSO4 , 24mM NaHCO3, 1mM KH2PO4, 0.02mM EDTA and 
10mM dextrose. It was equilibrated with 5% CO2 , 21% 02 and 74% N2 at 33°C. 
This resulted in a pH of 7.4, a p02 of 150 mm Hg and a pCO2 of 35mm Hg at 
33 °C (measured by a blood gas analyser, ABL-33; Radiometer, Copenhagen). 
2.2.3 Isolated Endothelial Cells 
Human microvascular endothelial cells (MVEC) were isolated as 
described previously [358, 359]. Human microvascular endothelial cells were 
isolated from the human foreskin and cultured in medium 199 supplemented with 
20mmol. L-1 HEPES (pH 7.3), L-glutamine and penicillin/streptomycin 
(BioWhittaker), newborn calf serum (Gibco), a crude preparation of endothelial 
cell growth factor (prepared from bovine brain) and human serum (obtained from 
a local blood bank). Human serum albumin was from Sanguin CLB (Amsterdam, 
the Netherlands). 
2.3 Data Analysis 
All data is expressed as means ± SE. Mean femoral blood flow (FBF), 
mean heart rate (HR) and mean arterial blood pressure (MAP) were calculated 
from 5 second sub-samples of the data, representing approximately 500 flow and 
pressure measurements every 15 minutes. Vascular resistance in the hind leg was 
calculated as mean arterial blood pressure in millimeters of mercury divided by 
femoral blood flow in milliliters per minute expressed as resistance units (R.U). 
Glucose uptake in the hindlimb was calculated as pmol.min -I . 
2.4 Statistical Analysis 
Details are given in individual chapters. 
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CHAPTER 3— Acute Effects of Wortmannin on Actions of Insulin In Vivo. 
3.1 INTRODUCTION 
Wortmannin first received widespread attention in 1987 as an inhibitor of 
agonist-induced superoxide anion production (respiratory burst) in neutrophils [360, 
361]. This was studied by Baggiolini etal. [360] who demonstrated that sub-micro 
molar concentrations of wortmannin were able to inhibit the respiratory burst in 
neutrophils induced by a number of receptor agonists, including N-
formylmethionylleucylphenylalanine (fMLP), C5a, leukotriene B4 (LTB4) or platelet 
activating factor (PAF). Studies using platelets later revealed the inhibitory effects of 
wortmannin appeared to be specific to types of G-protein-coupled receptors [362], 
however cellular processes triggered by phorbol esters were not effected [133]. 
Studies using adipose cells demonstrated that micro molar amounts of wortmannin 
inhibited insulin-stimulated glucose utilization in vitro without affecting the insulin 
receptor tyrosine kinase activity [135]. Studies using neutrophils identified the target 
for wortmannin inhibition in these cells to be at phophatidylinositol 3,4,5- 
triphosphate [PtdIns (3,4,5)P3] formation from phosphatidylinositol 4,5-bisphosphate 
[PtdIns (4,5)P2] by the enzyme phosphoinositide 3-kinase (PI3K) [133]. The 
concentrations of wortmannin required for the inhibition of PI3K in neutrophils were 
similar to those reported for the inhibition of fMLP-stimulated superoxide production 
by the same cell. From these observations it was noted that PI3K was the common 
site of wortmannin action for both the G protein-coupled fMLP receptors and those 
leading to superoxide formation [361, 363, 364]. Further evidence for the association 
between wortmannin inhibition and PI3K was observed using adipose cells treated 
with insulin which showed that wortmannin abolished the enhanced PI3K activity 
produced by insulin stimulation. Wortmannin blockade of PI3K activity due to 
insulin was also shown to effect metabolic outcomes resulting from insulin action, 
including 2-deoxyglucose uptake [135], reduction of13-adrenergic agonist induced 
lipolysis [135, 365] and cyclic AMP (cAMP) phosphodiesterase activation [365]. In 
addition, studies using Chinese hamster ovary (CHO) cells tranfected with the insulin 
receptor showed that wortmannin blocked translocation of GLUT4glucose 
transporters to the surface of the cell membrane in response to insulin [366]. 
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After the establishment of wortmannin as a potent and selective inhibitor of 
PI3K [132, 363, 364, 367, 368], it was found that it could act by covalently and 
irreversibly binding to the catalytic p110 subunit of PI3K [367, 369] as well as 
alkylate a lysine residue at the ATP-binding site of p110a [370]. Concentrations of 
wortmannin which fully inhibit PI3K have little effect on other signalling molecules. 
At nanomolar concentrations wortmannin has no effect on the functioning of myosin 
light-chain kinase (MLCK), protein kinases A, C and G [367], or kinases 
downstream of PI3K in insulin signalling such as components of the calmodulin-
dependant, cAMP dependant and cGMP-dependant protein kinases [371]; mitogen-
activated protein kinase [135] and p70 s6K [372, 373]. In skeletal muscle nanomolar 
concentrations of wortmannin can inhibit PI3K insulin-mediated glucose uptake 
[177, 374]. In contrast hypoxia and muscle contraction which both act to increase 
glucose uptake are not inhibited by wortmannin in rat skeletal muscle [136, 374]. 
Wortmannin at nanomolar concentrations, on the other hand has been shown to 
inhibit a number of signalling components including phospholipases such as PIP2- 
phospholipase C, phospholipase D and phospholipase A2 [375] and has also been 
shown to be non-selective within the PI3K family [134]. Although wortmannin 
selectively inhibits PI3K at very low concentrations, a number of other signalling 
pathways have the potential for cross-interferences when exposure to wortmannin is 
for extended periods [134]. 
Some studies involving the in vivo use of wortmannin have reported various 
toxic side effects in animals [376, 377]. Other in vivo studies have used wortmannin 
to test effects on tumour growth [378-380] and bone re-absorption [381] but have not 
examined effects on insulin action in vivo. It has been reported previously that when 
insulin is administered in vivo insulin-mediated microvascular perfusion is an early 
[27] and sensitive [63] event in muscle which aids delivery of insulin and nutrients. 
It has not been established if insulin-mediated microvascular perfusion in vivo is 
wortmannin sensitive, which requires intact associations between the 
microvasculature and muscle, as opposed to previous in vitro studies. 
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3.1.1 Aim of the Study 
The aim of the present study was to apply wortmannin acutely before and 
during a hyperinsulinemic euglycaemic clamp in rats in vivo to assess effects on 
haemodynamics and metabolic processes. 
3.2 RESEARCH AND DESIGN METHODS 
3.2.1 Animals 
Male hooded Wistar rats weighing 245 ± 3 g were raised in the University of 
Tasmania Animal House as described in section 2.1.1. These experiments were 
performed in accordance with the guidelines of the University of Tasmania Ethics 
Committee. 
3.2.2 In Vivo Experiments 
Hyperinsulinemic euglycaemic clamps were performed in non-fasted 
anesthetized rats as described in section 2.1.2. Once the surgery was completed, a 
period of equilibration of approximately 60 minutes was allowed so that leg blood 
flow and pressure could become stable and constant. Femoral blood flow in one leg 
was continuously measured from a Transonic ® flow probe positioned around the 
femoral artery. 
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3.2.3 Experimental Protocols 
The experimental protocols are shown in Figure 10. Rats were randomly 
allocated into one of the five experimental groups out lined in Table 2 (n = 8 per 
group). Rats received infusion 1 from -60 to 120 minutes and infusion 2 from 0 to 
120 minutes (see Table 2). 
Table 2: Treatment combinations for the five experimental groups (n = 8 per 
group). 
Group Infusion 1 	 Infusion 2 	 Abbrev. 
(-60 to 120 minutes) 	(0 to 120 minutes) 
1 	DMSO 	 saline 	 DS 
2 	Wortmannin (111 g.min-l .kg-1 ) 	saline 	 WS 
3 	Wortmannin (1jig.min -1 .14 1 ) 	insulin (10mU.min -1 .kg1 ) 
4 	DMSO 	 insulin (10mU.min -l .kg1 ) 	DI10 
5 	DMSO 	 insulin (20mU.min-1 .kg-1 ) 	D120 
Rats were infused with 0.5% (v/v) dimethysulfoxide (DMSO) or wortmannin 
(lug.min -1 .kg1 , Sigma Chemical Co., St. Louis, MO, USA) in 0.5% DMSO (Figure 
10). Wortmannin, which is insoluble in acieous solutions, was dissolved in 0.5% 
DMSO which was the vehicle for wortmannin.Wortmannin infusions were initiated 
by a bolus injection of 2.5tig in 0.20mL saline at t = -60 minutes (Figure 10) 
followed by a constant infusion (jugular vein) for 3 hours at ltig.min -1 .kg -1 . One hour 
later (t = 0 minutes) saline or insulin infusions (10 or 20mU.min -l .kg1 , Humulin R 
Eli Lilly, Indianapolis, IN, USA) were commenced and continued for 120 minutes 
(Figure 10). Glucose infusion 30% (w/v) was commenced 2 minutes after the 
commencement of insulin infusions at a rate to maintain euglycaemic assessed from 
arterial blood glucose samples. At t = 55 minutes a bolus injection of allopurinol (10 
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grnol.kg-1 ) was administered followed by infusions of 1-MX (0.4 mg.min -l .kg-1 .) and 
[3- 3H) glucose (0.11.1Ci.min -1 ). Infusions are indicated by the bars (Figure 10). 
Bolus 
Wortmannin 
(10pg.kg4 ) 
P 	 A-V 
o 	o 	• 0 0 • • 0 0 0 0 0 0 
1 	I 1 1 I 	1 1 1 I 1 	1 1 	1 	1 1 	1 1 1 1 1 I 	1 1 1 I 	1 1 1 Ill 1 1 	1 	1 1 	1 
-60 	-40 	-20 	0 	20 	40 	60 	80 	100 120 
DMSO or Wortmannin 
Saline or Insulin & Glucose 
1-MX & [3-3 1-figlucose 
d 
Bolus 
Allopurinol 
(10pmol.ke) 
Figure 10: Arterial and venous samples were collected at the times indicated as A-V 
for HPLC analysis and plasma glucose determination. Arterial blood glucose 
concentration was determined at times indicated by 0. Venous infusion periods are 
indicated the bars. Bolus infusion periods are indicated by 6. 
3.2.3.1 	Microvascular Perfusion 
Microvascular perfusion was determined by measuring the metabolism of 
infused 1-MX (Section 2.1.8.1). 1-MX was infused intravenously at a constant rate 
of 0.4 mg.min-l .kg-1 during the last 60 minutes of each experiment. A bolus injection 
of allopurinol was given in the carotid artery 5 minutes before the commencement of 
1-MX infusion (Figure 10). Allopurinol is converted to oxypurinol, the major 
inhibitor of the enzyme xanthine oxidase (details in section 2.1.8.1). At the end of the 
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experiment arterial (A) and femoral vein (V) blood samples were taken. Hind leg 
glucose uptake and 1-MX metabolism was calculated from the arterio-venous (A-V) 
difference multiplied by the flow value immediately before the A sample was taken. 
1-MX metabolism is an indicator of the perfused microvascular surface area as 
described in section 2.1.8.1. 
	
3.2.3.2 	Muscle Specific Glucose Uptake (R'g) 
At 45 minutes prior to the completion of the experiment, a 501.ICi bolus of 
[ 14C]2-DG was administered. Plasma samples (25gL) were collected at 5, 10, 15, 30 
and 45 minutes after the 2-DG injection to determine the time course for plasma 
radioactive decay. At the conclusion of the experiment, the muscles were removed, 
freeze clamped in liquid nitrogen and stored at -20 °C until 2-DG radioactivity assay 
as described in section 2.1.5.2. 
3.2.3.3 Whole Body Rate of Glucose Disposal 
A primed 211Ci continuous (0.111Ci.min -1 ) dose of D-[3- 3H] glucose was 
infused during the final 60 minutes of the experiment so that glucose homeostasis 
could obtain a steady state. Arterial plasma samples were taken at 105 and 120 
minutes to determine the plasma [ 3H] glucose radioactivity so that the rate of hepatic 
glucose disappearance (Rd) and rate of hepatic glucose appearance (Ra) could be 
calculated (details are given in 2.1.5.1). 
3.2.3.4 	Blood Sampling 
Arterial samples were taken at the times indicated (Figure 10) for blood 
glucose measurements. An arterial blood sample (0.5mL) was taken from the carotid 
artery at the end of the experiment. This blood sample was used for 1-MX assay and 
[3-3 H]-glucose specific activity measurement. A sample of venous blood (0.5mL) 
was taken from the femoral vein of left leg and was used for subsequent 1-MX assay 
and HLGU assay. A glucose analyser (Model 2300 Stat plus, Yellow Springs 
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Instruments, Yellow Springs, OH, USA) was used to determine whole body glucose 
(by the glucose oxidase method) during the insulin clamp. 
3.2.4 Plasma Insulin Assay 
Arterial plasma samples were taken before the commencement and at the end 
of the experimental procedures. Additional experiments were conducted to examine 
the time course increases of plasma insulin with wortmannin alone treatment. Plasma 
insulin was determined using the ELISA assay (ELISA, Mercodia AB, Sweeden) 
using rat insulin standards (section 2.1.3.1.2). 
3.2.5 Western Blots for P-Akt 
Tissue samples for the homogenates were obtained at the end of the 
experiment. Liver, muscle (taken in situ) and aorta (as quickly as possible after 
euthanising the rat) samples were removed and freeze clamped using liquid nitrogen 
cooled tongs and then stored at -80 °C for subsequent determination of P-Akt and 
Akttotat by Western blot analysis (section 2.1.10) 
3.2.6 Data Analysis 
All data are expressed as means ± SE. Data analysis was conducted as 
described in section 2.3. 
3.2.7 Statistical Analysis 
Repeated measures two-way analysis of variance was used to test the 
hypothesis that there were no differences between treatment groups for change in 
heart rate, change in blood pressure, change in femoral blood flow and change in 
vascular resistance through out the time course. When a significant difference (P < 
0.05) was found, pair wise comparisons by the Student-Newman-Keuls post hoc test 
were used to determine at which sampling times the differences were significant. 
Statistical significance of differences between treatments for arterial glucose (at the 
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end of the experiment), plasma insulin, GIR (at the end of the experiment), HLGU, 
Ra, Rd, microvascular perfusion and the ratio of P-Akt/Akttotal, arterial 1-MX 
concentration (data not shown) and oxypurinol concentration (data not shown) were 
determined by one way ANOVA. The ratio of P-Akt/Akt totai were determined by two 
way ANOVA. When a significant difference (P <0.05) was found, pair wise 
comparisons by the Student-Newman-Keuls post hoc test were used to determine at 
which sampling times the differences were significant. These tests were performed 
using SigmaStatTM statistical program (Jandel Software, version 2.03) 
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3.3 RESULTS 
3.3.1 Plasma Insulin and Glucose 
Table 3 shows blood glucose (BG) and plasma insulin values measured at the 
end of the experiment for each of the five protocols: DS, WS, W110, D110 and D120. 
The BG values were similar for all five protocols (ie., —5mM). In protocols involving 
insulin infusion, concentrated glucose (30%) solution was infused in order to 
maintaining blood glucose at a constant basal value (Figure 12B-C). The plasma 
insulin values show significant differences between the groups. Insulin infusions of 
10 and 20mU.min-l .kg-1 increased the basal value of 410 ± 49 to 1680 ± 430 and 
5060 ± 320 pM respectively. Wortmannin treatment alone significantly increased 
plasma insulin to approximately 5,000 pM (Table 3) and this was not further 
increased by co-infusion of 10mU.min-l .kg-1 insulin and wortmannin. In summary all 
groups involving wortmannin treatment as well as 20mU.min -1 .14 1 insulin had a 
plasma insulin value of approximately 5000 pM at the end of the experiment (Table 
3). 
The time course for plasma insulin during the wortmannin treatment is shown 
in Figure 11. Plasma insulin increased significantly after 2 hours of wortmannin 
infusion and continued to increase to approximately 5,000 pM by the end of the 3 
hour infusion period. 
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Table 3: Blood glucose and plasma insulin values at the end of the experiments. 
Details are given in Figure 10. 
TREATMENT DS DIDD D120 WS Wfio 
Blood Glucose 
(mmo1.1: 1 ) 
Plasma Insulin 
(pmo1.1: 1 ) 
5.47 ± 0.23 
410 ± 49t# 
5.22 ± 0.12 
1680 ± 430*t 
4.81 
5060 
± 0.011 
± 230*# 
5.36 0.31 
5450 ± 770*# 
4.64 ± 0.3 
4090 ± 490*# 
Values are means ± SE from groups (n = 8) determined at t = 120 minutes: vehicle 
(dimethylsulfoxide) + saline (DS), vehicle + insulin 10mU.min -l .kg-1 (DI10), vehicle 
+ insulin 20mU.min-l .kg-1 (DI20), wortmannin + saline (WS) and wortmannin + 
insulin 1 OmU.min -l .kg-1 (W110). * Significantly different (P<0.05) from DS values; 
# Significantly different from DI 1 0; t significantly different from D120. 
Plasma Insulin 
4..... 9000 
.--! 
Z 6000 
E 
0. 
5. 3000 z cf) C 
* 
-60 -30 	0 	30 60 90 120 
Time (min) 
Figure 11: Time course for plasma insulin during wortmannin alone treatment. 
Details are given in Figure 10. Values are means ± SE. * Significantly different 
from 
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t = -60 minute values (n = 4). 
3.3.2 Glucose Metabolism 
Figure 12 shows time courses for blood glucose (BG) for each of the five 
experimental groups and glucose infusion rate (GIR) for experimental groups 
involving insulin. During the wortmannin + saline treatment, blood glucose started to 
increase approximately 40 minutes after saline infusion but this increase returned to 
baseline values by the end of the experiment (Figure 12A). During the insulin clamp 
conditions, blood glucose was maintained at euglycaemia by infusion of 30% 
glucose (Figure 12B). Figure 12C shows the time course data for the glucose 
infusion rate (GIR) required to maintain euglycaemia which is an index of insulin 
sensitivity. Co-infusion of wortmannin with 10mU.min -l .kg-1 saw an initial rise 
followed by a decrease in the GIR in the first 30 minutes which took approximately 1 
hour to stabilise. Values for GIR at the end of the experiment are shown in Figure 
13A. Both doses of 10 and 20mU.min -1 .kg-1 caused an increase in glucose 
requirement to maintain euglycaemia, while wortmannin showed a significant 
inhibition of glucose disposal in the 10mU.min -l .kg1 insulin group (Figure 12C). 
Hind leg glucose uptake (HLGU, Figure 13B) calculated from the A-V 
difference (glucose extraction) multiplied by the FBF showed a significant 
stimulatory effect in the both 10 and 20mU.min -1 .kg-1 insulin groups. Wortmannin 
alone was also stimulatory but a combination of wortmannin plus 10mU.min -l .kg-1 
insulin was lower than 20mU.min -1 .14 1 insulin alone (Figure 13B), despite 
equivalent plasma levels. Values for rate of appearance (Ra) and rate of 
disappearance (Rd) are shown in Figure 13C-D. Rd is an index of the whole body 
glucose disappearance rate during insulin stimulation and Ra is calculated as the 
difference between the GIR and Rd and reflects the liver insulin sensitivity (Details: 
Chapter 2: section 2.1.5.1, page 48). Ra was significantly inhibited by both doses of 
insulin. Wortmannin alone significantly increased Ra by approximately 30% 
compared with saline. When insulin 10mU.min -l .kg-1 and wortrnannin were 
combined Ra was significantly increased, demonstrating the ability of wortmannin to 
prevent insulins suppression of Ra. Values for Rd followed a similar pattern to 
HLGU, with each dose of insulin stimulating glucose uptake by 72 and 144 
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umol.min-l .kg-1 for 10 and 20 mU.min-l .kg-1 insulin respectively (Figure 13D). The 
wortmannin treatment alone significantly increased Rd and wortmannin and 
10mU.min-l .kg-1 insulin showed no significant difference from wortmannin alone. 
The combination of wortmannin and 10mU.min -l .kg1 insulin was lower than 
20mU.min-l .kg-1 , even though the plasma insulin levels for these two groups were 
similar (Table 3). 
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Saline 
	 Insulin 
Blood Glucose Blood Glucose 
Glucose Infusion Rate 
20 	40 	60 	80 	100 120 
Time (min) 
Saline 
	
Insulin 
—II— Insulin 20mU.min -1 .kg -1 
—0— Saline 	 —0— Insulin 10mU.miri 1 .kg -1 
—II— Saline + wortmannin 	—v— Insulin 10mU.min -1 .kg -1 + wortmannin 
Figure 12: Time course for the effect of wortmannin on blood glucose (BG) 
in control (saline, A) and insulin infusions (B) and for whole body glucose infusion 
rate (GIR, C) to maintain euglycaemia in insulin clamps. Details are given in Figure 
10. Values are means ± SE (n = 8 per group). 
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Figure 13: Glucose infusion rate (GIR, A), hindleg glucose uptake (HLGU, 
B), glucose appearance (Ra, C) and glucose disposal (Rd, D). Details are given in 
Figure 10. Values were determined at the end of the experiment and are means ± SE. 
* Insulin treated significantly different (P<0.05) from corresponding saline treated 
values; # Wortmannin treated significantly different from corresponding vehicle 
treated values. i• 20mU.min -l .kg-1 insulin significantly different from 
larnU.min-1 .kg-1 treated (n = 8 per group). 
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3.3.3 Haemodynamic Effects 
Figure 14 shows the time courses for change in heart rate (AHR) and blood 
pressure (ABP) and Figure 15 shows the time courses for change in femoral blood 
flow (AFBF) and vascular resistance (AVR) over the preceding 60 minutes before 
and during saline (control) or 120 minute hyperinsulinemic euglycaemic clamp. 
Figure 14A-B shows the AHR for all groups. Wortmannin + saline caused a 
gradual decrease in HR compared with saline which was significant beginning at 
t = -15 minutes and concluding at t = 60 minutes then gradually returning to near the 
basal rate until the conclusion of the experiment (Figure 14A). The HR in the 
wortmannin + insulin 10mU.min -1 .kg1 group followed a similar pattern to that of 
wortmannin alone group. The HR in the wortmannin + insulin group was 
significantly decreased compared with insulin from t = 0 until t = 60 minutes, then 
gradually returned to near the basal rate until the conclusion of the experiment 
(Figure 14B). There were no significant differences between the HR in the 
10 mU.min-l .kg-1 insulin and the 20mU.min -l .kg-1 insulin groups (Figure 14B). 
Figure 14C-D shows ABP for all groups. During the wortmannin + saline 
treatment, there was a significant increase in BP which began at approximately the 
same time as the decrease in heart rate (t = -15 minutes) and remained significantly 
increased until the end of the experiment (Figure 14C). There was also an increase in 
BP in the wortmannin + insulin 10mU.min -l .kg-1 co-infusion group which began at t 
= -30 minutes and followed a similar pattern to the wortmannin + saline group. There 
were no significant differences between the BP in the 10 mU.min -l .kg-1 insulin and 
the 20mU.min-l .kg1 insulin groups (Figure 14D). 
Figure 15A-B and Figure 15C-D show the effects of wortmannin and insulin 
on AFBF and AVR for all groups. Both 10mU.min -l .kg-1 and 20mU.min-l .kg-1 
insulin groups gradually increased FBF, by approximately 0.5m1.min -1 compared 
with the basal value, over the time course of the experiment after the commencement 
of insulin infusion (Figure 15B). Groups which included wortmannin (wortmannin + 
saline and wortmannin + 10mU.min -l .kg1 insulin) resulted in a decrease in the FBF 
below basal. In the wortmannin + saline group there was a trend for the FBF to 
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decrease below basal at t = 45 minutes and this trend continued until the end of the 
experiment, attaining significance for the last 15 minutes of the experimental period 
(Figure 15A). During the wortmannin + insulin treatment there was a significant 
decrease below basal values at t = 30 minutes which continued to significantly 
decrease until the end of the experiment (Figure 15B). In summary, wortmannin + 
insulin 10mU.min-l .kg1 lowered the FBF below that of 20mU.min d .kg-1 insulin and 
so blocked the stimulatory effects that insulin has on FBF, as each group had a 
similar value for plasma insulin (Table 3). 
Figure 15C-D shows the effect of wortmannin on VR. Wortmannin caused a 
significant increase in vascular resistance in both wortmannin + saline and 
wortmannin + 10mU.min -I le insulin groups which became significant at t = 15 
minutes and t = 30 minutes respectively and continued to steadily increase until the 
conclusion of the experiment (Figure 15C-D). 
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Figure 14: Time course for the effect of wortmannin on changes in heart 
rate (AHR, A & B) and blood pressure (ABP, C & D) in control (saline) and insulin 
infusions. Details are given in Figure 10. Values are given as means ± SE. * 
Indicates a significant difference (P<0.05) between wortmannin + saline treatment 
and vehicle + saline treatment. # Indicates a significant difference between 
wortmannin + insulin treatment and both vehicle + insulin treatments (n = 8 per 
group). 
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Figure 15: Time course for the effect of wortmannin on changes in femoral 
blood flow (AFBF, A & B) and vascular resistance (AVR, C & D) in control (saline) 
and insulin infusions. Details are given in Figure 10. Values are given as means ± 
SE. * Indicates a significant difference (P<0.05) between wortmannin + saline 
treatment and vehicle + saline treatment. # Indicates a significant difference between 
wortmannin + insulin treatment and both vehicle + insulin treatment (n = 8 per 
group). 
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3.3.4 1-MX Metabolism: Microvascular Perfusion 
Microvascular perfusion, measured by MXD and determined by the A-V 
differences and FBF at the end of the experiment (t = 120 minutes) is shown in 
Figure 16. There were no significant differences in arterial 1-MX or oxypurinol 
concentration (data not shown) beween all five experimental groups. The mean 
arterial 1-MX concentration and mean oxypurinol concentration was 22.29 ± 0.089 
gmol.L-1 and 4.86 ± 0.15 gmol.L -1 respectively. Insulin 10mU.min1 .kg-1 
significantly increased MXD compared with the saline control. Wortmannin alone 
was not significantly different from saline. Wortmannin plus 10mU.min -l .kg-1 insulin 
was also not significantly different from saline indicating that the stimulatory effects 
insulin had to increase MXD had been completely blocked by wortmannin (Figure 
16). 
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Microvascular Perfusion 
Saline 	Insulin 
Insulin Saline 
CI Saline 	 I 	I insulin 10mU.min -1 .kg-1 
NM Saline + wortmannin NM insulin 10mU.min -1 .kg-1 + wortmannin 
Figure 16: Effect of wortmannin, insulin and a combination of wortmannin + insulin 
on hindleg muscle microvascular perfusion determined from 1-MX metabolism. 
Details are given as in Figure 10. Values were determined at the end of the 
experiments (t = 120 minutes) and are means ± SE. * Insulin treated significantly 
different (P < 0.05) from corresponding saline treated value; # Wortmannin treated 
significantly different from corresponding vehicle treated value (n = 8 per group). 
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3.3.5 Western Blots for P-Akt and Akttotai 
Figure 17A-C shows data and representative Western blots for 
phosphorylated Akt (P-Akt) and total Akt (Akt total) in liver (A), muscle (B) and aorta 
(C) determined by the Western blot technique. The antibodies were directed to the 
phospho-Ser473 motif and to Akt. Results are expressed as the ratio P-Akt/Akttotai. 
During the insulin treatment (20 mU.min-1 .kg-1 ) the relative proportion of 
P-Akt was significantly increased compared with saline in all tissues. Wortmannin 
significantly inhibited the insulin mediated increase in P-Akt/Akttotal in the liver and 
aorta but this trend for decrease did not reach significance in the skeletal muscle. 
There was also an increase in the P-Akt/Akttotal in the wortmannin + saline muscle 
group compared with saline, possibly due to the relatively increased levels of plasma 
insulin concentrations (Table 3), but this significant increase was not observed in 
liver and aorta. 
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Figure 17: Effect of wortmannin, insulin and a combination of wortmannin + 
insulin on phosphorylation of Akt in liver (A), skeletal muscle (B) and aorta (C). 
Details are given in Figure 10 and the materials and methods (section 2.1.10). Ratios 
of P-Akt to Akttotal  have been determined by image analysis of gel bands for vehicle 
treated rats with either saline or 20mU.min -l .kg-1 insulin (open bars) and wortmannin 
treated rats with either saline or 10mU.min -l .kg-1 insulin (filled bars).* Insulin 
significantly different (P <0.05) from corresponding saline treated values; 
# Wortmannin treated significantly different from corresponding vehicle treated 
values (n =4 per group). 
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3.4 DISCUSSION 
The main findings of the present study are that systemically administered 
wortmannin in vivo inhibited the haemodynamic effects of insulin; including total 
blood flow and microvascular perfusion as well as glucose uptake. These results 
suggest that limb blood flow and microvascular perfusion are controlled by an 
insulin-signalling cascade involving PI3K, the target for wortmannin inhibition, 
which is coupled with metabolic effects. The study was undertaken because the 
haemodynamic effects of insulin to increase limb blood flow and microvascular 
perfusion cannot be studied in vitro. This study represents the first report on the use 
of wortmannin to assess effects on insulin action in vivo and particularly to test 
whether insulin's control of microvascular perfusion in muscle is wortmannin 
sensitive. 
When administered at the low dose used in the current study, there were 
several unwanted side effects associated with systemic wortmannin infusion in vivo. 
These unwanted side effects included decreases in heart rate and increases in blood 
pressure, vascular resistance and plasma insulin. An unexpected finding of in vivo 
infusion of wortmannin was the marked increase in plasma insulin by 10 to 20 fold 
above basal. This increase in plasma insulin occurred independently to any prior 
increase in blood glucose concentration. An explanation for this response is not clear 
as previous in vitro experiments using isolated f3-cells, by others have found that 
wortmannin can both inhibit [382] and stimulate [383-385] glucose-mediated insulin 
release. A tissue-specific knockout of the 13-cell insulin receptor (PIRKO) displays an 
insulin secretory defect with a loss of insulin release in response to glucose [386]. 
Hence in the current study, the increase in insulin suggests that wortmannin may be 
acting on pancreatic I3-cells by an insulin receptor independent pathway. The 
observed increase in insulin with wortmannin infusion is likely to be due to an 
increase in insulin secretion but it is also possible that the clearance of insulin is 
affected by wortmannin treatment. Although not carried out in this study, further 
studies to resolve these possibilities would involve performing additional 
experiments using local infusion of wortmannin via the epigastric artery. Local 
infusion could eliminate other tisse actions. Performing a C-peptide assay would 
determine if wortmannin is increasing insulin secretion in vivo. 
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The causes for the increase in BP and VR by wortmannin are unknown but 
may be the result of inhibition of PI3K specific vasodilatory action at the peripheral 
resistance sites or because of central nervous system actions of wortmannin. The 
change in VR in the current study appears to parallel changes in plasma insulin levels 
caused by wortmannin (Figure 11 and Figure 15C-D). Insulin regulates vascular tone 
by stimulating both vasodilator and vasoconstrictor effects. Insulin has been shown 
to induce both vasodilation by activation of Akt, which enhances activity of eNOS 
[387] as well as vasoconstriction through endothelin release from the muscle 
vasculature [388]. Impairment of insulin mediated vasoreactivity in the muscle 
vasculature may be due to an imbalance between insulin-mediated nitric oxide and 
endothelin production. Thus, in the presence of wortmannin, the increased plasma 
insulin and associated endothelin release may be the cause for the increase in VR and 
contribute to the raised BP [389]. 
The rise in plasma insulin produced by wortmannin alone was such that at the 
end of the experiment the plasma levels were approximately 5,000 pM. Plasma 
insulin levels produced by infusion of 20mU.min -l .kg-1 were similar to those 
produced in the wortmannin and wortmannin + 10mU.min -l .kg -1 insulin groups. 
From the comparisons between these three groups, where the concentration of 
plasma insulin was equivalent, it is clear that the effect of insulin to increase either 
FBF or microvascular perfusion was completely inhibited by wortmannin. At the 
higher plasma insulin concentration generated by infusion of 20mU.min 1 .kg-1 
insulin, GIR was further increased above that of 10mU.min -1 .kg-I . In the wortmannin 
+ insulin 10mU.min -l .kg-1 however GIR was completely blocked even at the same 
high level of plasma insulin (-5,000pM). A similar outcome was evident when the 
data for Rd and HLGU were examined and 20mU.min -1 .kg-1 insulin was compared. 
The effects of wortmannin on metabolic or haemodynamic effects that could 
be attributed to either liver or the vasculature were generally marked and greater than 
those associated with muscle. The inhibitory effects of wortmannin on the liver and 
muscle vasculature included insulin-mediated changes in Ra (liver), liver P-
Akt/Akttotai, FBF (muscle vasculature) and 1-MX metabolism (muscle vasculature). 
The partial inhibitory effects of wortmannin on muscle included Rd (principally 
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muscle), HLGU and muscle P-Akt/Akttotal. In the aorta, insulin-stimulated increases 
in P-Akt/Akttota i, were significantly blocked by wortmannin. The different responses 
to wortmannin by liver and aorta compared with the muscle may result from a 
relatively lower delivery of wortmarmin to muscle. In liver, the endothelial barrier is 
incomplete, and delivery of wortmannin, to the liver plasma membrane insulin 
receptor signalling cascade would be relatively unrestricted. Thus, the insulin-
mediated inhibition of Ra was reversed, with wortmannin treatment. It is also likely 
that the delivery of wortmannin to vascular endothelial cells of aorta is unrestricted 
which would explain the significant inhibition of insulin-mediated increases in aorta 
P-Akt/Akttotal, FBF and microvascular perfusion. 
The finding that indexes of insulin action in muscle such as Rd, HLGU and 
muscle P-Akt/Akttotal were only partly blocked by wortmannin may in part reflect the 
constraints imposed by the muscle vasculature on delivery of wortmarmin to the 
interstitium and myocyte insulin receptor signalling cascade. Blockade of insulin-
mediated microvascular perfusion would reduce delivery not only of insulin and 
glucose but also wortmannin. Reduced delivery of insulin and glucose would give 
rise to a reduced Rd and HLGU. Based on previous studies where insulin-mediated 
microvascular perfusion has been blocked by a 5-hydroxytryptamain agonist [55], 
tumour necrosis factor-a (TNFa) [390], free fatty acids [391], or glucosamine [392], 
this could amount to approximately 50% inhibition of the insulin-mediated increase 
in muscle glucose uptake, with the expectation of a similar magnitude of inhibition 
of Rd and muscle P-Akt/Akt -total- In addition to this, it appears likely that the relatively 
water-insoluble wortmannin is unable to fully diffuse to those myocytes that are 
unaffected by microvascular perfusion (i.e., where insulin delivery is unrestricted). 
Consequently, a reduced diffusion of wortmannin to these myocytes would limit the 
extent of inhibition of insulin action and thus, for the combination of wortmannin + 
insulin HLGU, Rd and muscle P-Akt/Akttotal were not fully inhibited compared with 
liver (Figure 13B&D and Figure 17). 
It has been found by a number of workers that insulin-mediated increase in 
limb blood flow is nitric oxide dependant [41, 89]. Insulin has been shown to induce 
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vasodilation by activation of Akt which enhances Ser i m phosphorylation and 
activity of eNOS [84, 387]. It is also possible that microvascular perfusion is 
controlled at the terminal arterioles where receptor tyrosine kinase on endothelial 
cells initiates a cascade involving insulin receptor substrate-1, PI3K, Akt and 
phosphorylation and activation of endothelial nitric oxide synthase. There is 
evidence from cultured endothelial cells to support such a relationship [84]. There is 
also evidence which suggests that insulin-mediated microvascular perfusion is a 
locally mediated response from studies done using the human forearm [57]. Thus the 
present findings add support to the concept that insulin mediates perfusion of the 
muscle microvasculature by local control at the terminal arterioles which is 
susceptible to inhibition by wortmannin at the step involving PI3K. 
Finally, it is important to note that this study is built on the assumption that 
wortmannin at the dose used has specifically inhibited only PI3K of the insulin-
signalling cascade. However, non specific effects of wortmannin cannot be entirely 
ruled out. Low nanomolar concentrations (5-100nM) are considered to be selective 
for PI3K inhibition [379]. In vivo, a single bolus injection of lmg wortmarmin per 
kilogram body weight was considered by Davol et al. [379] to give a similar 
outcome in reducing implanted tumour cell volumes as noted for 5-100nM 
wortmannin in vitro. The cumulative dose of a constant infusion of 1 mg.min -l .kg-1 
wortmannin used in the present study was only 180gg.kg-1 spread over the 180 
minutes infusion period and thus likely to be somewhat lower than the peak 
concentration achieved by Davol etal. [379] following a bolus dose of lmg. In 
isolated beta-cells, the effect of wortmannin has been reported to occur at 
concentrations as low as 1 OnM [385] and at 50 nM gave similar results to 101.tM 
LY294002, another PI3K specific inhibitor [385]. In muscle wortmannin inhibits 
insulin-mediated glucose uptake in either perfused rat hindlimb [393] or isolated 
incubated epitrochlearis muscles [374] with a half-maximum of —10nM. Less 
specific effects such as the inhibition of contraction-induced glucose uptake are 
either absent (11.IM; [374]) or require even higher concentrations of wortmannin (eg. 
3 and 10p,M; [393]). A recent study by Wang et al. [394] reported that the vascular 
effects of much larger bolus doses (1,000-7,000 ptg.kg -I ) of wortmannin. In that 
study, wortmannin caused a reduction in BP at the high doses because of inhibition 
of myosin light-chain phosphorylation. In contrast, in this study with a lower dose of 
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wortmannin, there was a modest increase in BP and femoral VR. Thus, in the present 
study where the peak of wortmannin concentrations was likely to have been <100 
nM, non-specific effects were likely to be minimal. 
In summary, wortmannin infused in vivo at concentrations likely to 
specifically inhibit PI3K had profound effects on insulin release and insulin action. 
Plasma insulin levels increases markedly, and the haemodynamics effects of insulin 
of increased limb blood flow and microvascular perfusion were completely inhibited, 
as was the insulin-mediated inhibition of hepatic glucose output. Delivery of 
wortmannin to the myocytes may be restricted and insulin-mediated glucose uptake 
and Rd were only partially inhibited but this may be the result of reduced delivery of 
insulin and glucose because of the total inhibition of insulin-mediated microvascular 
perfusion. 
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4.1 INTRODUCTION 
The insulin mediated increases in total blood flow to skeletal muscle 
vasculature has been demonstrated by a number of researchers in humans [41, 395] 
and animals [55, 396]. It has been suggested that insulin stimulates increased 
perfusion in skeletal muscle to facilitate its own delivery and the delivery of glucose 
for increased glucose disposal [25]. Insulin mediated increases in skeletal muscle 
blood flow are blunted in insulin resistant subjects suggesting that reduced muscle 
perfusion may contribute to the insulin resistance observed in these individuals 
[338]. 
Insulin increases nitric oxide (NO) production as part of its action to increase 
limb blood flow and this has been demonstrated both in vitro [397-399] and in vivo 
[41, 89]. NO, a potent dilator, is produced by nitric oxide synthase (NOS) which is 
located in the vascular endothelium [400] and myocytes [401]. It has also been 
demonstrated that endothelial cells contain insulin receptors activation of which can 
lead to eNOS phosphorylation [38], suggesting a direct action of insulin on the 
endothelium. This is supported by the finding that mice which are eNOS deficient 
are hypertensive and resistant to insulin-mediated increases in muscle glucose uptake 
[402, 403]. 
Studies by Steinberg et al. [41] and Scherrer etal. [89] have demonstrated that 
infusion of a nitric oxide synthase inhibitor completely abolishes insulin-induced 
increases in total blood flow to muscle in humans. Further, Vincent et al. [27, 88] 
and Roy et al. [404] showed that infusions of a NOS inhibitor during a 
hyperinsulinemic euglycaemic clamp decreased insulin mediated glucose uptake in 
rat skeletal muscle. In the same studies Vincent found that in addition to a significant 
reduction in glucose uptake there was a corresponding decrease in microvascular 
perfusion [27, 88]. Taken together these studies suggest a physiological role for 
insulin on the vasculature. 
In studies reporting the involvement of nitric oxide in insulin-mediated glucose 
uptake in rat skeletal muscle, such as the studies performed by Vincent et al. [27, 
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88], systemic infusions of L-NAME were used. In these studies, infusion of L-
NAME raised blood pressure, completely inhibited insulin mediated increases in 
limb blood flow (at concentrations of insulin which raised blood flow), 
microvascular perfusion and blunted glucose uptake measured in the hindlimb. NOS 
inhibitors, when administered systemically, may access central sites which may 
participate in the effects observed. A study by Shankar et al. [90] demonstrated that 
acute ICV administration of N ° -mono-methyl-L-arginine (L-NMMA), a competitive 
inhibitor of nitric oxide synthase (NOS), in Sprague-Dawley rats resulted in the 
development of peripheral insulin resistance. These effects occurred without any 
detectible presence of L-NMMA in the peripheral blood. In addition, Bradley et al. 
[91], demonstrated that acute central ICV administration of L-NMMA in rats 
resulted in impaired whole body glucose uptake, skeletal muscle glucose uptake and 
microvascular perfusion. The same dose of L-NMMA given systemically had no 
effect. Conversely, Baron et al. [405] demonstrated in human subjects that local 
infusion of a NOS inhibitor, thus excluding central effects of L-NAME 
administration, abolished insulin-induced increases in total flow and reduced glucose 
uptake by approximately 30% in lean humans. 
Total limb blood flow is controlled by medium sized arterioles that control 
vascular resistance. Thus far, the involvement of NO in insulin's vascular action on 
muscle has been largely assessed by measurement of total limb blood flow [5, 89, 
399] with the exception of the study by Vincent et. al. [88]. The present study was 
designed to determine whether NOS inhibition affects insulin mediated 
microvascular perfusion and glucose disposal though local administration of the 
inhibitor thus isolating the effects to the hind limb and avoiding unwanted systemic 
effects, such as increased blood pressure and possible interaction with central sites. 
The effect of local infusion of L-NAME on insulin action in muscle using rodents 
has not been previously assessed. 
4.1.1 Aim of the Study 
The aim of the present study is to explore the relationship between 
microvascular perfusion and activation of NOS and assess whether this pathway is 
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involved in insulin mediated microvascular perfusion and muscle glucose 
metabolism by use of local NOS inhibition (intra-arterial infusion into one leg). 
4.2 RESEARCH AND DESIGN METHODS 
4.2.1 Animals 
Male Hooded Wistar rats (weighing 255 ± 2g were raised in the University of 
Tasmania Animal House as described in section 2.1.1. These experiments were 
performed in accordance with the guidelines of the University of Tasmania Ethics 
Committee. 
4.2.2 Surgical Preparation 
In vivo experiments were performed on non-fasted anethetised rats as described 
in section 2.1.2. Epigastric cannulations were performed as described in section 
2.1.2.2. A schematic drawing showing the positioning of cannulae and flow probes is 
given in Chapter 2 (Figure 6, page 44). On completion of the surgery a period of 
equilibration of approximately 60 minutes was allowed so that leg blood flow and 
pressure could become stable and constant. 
4.2.3 Preliminary Experiments 
Preliminary experiments were conducted to determine a dose of N'-L-nitro-
arginine-methyl ester (L-NAME, Sigma Chemicals, St. Louis, MO) that would 
produce a suppression in femoral blood flow during physiological insulin infusion 
without effects on mean arterial blood pressure or heart rate. The aim of this protocol 
was to ensure that the effect of L-NAME occurred prior to insulin-induced 
vasodilation and microvascular perfusion. 
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4.2.4 Experimental Protocols 
The experimental protocols are shown in Figure 18. Rats were randomly 
allocated into three experimental groups (n = 6 per group): 
1. Systemic saline and local L-NAME (101.1mo1.1 -1 , in the test leg) 
2. Systemic insulin (3mU.min-l .kg-1 ) and local saline 
3. Systemic insulin (3mU.min -l .kg-1 ) and local L-NAME (101.1mol.1 -1 , in the 
test leg) 
In each group local infusions of either L-NAME (10p.mol.1 -1 ) or saline commenced at 
0 minutes and concluded at 75 minutes. The systemic infusions of either insulin 
(3mU.min-l .kg-1 ) or saline commenced at 15 minutes and concluded at 75 minutes. 
L-NAME infusion was commenced locally (epigastric artery) into the test leg 15 
minutes prior to the commencement of systemic insulin infusion (3mU.min -l .kg-1 ). It 
was found that the dose of L-NAME used could be infused for 75 minutes without 
any observable systemic effects. The rate of infusion of L-NAME into the test leg 
was adjusted according to the femoral blood flow so that the concentration of 
L-NAME into the test leg remained at lOpM at all times. L-NAME is a competitive 
inhibitor for each of the three common isoforms of NOS. 
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Protocol 
Bolus 
Allopurinol 
3 
(10prnol.kg-1) 	H-2DG A-V 
P ? 
. . . . . . . 	. 
-60 	-40 	-20 0 	20 	40 	60 	80 
Time (min) 
Local L-NAME lOpM or Saline in one leg 
 
Systemic 3mU.miri 1 kg -1 insulin 
& Glucose or Systemic Saline  
1-MX 
Figure 18: Animals were subject to a 1 hour euglycaemic clamp at 3mU.kg -l .min-1 
insulin or saline infusion. The epigastric artery of the test leg was cannulated for 
local administration of L-NAME into the femoral artery. Arterial blood samples (6) 
were taken for glucose and lactate analysis. A bolus injection (i.v) of allopurinol 
(101.1mol.kg -1 ) is indicated by P and preceded 1-MX infusion (20mg.min-l .kg-1 ) as 
indicated by the bar. A [ 3H] 2-DG bolus was given at t = 65 minutes as indicated by 
P . Arterial and venous blood samples were taken (indicated as A-V) for plasma 
glucose determination. The gastrocnemius group of muscles was freeze clamped at 
t = 75 minutes for R'g determination. 
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4.2.4.1 	Microvascular Perfusion 
Microvascular perfusion was determined by measuring the metabolism of 
infused 1-MX (Section 2.1.8.1). 1-MX was infused intravenously at a constant rate 
during the last 60 minutes of each experiment to produce a plasma concentration 
between 17 and 20pmol.1 -1 . Plasma (100RL) from arterial and leg venous blood 
samples taken at the end of the experiment was mixed with 2011L of 2M perchloric 
acid (PCA) and centrifuged for 10 minutes. The supernatant was used to determine 
1-MX, 1-MU, allopurinol and oxipurinol concentrations by reverse-phase HPLC as 
previously described (section 2.1.8.1). Microvascular perfusion, expressed as 1-MX 
disappearance (MXD) was calculated from arterio-venous plasma 1-MX difference 
multiplied by femoral blood flow [49]. 
4.2.4.2 Technique for 2-Deoxy Glucose Measurement 
The traditional assay for 2-DG uptake requires a 45 minute sampling period 
for measurement of the plasma decay curve. In this study the insulin clamps were 
performed for one hour requiring the 2-DG uptake to be measured over a shorter 
time period. For the present study a 2-DG protocol was used where the 2-DG glucose 
uptake was measured over a period of 10 minutes at the end of the experiment. The 
averaged plasma specific activity of [ 3H] 2-DG was obtained by continuous arterial 
blood withdrawal for 10 minutes at 501.1L.min-1 immediately after administering the 
2-DG bolus via the jugular vein.. At the conclusion of the experiment the soleus, 
plantaris, gastrocnemius white and gastrocnemius red group of muscles were clamp 
frozen together using liquid nitrogen cooled tongs and stored at -20°C for subsequent 
2-DG uptake assay as described in section 2.1.5.2. 
4.2.4.2.1 Blood Sampling 
Arterial samples were taken at the times indicated (Figure 18) for blood 
glucose measurements. An arterial blood sample (0.5mL) was taken by withdrawing 
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blood (500—min -1 ) for 10 minutes from t = 65 to 75 minutes from the carotid artery 
using a syringe pump (AL-1000 syringe pump, World Precision Instruments, 
Sarasota, FL, USA.) at the end of the experiment. This blood sample was used for 
the 1-MX assay and a [ 3H] 2-DG specific activity measurement. The femoral vein of 
each leg was used for venous sampling, using a 29G insulin syringe (Becton and 
Dickinson). A sample of venous blood (300gL) was taken from the femoral vein of 
the test and control legs in rapid succession and used for subsequent 1-MX assay. A 
glucose analyzer (Model 2300 Stat plus, Yellow Springs Instruments, Yellow 
Springs, OH) was used to determine whole blood glucose (by the glucose oxidase 
method) during the insulin clamp. 
4.2.5 Data Analysis 
All data are expressed as means ± SE. Data analysis was conducted as 
described in section 2.3. 
4.2.6 Statistical Analysis 
In order to determine statistical differences between treatment groups during 
time course experiments, a two-way repeated measures analysis of variance 
(ANOVA) was used. The two-way ANOVA was used to test the differences among 
treatment groups for femoral blood flow, blood pressure, heart rate, vascular 
resistance and glucose infusion rate (GIR) throughout the experimental time course. 
When a statistical difference (P <0.05) was found between the treatment groups, pair 
wise comparisons by the Student-Newman-Keuls post hoc test was used to determine 
which time and treatments were significantly different. A paired student's t-test was 
used in order to determine statistical differences between treatment groups for 
muscle glucose uptake (R'g) and microvascular perfusion at the conclusion of the 
experiment. When a significant difference (P <0.05) was found pair wise 
comparisons by the Student-Newman-Keuls post hoc test was used to determine 
which treatments were significantly different. These tests were performed using the 
statistical program Sigma StatTM  (Jandel Software, version 2.03). 
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4.3 RESULTS 
4.3.1 Glucose Metabolism 
Figure 19A shows the time courses for blood glucose (BG) for all three 
experimental groups. There was no significant difference between the blood glucose 
values for the three treatment groups. In the groups which received systemic insulin, 
blood glucose was maintained at or around basal by infusing a 30% glucose solution. 
Figure 19B shows the time course for the GIR for the experiments which 
received systemic insulin infusion. The GIR required to maintain euglycaemia 
reached a plateau at t = 60 minutes and remained unchanged for the final 15 minutes 
of the experiment. The GIR during the systemic insulin + local L-NAME and the 
systemic insulin and local saline experiments was not significantly different between 
the two groups throughout the experimental time course. 
Figure 20 shows the 2-deoxy glucose uptake (R'g) for the combination of the 
lower leg muscles. The R'g in the L-NAME test leg within the systemic saline group 
was not significantly different from the contra-lateral control leg. The R'g in the 
L-NAME test leg within the systemic insulin group was significantly (P < 0.05) 
decreased by approximately 20% compared with the contra-lateral control leg. The 
R'g in the local saline test leg within the systemic insulin group was not significantly 
different from the contra-lateral control leg. The R'g in the control leg in both 
systemic insulin groups was significantly (P <0.001) increased compared with the 
control leg in the systemic saline group. 
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Figure 19: Time course for the effect of local L-NAME (•) or local saline (0) 
during systemic insulin and effect of local L-NAME (V) during systemic saline 
treatment on blood glucose (BG, A) and glucose infusion rate (GIR, B). Local 
L-NAME or saline infusion was commenced at 0 minutes and systemic insulin or 
systemic saline was commenced at 15 minutes. Details are given in Figure 18. 
Values are given as means ± SE. (n = 6 per group). 
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Hindleg 2-Deoxy glucose Uptake 
Systemic 	 Systemic 
Saline Insulin 3mU 
Figure 20: Effect of local L-NAME (filled bars) on systemic saline and systemic 
insulin and effect of local saline (grey bar) on systemic insulin treated animals on 2- 
deoxyglucose uptake (R'g) of the lower leg muscles. Details are given in Figure 18. 
Values were determined at the end of the experiment (t = 75 minutes) and are means 
± SE. * significantly different (P < 0.05) from the contra-lateral leg. 
# significantly different (P <0.001) from the corresponding control leg in the 
systemic saline group. 1' significantly different (P <0.001) from the corresponding 
treated leg in the systemic saline group (n = 6 per group). 
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4.3.2 Haemodynamic Effects 
The dose of L-NAME infused was determined in preliminary experiments 
(data not shown) aimed at maintaining the dose in the test leg to 10[iM without 
changes in FBF in the contra-lateral control leg, heart rate (HR) or mean arterial 
pressure (MAP). 
Figure 21 shows time courses for mean arterial pressure (MAP) and heart 
rate. There were no significant differences between MAP or heart rate values for the 
three treatment groups throughout the time course. The values for MAP before the 
commencement of L-NAME infusion were 110 ± 2.3 (saline) and 115 ± 2.5 (insulin). 
After 75 minutes of L-NAME infusion there was no significant change in MAP and 
the values were 112 ± 3.4 (saline) and 112 ± 4.1 (insulin). 
Figure 22 shows the change in FBF (AFBF) for the treatment leg and contra-
lateral control leg for all three treatment groups. Figure 22A shows that the FBF in 
the contra-lateral control leg in the systemic saline group remained stable and 
constant over the experimental time course. The FBF in the L-NAME test leg within 
the systemic saline group was significantly decreased compared with the contra-
lateral control leg, commencing at t = 50 minutes and continuing until the end of the 
experiment. Figure 22B shows that the FBF in the contra-lateral control leg increased 
by approximately 0.6 mL.min -I after 50 minutes of systemic insulin infusion. FBF in 
the L-NAME test leg within the systemic insulin group did not change from basal 
and was significantly decreased compared with the contra-lateral control leg, 
commencing at t =40 minutes and continuing until the end of the experiment. The 
slight decrease in the FBF observed at t = 75 minutes is likely to be due to blood 
sampling for 1-MX and [ 3H] 2-DG assays. Figure 22C shows that in the systemic 
insulin group the FBF in the saline test leg and contra-lateral control leg increased by 
approximately 0.4 mL.min -I after 60 minutes of systemic insulin infusion. FBF in the 
saline test leg was not significantly different compared with the contra-lateral control 
leg. The slight decrease in the FBF at t = 75 minutes may be attributed to blood 
withdrawal for 1-MX and [ 3 H] 2-DG assays. 
105 
CHAPTER 4 — Effects of NOS Inhibition on Actions of Insulin in Muscle. 
Figure 23 shows the change in vascular resistance (AVR) for the test leg and 
contra-lateral control legs for the three treatment groups. Figure 23A shows that the 
VR in the L-NAME test leg within the systemic saline group was significantly 
increased compared with the contra-lateral control leg, commencing at t = 50 
minutes and continuing until the end of the experiment. Figure 23B shows that the 
VR in the L-NAME test leg within the systemic insulin group decreased slightly by 
the end of the experiment but remained higher than the contra-lateral control leg, this 
was significant from t = 40 minutes until the end of the experiment. Figure 23C 
shows the VR of the local saline test leg within the systemic insulin group was not 
significantly different from the contra-lateral control leg. Both the control and test 
legs displayed a similar trend to decrease VR over the time course of the experiment. 
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Figure 21: Time course for the effect of local L-NAME (•) or local saline (e) 
during systemic insulin and effect of local L-NAME (V) during systemic saline 
treatment on mean arterial pressure (MAP) and heart rate (HR). Local L-NAME or 
saline infusion was commenced at 0 minutes and systemic insulin or systemic saline 
was commenced at 15 minutes. Details are given in Figure 18. Values are given as 
means ± SE (n = 6 per group). 
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Figure 22: Time course for the effect of local L-NAME (V .) during systemic saline 
(V- ) and the effect of local L-NAME (•) or local saline (•) during systemic insulin 
(0) treatment for change in femoral blood flow (AFEIF). Local L-NAME or saline 
infusion was commenced at 0 minutes and systemic insulin or systemic saline was 
commenced at 15 minutes. Details are given in Figure 18. Values are expressed as 
means ± SE. * significantly different (P <0.05) from the contra-lateral leg, (n = 6 
per group). 
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Figure 23: Time course for the effect of local L-NAME (V -) during systemic saline 
(V-) and the effect of local L-NAME (•) or local saline (0) during systemic insulin 
(0) treatment on change in vascular resistance (AVR). Local L-NAME or saline 
infusion was commenced at 0 minutes and systemic insulin or systemic saline was 
commenced at 10 minutes. Details are given in Figure 18. Values are expressed as 
means ± SE. * significantly different (P <0.05) from the contra-lateral leg, (n = 6 
per group). 
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4.3.3 Microvascular Perfusion 
Figure 24 shows the 1-MX disappearance (MXD) (measure of microvascular 
perfusion) for the test and control legs taken at the conclusion of the experiment 
(t = 75 minutes) in each experimental group. There were no significant differences in 
arterial 1-MX and oxypurinol concentrations (data not shown) between all three 
groups in the study. The mean arterial 1-MX concentration and mean oxypurinol 
concentration was 18.85 ± 0.711.tmo1.L 1 and 5.26 ± 0.36 gmol.L-I respectively. 
The microvascular perfusion in the L-NAME test leg within the systemic 
saline group was not significantly different from the contra-lateral control leg. 
Microvascular perfusion in the L-NAME test leg within the systemic insulin group 
was significantly (P <0.05) decreased by approximately 25% compared with the 
contra-lateral control leg. The microvascular perfusion in the saline test leg within 
the systemic insulin group was not significantly different from the contra-lateral 
control leg. Microvascular perfusion in the control leg in both systemic insulin 
groups was significantly (P <0.05) increased compared with the control leg in the 
systemic saline group. Microvascular perfusion in the local saline test leg in the 
systemic insulin group significantly increased compared with the L-NAME test leg 
in the systemic saline group (Figure 24). 
110 
-r- 
1 0 
8 
1 0 
0 
2 
CHAPTER 4 — Effects of NOS Inhibition on Actions of Insulin in Muscle. 
Microvascular Perfusion 
Systemic Saline 	 Systemic Insulin 
\e4 
,2,NV Co vcr- 
" 	
\fel 	voe oeg \52" 
oG2NV CP° 	\pc?' C, 
Figure 24: Effect of local L-NAME (filled bars) during systemic saline and systemic 
insulin and effect of local saline (grey bars) during systemic insulin treated animals 
on measurement of microvascular perfusion (MXD). Details are given Figure 18. 
Values were determined at the end of the experiment (t = 75 minutes) and are means 
± SE. * significantly different (P <0.05) from the contra lateral leg. # significantly 
different from the corresponding control leg in the systemic saline group. 
1 significantly different (P <0.05) from the corresponding treated leg in the 
systemic saline group (n = 6 per group). 
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4.4 DISCUSSION 
The main findings of this study are that local NOS inhibition attenuated 
increases in total blood flow, skeletal muscle glucose uptake and microvascular 
perfusion in the test leg during physiological insulin (3mU.min -1 .kg-i ) infusion in rats 
in vivo. These results suggest that microvascular blood flow effects are coupled with 
metabolic effects in the presence of insulin and that a nitric oxide (NO) producing 
mechanism is activated in muscle by insulin. Local NOS inhibition had no effect on 
blood pressure or heart rate which indicates that the observed effects on blood flow, 
glucose uptake and microvascular perfusion were due to local and not systemic 
action of the NOS inhibitor. 
When given locally (via the epigastric artery of the systemically treated rat) the 
unwanted systemic side effects associated with systemic L-NAME infusion were 
eliminated. This novel technique facilitated the observation of the direct local NOS 
inhibitory effect of L-NAME on insulin action. The current study provides evidence 
that local L-NAME infusion, at the dose used, caused negligible systemic effects. 
The vasoconstrictor effects were limited to the test leg and effects on blood pressure, 
heart rate and FBF in the contra-lateral leg were absent. Previous studies by others 
have shown that systemic NOS inhibitors cause a marked rise in blood pressure 
which in turn triggers compensatory responses [88, 406] which may be due to central 
and sympathetic mechanisms [407]. It is possible that, when systemically infused, 
substances such as L-NAME may cross the blood brain barrier and thus trigger 
whole body responses. It has been reported that when administered systemically L-
NAME can cross the blood brain barrier within 2 hours in rats resulting in reduction 
of NOS brain activity [408]. Studies by Shankar et al. [90] and Bradley etal. [91] 
revealed that ICV NOS inhibitor administration resulted in development of 
peripheral insulin resistance. An advantage of locally infused L-NAME is that the 
contra-lateral leg can be used as a control and that the effects of local NOS inhibition 
can be studied in isolation in vivo. 
Studies by Vincent et al. [27, 88] are the only studies where the effect of NOS 
inhibition on insulin action in muscle microvasculature has been observed. In one 
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particular study [88], rats were infused for 2 hours with either saline, insulin 
(10mU.min-l .kg-1 ), L-NAME (3mg.kg-I bolus followed by a continuous infusion of 
50gg.min-1 .kg-i ) or insulin plus L-NAME. The L-NAME was administered 
systemically by an initial bolus and then a continuous infusion which resulted in an 
increase in mean arterial pressure. Despite the differences in local versus systemic 
administration of L-NAME the results from the Vincent et al. [88] study and the 
present study are very simular. The combination of systemic L-NAME and insulin in 
the Vincent et al. [88] study blocked the effect of insulin on total limb flow and 
microvascular perfusion and blunted glucose uptake. 
One of the key focuses of the current work was to explore the relationship 
between microvascular perfusion and NOS inhibition and determine whether this 
pathway is involved in the physiological processes leading to microvascular 
perfusion. It has been previously reported that insulin acts on the muscle vasculature 
causing microvascular perfusion which increases the delivery of nutrients and itself 
to the muscle myocytes [2, 49]. In the current study, it was observed that insulin at 
physiological doses increased microvascular perfusion as determined by 1-MX 
metabolism. Local infusion of L-NAME inhibited microvascular perfusion in the 
presence of physiological insulin; which indicates that insulin-mediated 
microvascular perfusion is NO dependant. This is in agreement with Vincent et al. 
[88] who reported that systemic L-NAME infusion completely abolished insulin 
mediated (10mU.min-l .kg-1 ) microvascular perfusion. The finding that insulin-
mediated microvascular perfusion was blocked by L-NAME contrasts with a study 
by Ross et al. [409] who showed that contraction mediated microvascular perfusion 
was not blocked by local L-NAME, indicating that different mechanisms are 
involved in insulin and exercise mediated microvascular perfusion. 
Studies by Baron and his colleagues showed that insulin increased total muscle 
blood flow and that this effect was impaired in states of insulin resistance [410, 411]. 
A number of studies have also demonstrated that insulin increases total flow and 
provided evidence that NO-dependant mechanisms are associated with this effect 
[41, 88, 89, 404]. In the present study, local L-NAME infusion significantly 
decreased the FBF response to a physiological dose of systemic insulin. This 
vasoconstrictor effect of L-NAME was also seen in the presence of saline where 
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local L-NAME decreased the FBF in the test leg compared with the contra lateral 
leg. This data is in agreement with Vincent et al. who demonstrated that systemic L-
NAME significantly decreased FBF in the presence of 10mU.min -1 .kg-1 insulin as 
well as in the presence of saline [88]. 
As previously discussed, insulin has been shown to increase total flow and 
microvascular flow which is associated with a NO-dependant mechanism. Insulin 
receptors have been demonstrated on endothelial cells of both large and small blood 
vessels [412]. Studies by Chen and Messina have demonstrated that dilation of 
skeletal muscle arterioles by insulin is endothelium dependant and nitric oxide 
mediated [397]. It was demonstrated that insulin can induce vasodilation of first 
order arterioles in the perfused rat cremaster muscle and that this dilation can be 
blocked with the NOS inhibitor N'-nitro-L-arginine (L-NNA). In addition, removal 
of the arteriole endothelium prevented insulin mediated dilation. This effect was also 
demonstrated by Eringa et al. [388] who confirmed that insulin induces nitric oxide 
activity in rat cremaster first-order arterioles. Work done using vascular endothelial 
cell cultures has revealed that insulin stimulates a rapid dose-dependant increase in 
NO [413]. Studies using human subjects have shown that systemic hyperinsulinemia 
in skin augments nitric oxide mediated vasodilation and induces recruitment of 
capillaries [414]. It has also been demonstrated that endothelial NOS knockout mice 
are hypertensive and are not capable of increasing muscle blood flow [403] or 
glucose uptake [402, 403] in response to insulin to the same extent as wild type mice. 
In summary, work using endothelial cell cultures, isolated vessels and in vivo studies 
reporting a direct vasodilatory effect of locally administered insulin point to an 
endothelium insulin receptor mechanism being responsible for the vascular responses 
to insulin. In contrast, the observation that vascular endothelial cell insulin receptor 
knock-out (VENIRKO) mice had normal fasting glucose and insulin levels and were 
not insulin resistant challenges the role for endothelial insulin receptors in insulin 
action. 
In the present study local L-NAME infusion partially blocked (30%) insulin-
mediated glucose uptake. Vincent et al. have previously reported that systemic 
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L-NAME reduced insulin-mediated glucose uptake measured from FBF and arterio-
venous difference [88]. Another study by Roy et al. [404] found that systemic 
L-NAME infusion during an insulin clamp in rats significantly blunted the whole 
body glucose disposal (16%) and muscle 2-DG (30%). The present study builds on 
the previous study by Vincent et al. since we have also provided a measure of muscle 
glucose uptake by the 2-DG method. The present study measured glucose uptake by 
the radioactive 2-Deoxyglucose uptake method which includes a direct measurement 
from the rat calf muscles. 
This in vivo study demonstrates that NO is required for insulin-mediated 
microvascular perfusion to occur and is partly involved in glucose uptake during 
physiological insulin. An in vitro study by Baton et al. revealed that NOS inhibition 
(by L-NMMA) had no effect on insulin-stimulated 2-deoxy glucose uptake in 
isolated extensor digitorum longus muscles [415]. This finding indicates that the in 
vivo effect of NOS inhibition in the present study to blunt muscle glucose uptake 
may be attributed to the inhibition of the vascular effects of insulin. It cannot be 
ruled out however that L-NAME may have secondary effects which inhibit glucose 
disposal. 
In conclusion, this study demonstrates that local L-NAME infusion blocks 
insulin mediated increases in total blood flow and microvascular perfusion as well as 
partially attenuating skeletal muscle glucose uptake. These findings suggest that 
nitric oxide is critical for microvascular perfusion and is involved in the normal 
increases in skeletal muscle glucose uptake during physiological insulin. Thus this 
study demonstrates that an impaired vascular responsiveness to insulin, due to NO 
inhibition, may contribute to insulin resistance. 
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5.1 INTRODUCTION 
Skeletal muscle AMP-kinase (AMPK) activity increases in response to muscle 
contraction which has been demonstrated in vivo [416] and in vitro [177]. Activation 
of AMPK can lead to muscle glucose uptake and this process can occur 
independently of insulin [286, 416, 417]. AMPK can be pharmacologically activated 
by 5-aminoimidazole-4-carboxamide-1-13-D-ribofuranoside (AICAR) in resting 
muscle [418]. Experiments using muscle treated with AICAR in vitro have 
established that AMPK-mediated glucose uptake involves GLUT4 translocation to 
the cell surface [314, 419-421]. 
AMPK is expressed in vascular endothelial cells [308] and smooth muscle 
cells [422]. A number of studies have shown that AMPK phosphorylates and 
activates endothelial nitric oxide synthase (eNOS) on its serine residue (Ser 1177) 
[265, 307, 308, 423]. There is evidence that AMPK may mediate its effects of 
increasing glucose transport in part through an interaction with the vasoactive 
substance nitric oxide (NO) [424]. AMPK has been shown to regulate endothelial 
function. In conduit arteries, AMPK activation enhances endothelium-dependant 
vasodilation [235]. In addition, AMPK associates with eNOS in the microcirculation 
of the heart [307], suggesting a role for AMPK in the regulation of NO activity in 
the microvasculature. 
Activation of AMPK by AICAR has been found to enhance insulin-mediated 
glucose uptake in muscle and ameliorate insulin resistance [339]. Insulin mediated 
glucose uptake involves enhancement of nutritive muscle blood flow in normal 
individuals [2]. It is possible that the effects of AICAR to increase muscle glucose 
uptake in insulin resistance in vivo may also be mediated to some extent by the 
muscle microcirculation. Additionally AMPKa2 knockout mice display insulin 
resistance in vivo but not in isolated muscles obtained from these animals where - 
nutrients are accessed by diffusion independently of the vasculature [286, 425]. 
Despite these findings the direct effects of AMPK on the muscle microcirculation in 
vivo have not been demonstrated. Activation of the AMPK pathway is an attractive 
therapeutic target for type 2 diabetes and its role in vascular perfusion requires 
further investigation. 
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5.1.1 Aim of the Study 
The aim of this study was to investigate whether a low dose AICAR infusion, 
below the thresh hold for effects on glucose uptake, acutely causes microvascular 
perfusion in vivo. The vasodilatory effects of AICAR on muscle resistance arteries 
in vitro and activation of AMPK in human microvascular endothelial cells were also 
studied. 
5.2 RESEARCH AND DESIGN METHODS 
5.2.1 Animals 
For the in vitro experiments; in Amsterdam, male Harlan Wistar rats 
weighing 324 ± 9 g were kept at a constant temperature of 21 ± 0.6°C, on a 12h 
light/dark cycle and allowed free access to standard laboratory rat chow and water. 
These experiments were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee of the Vrije University Medical 
Center. 
For the in vivo experiments; in Hobart, male Hooded Wistar rats weighing 
245 ± 13 g were raised in the University of Tasmania Animal House as described in 
section 2.1.1. These experiments were performed in accordance with the guidelines 
of the University of Tasmania Ethics Committee. 
5.2.2 In vitro Experiments 
5.2.2.1 	Preparation of Isolated Resistance Arteries 
Vasoreactivity studies were performed on muscle resistance arteries. First 
order arterioles (passive inner diameter 176 ± 6 microns) were isolated from the 
cremaster muscle of male Wistar (Harlan) rats. A 1-2mm long segment was 
transferred to a pressure myograph and the pressure inside the vessel was set to 
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65mmHg and the surrounding temperature set to 34 °C. Experiments were performed 
under low flow conditions and the vessels were exposed to vasoactive substances by 
adding them to the vessel chamber. Details are given in 2.2.2. 
Effects of direct AMPK activation on vascular function were studied by 
exposing the cremaster resistance arteries to the AMPK agonist AICAR 
(2mmol.L -1 ). AMPK phosphorylation at 'Thr 172 , a necessary step in its activation, 
was determined by Western blot. The acute effects of AMPK activation using the 
muscle resistance arteries were monitored for 30 minutes after the addition of 
AICAR (2mmol.L -1 ). Effects of AMPK activation on endothelium dependant and 
independent vasodilation were studied by testing responses to acetylcholine and 
sodium nitroprusside (SNP) before and after pre-treatment with AICAR (data not 
shown). To confirm that the effects of AICAR on vascular diameter were mediated 
by AMPK, vasoreactivity to AICAR was studied in the presence of the selective 
inhibitor for AMPK [426], 644-(2-Piperidin-l-ylethoxy)pheny1]-3-pyridin-4- 
ylpyrazolo[1,5-a] pyrimidine (compound C, 401.1mol.L -1 ). To examine the role of NO 
in AICAR-induced vasodilation, arteries were exposed to AICAR in the presence of 
the NO synthase inhibitor N-Nitro-L-Arginine (L-NA, 0.1mmo1.1: 1 Sigma-Aldrich, 
St. Louis, MO). When more than 1 artery segment was isolated from the same 
muscle, they were assigned to different groups. 
5.2.2.2 	Preparation of Isolated Endothelial Cells 
Human microvascular endothelial cells were isolated from the human 
foreskin (section 2.2.3, page:65). MVECs were treated with AICAR (2mM) for 0 
(controls), 15 and 30 minutes or AICAR (2mM) and compound C for 30 minutes. 
5.2.2.3 Enzyme Activation and Phosphorylation 
For the determination of AICAR-mediated activation of AMPK in human 
microvascular endothelial cells equal amounts of protein (10[tg/lane) were separated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 5% to 8% gels, 
transferred to a nitrocellulose membrane and incubated with the primary antibody 
overnight (1:1000). After washing and addition of the secondary antibody, protein 
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bands were visualized with ECL reagent (Amersham Biosciences). Blots were 
stained with antibodies directed at Thr 172 phospho-AMI3Ka and Ser79 phospho-acetyl 
CoA Carboxylase (pACC) (Cell signalling technology). Densitometry of 
immunoblots was performed using AIDA software (Raytest, Straubenhardt, 
Germany) and untreated vessel samples (control) set at 1 and compared to treated 
vessels from the same animals. 
5.2.3 In vivo Experiments 
In vivo experiments were performed on non-fasted anesthetised rats as 
described in section 2.1.2. Once the surgery was completed, a period of equilibration 
of approximately 60 minutes was allowed so that leg blood flow and pressure could 
become stable and constant. 
5.2.3.1 	Experimental Protocols 
The experimental protocols are shown in Figure 25. There were two formats of 
this protocol, a and b. Protocols a and b shared the following details: Rats were 
allocated into two experimental groups (n = 6 per group). 
1. Saline 
2. AICAR (3.75 mg.miri l .kg1 ) 
Rats were infused with saline or AICAR (Sigma Chemical Co., St. Louis, MO, 
USA). AICAR infusions were initiated by a bolus injection of 20 mg.kg -1 in 0.20 mL 
saline at t = 0 minutes followed by a constant infusion (jugular vein) for 1 hour at 
3.75 mg.min -1 .kg-1 . Infusions are indicated by the bars in Figure 25. 
In protocol a, arterial and venous blood and plasma samples were collected 
at t = 60 minutes and glucose and lactate concentrations were determined. Femoral 
blood flow (FBF) was recorded throughout the protocol. Blood plasma samples were 
taken at t = 60 minutes and stored at -20°C for subsequent determination of AICAR 
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concentration. The gastrocnemius group of muscles was removed at t = 60 minutes 
and stored at -80°C for later determination of AICAR and ZMP content. 
Femoral blood flow measurements could not be made in protocol b due to 
microbubble infusion interfering with the signal of the transonic flow probe. In 
protocol b, contrast enhanced ultrasound (CEU) measurements of microvascular 
perfusion were made by microbubble (MB) infusion at three different time periods; 
immediately before AICAR infusion (basal, t = 0 minutes), after 1 hour of AICAR 
infusion (t = 60 minutes) and during muscle contraction (t = 70 minutes). 
Microbubble infusion periods are indicated in Figure 25. The microbubble infusion 
period consisted of a 10 minute infusion equilibration followed by 10 minutes of 
CEU measurements (pulsing interval curves). Muscle contraction (2Hz, 0.1ms and 
30-35 volts) was performed in protocol b and commenced at t = 60 minutes for a 
duration of 10 minutes. 
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Figure 25. Arterial blood samples (4) were taken for glucose analysis. A bolus 
injection (intra venous) of AICAR (20 mg.kg -1 ) is indicated by 4 and preceded 
AICAR infusion (3.75 mg.min -1 .kg-1 ) as indicated by the bar. In protocol a at t = 60 
minutes; arterial and venous blood samples were taken (indicated by A-V) for 
plasma glucose determination, arterial plasma was sampled for AICAR 
concentration (indicated by R-) and the gastrocnemius group of muscles was freeze 
clamped for the determination of AICAR and ZMP content. In protocol b 
microbubble infusion (401.1L.min -1 ) and periods where ultrasound measurement of 
microvascular volume and flow rate were made are shown by CEU. Muscle 
contraction (field stimulation: 2Hz, 0.1msec, 30-50V) is indicated by EX. 
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5.2.3.2 Plasma AICAR Assay 
Arterial blood samples were taken at the end of the experiment (Figure 25, 
protocol a). Plasma AICAR was determined using HPLC analysis as described 
previously (section 2.1.9). 
5.2.3.3 Skeletal Muscle AICAR and ZMP Assay 
The gastrocnemius group of skeletal muscles was removed (taken in situ) at 
the end of the experiment (t = 60 minutes) and freeze clamped with aluminium tongs 
pre-cooled in liquid nitrogen (protocol a, Figure 25) and stored at -80 °C until 
subsequent determination of AICAR and ZMP concentration using HPLC (section 
2.1.9). 
5.2.3.4 	Microvascular Perfusion In Vivo 
The thigh muscle of the left hindlimb was imaged in short axis with a linear 
array transducer which was secured for the duration of the experiment and connected 
to an ultrasound system (L7-4 transducer, HDI-5000, ATL Ultrasound). The muscles 
in the region of interest were essentially the adductor magnus and semimembranosus 
muscles. Intermittent imaging was performed using pulsing intervals (PI) ranging 
from 0.5 to 15 seconds to allow incremental microvascular replenishment with 
microbubbles between each pulse until the volume within the beam was completely 
refilled. Several frames were obtained at each PI. Data was analysed as described 
using QLABTM Software (Version 2.0, Phillips Ultrasound, Bothwell, section 
2.1.8.2). 
5.2.3.4.1 Microbubbles 
Albumin microbubbles (OptisonTM,  GE Healthcare) were diluted 1:5 with 
perfluoropropane gassed saline and infused at 40 tiLmin 1 via the left jugular vein 
using a polyethylene cannula (PE 20, Intramedic®) for the duration of the data 
acquisition. 
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5.2.4 Data Analysis 
For the in vitro studies; steady-state responses are reported as mean changes 
in diameter from baseline (in percent) ± standard error (SE). The baseline diameter 
was defined as the arterial diameter just before the addition of AICAR. For the in 
vivo studies; all data are expressed as means ± SE. Data analysis was done as 
described in section 2.3. 
5.2.5 Statistics for In Vitro Studies 
In order to determine statistical differences between treatment groups during 
time course experiments, a two way repeated measures analysis of variance 
(ANOVA) was used. Differences between SNP responses in the absence and 
presence of AICAR at each concentration in vitro were assessed by a two-way 
ANOVA and Student-Newman-Keuls post hoc tests. Percent diameter change 
responses to AICAR and differences in pACC staining were tested with one-way 
ANOVA. Differences were considered statistically significant when P <0.05. 
5.2.6 Statistics for In Vivo Studies 
A repeated measures two way analysis of variance was used to ascertain the 
differences between treatment groups for multiple data points during the experiment. 
When a significant difference (P < 0.05) was found between treatments the Student-
Newman-Keuls post hoc test was used to determine which time and treatments were 
significantly different. (for mean arterial pressure, femoral blood flow and change in 
heart rate). 
In order to ascertain the difference between the treatment groups at the end 
of the experiment (120 minutes) a two way analysis of variance was used. When a 
significant difference (P <0.05) was found the Student-Newman-Keuls post hoc test 
was used to determine which treatments were significantly different (for 
microvascular volume and microvascular flow rate). 
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An unpaired student's t-test was used to determine whether there was a 
significant difference (P <0.05) between the blood glucose and hindleg glucose 
uptake values for saline and A1CAR treatments. All tests were performed using 
Sigma StatTM  statistical program (Jandel Software Corp.). 
5.3 RESULTS 
5.3.1 In Vitro Effects of AICAR 
5.3.1.1 	Effects of AICAR on Isolated Resistance Arteries 
During the equilibration period all vessel segments developed spontaneous 
tone, reducing the diameter by 94 ± 7 pm (54 ± 3%) to 82 ± 7 1.1,M. Vessels were 
responsive to the endothelium-dependant vasodilator acetylcholine (ACh, 0.1 [IM) 
which caused a 43 ± 11 % dilation (data not shown). 
Figure 26 shows the change in diameter of muscle resistance arteries treated 
with AICAR. The percent diameter change in the AICAR alone group showed a 
marked vasodilation (18 ± 5%) from the initial basal value, indicating that A1CAR 
was acting as a dilator. The percent diameter change in the L-NA group showed a 
5% percent decrease (vasoconstriction) which was significant (P < 0.01) when 
compared to the AICAR group. The vasoconstriction in the L-NA alone group due 
to inhibition of NO synthesis indicates the presence of basal NO synthesis. The 
vasodilation observed with AICAR treatment was abrogated by inhibition of NOS 
(with L-NA; P<0.001) or AMPK (with compound C, P<0.05). AICAR induced a 
small vasodilation during AMPK inhibition with compound C (6±3 %), however 
this was not significantly different compared with the initial basal value (P = 0.12). 
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Figure 27 shows the effect of treatment of muscle resistance arteries with 
SNP in the presence or absence of AICAR. In paired experiments, pre-treatment of 
resistance artery segments with AICAR for 30 minutes was significantly (P < 0.01) 
greater compared to the untreated group at each concentration of SNP. The data 
indicates that AICAR had a secondary effect to sensitize the resistance arteries to the 
vasodilatory action of sodium nitroprusside (Figure 27). 
5.3.1.2 	Effects of AICAR on Endothelial Cells 
In microvascular endothelial cells AICAR induced a time-dependant 
phosphorylation of AMPKa at Thr 172 and a four fold increase of AMPK activity, 
measured by phosphorylation of the AMPK substrate ACC at Ser 79 (Figure 28). This 
increase was abolished by the AMPK inhibitor compound C (Figure 28). 
126 
AICAR 
L-NA 
Compound C 
0 
5 
co 
25 
-5 
-10 
CHAPTER 5 — Microvascular Actions of AICAR In Vitro and In Vivo. 
Figure 26: Effect of AICAR (2 mmol.L -1 ) alone or in combination with the NOS 
inhibitor L-NA (0.1 mmol.L-1 ) or the AMPK inhibitor compound C (40 imo1.L -1 ) on 
muscle resistance arteries. Responses were studied for 30 minutes after addition of 
AICAR and steady-state responses are given. Values are means ± SE (n = 4 - 6 per 
group). * Significantly different (P <0.01) from AICAR alone treatment. 
(Data provided by Dr. Etto C. Eringa, Laboratory for Physiology, Institute for 
Cardiovascular Research (ICaR-VU), VU University Medical Center, Amsterdam, 
The Netherlands.) 
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Figure 27: Effect of treatment of muscle resistance arteries with the presence or 
absence of AICAR and the NO donor sodium nitroprusside (SNP). Responses were 
studied for 30 minutes after addition of AICAR or vehicle and SNP. Steady state 
responses are given. Values are means ± SE (n = 4 - 6 per group). * AICAR treated 
significantly different (P < 0.01) from untreated. 
(Data provided by Dr. Etto C. Eringa, Laboratory for Physiology, Institute for 
Cardiovascular Research (ICaR-VU), VU University Medical Center, Amsterdam, 
The Netherlands.) 
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Figure 28: A time course for the effect of AICAR treatment (2mM) for 0 to 30 
minutes on Thr 172 phosphorylation of AMPKa and Ser79 phosphorylation of ACC in 
human microvascular endothelial cells and the effect of pre-treatment with the 
AMPK inhibitor compound C. One representative Thr 172 pAMPKa and Ser79 pACC 
Western blot is displayed. Values are means ± SE (n = 3). * AICAR 30 minutes 
treated significantly different (P < 0.01) from AICAR 0 minutes treated. 
# Compound C treated is significantly different (P < 0.01) from AICAR 30 minutes 
treated. 
(Data provided by Dr. Etto C. Eringa, Laboratory for Physiology, Institute for 
Cardiovascular Research (ICaR-VU), VU University Medical Center, Amsterdam, 
The Netherlands.) 
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5.3.2 In Vivo Effects of AICAR 
5.3.2.1 	Plasma and Muscle AICAR and Muscle ZMP Content 
Table 4 shows plasma AICAR and muscle AICAR and ZMP values 
measured at t = 60 minutes for experiments with AICAR treatment 
(3.75mg.min -l .kg-1 ). AICAR content in both the muscle and plasma samples have 
shown an increase from a basal value of zero (data not shown). The ZMP levels in 
the muscle have also shown a corresponding increase due to AICAR treatment 
(Table 4). 
Table 4: Plasma and muscle AICAR and muscle ZMP contents from AICAR 
treated animals taken at the end of the experiments. 
 
AICAR 	ZMP 
(nmol.g wet wt-1 ) 	 (nmol.g wet wt-1 ) 
 
AICAR 
(nmo1.1: 1 ) 
Plasma 266 ± 12 Gastrocnemius 
group 
98 ± 9 	 207 ± 27 
 
    
Details of sampling are given in Figure 25. Values are means ± SE (n = 4 muscle, 
n = 10 plasma). 
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5.3.2.2 	Glucose Metabolism 
Figure 29 shows the effect of AICAR on arterial blood glucose concentration at 
the end of the experiment (t = 60 minutes). The blood glucose concentration in the 
AICAR group was not significantly different compared with the saline alone group. 
Figure 30 shows the effect of AICAR on hind leg glucose uptake taken at the 
end of the experiment (t = 60 minutes) for the saline and AICAR 
(3.75mg.min-l .kg-1 ) groups. There was no significant difference between the hind 
leg glucose uptake values for the two groups. 
In summary no glucose infusion was required to maintain blood glucose 
levels during AICAR infusion alone and there was no stimulation of hind leg 
glucose uptake. 
Blood Glucose 
Figure 29: Blood glucose values for saline (open bar) and AICAR (filled bar) 
treatments. Values are determined at the end of the experiment (t = 60 minutes). 
Details are given in Figure 25. Values are means ± SE (n = 6-10). 
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Figure 30: Hindleg glucose uptake values for saline (open bar) and AICAR (filled 
bar) treatments. Values are determined at the end of the experiment (t = 60 minutes) 
Details are given in Figure 25. Values are means ± SE (n = 6-10). 
5.3.2.3 Haemodynamic Changes 
Figure 31 shows the time courses for mean arterial blood pressure, femoral 
blood flow and changes in heart rate over the 60 minute experimental period during 
saline (control) or AICAR infusion. 
Figure 31A-B shows that there was no effect of AICAR on mean arterial 
pressure and femoral blood flow. Figure 31C shows that after 60 minutes of infusion 
AICAR caused a decrease in heart rate by approximately 40 bpm from a basal value 
of 312 ± 9 bpm. The decrease in heart rate caused by AICAR was significant (P < 
0.05) 15 minutes after the commencement of AICAR infusion and continued to 
decrease until the end of the experiment. 
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Figure 31: Effect of AICAR on mean arterial blood pressure (BP, A), femoral 
arterial blood flow (FBF, B) and change in heart rate (AHR, C). Mean values are 
shown for saline (n = 14) and AICAR (n = 10) treated rats. * Significantly different 
(p< 0.05) from saline values. 
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5.3.2.4 	Microvascular Perfusion 
Figure 32 and Figure 33 show changes in microvascular perfusion (reflected 
by an increase in the microvascular volume filled by microbubbles) in a 
representative experiment for the three treatments: saline, AICAR and contraction. 
Figure 32 shows a representative image taken at a 15 second pulsing interval 
showing changes in signal intensity indicated by colour saturation ranging from blue 
(the least intense) to red (the most intense). The colour saturation increased with 
AICAR treatment, compared with saline and further increased with muscle 
contraction. Figure 33 shows a representative pulsing interval curve showing that 
AICAR increased microvascular perfusion (A-value) by approx 17 Al, compared 
with basal and this was further increased with contraction treatment which increased 
by approx 28 Al, compared with basal. Figure 33 also shows that contraction 
treatment resulted in a 2 fold increase in microvascular flow rate (MFR) (fl-value) 
compared with saline and AICAR treatments. 
Figure 34 shows the effect of saline, AICAR and muscle contraction on 
microvascular volume (MV) and microvascular flow rate (MFR) taken at the 
commencement (t = 0 minutes) and completion of the experiment (t = 60-70 
minutes). Figure 34A shows that saline infusion had no effect on the MV whereas 
contraction increased the MV compared with basal. Figure 34B shows that AICAR 
increased the MV compared with basal which was significant (P < 0.05) and this 
was further increased by contraction which was also significant (P < 0.05). Figure 
34C shows that saline infusion had no effect on the MFR whereas contraction 
increased MFR which was significant (P <0.05) compared with basal treatments. 
Figure 34D shows that AICAR treatment had no effect on the MFR compared with 
saline. In contrast contraction increased the MFR which was significant (P <0.05) 
compared to the saline and AICAR treatments (Figure 34D). 
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Figure 33: Representative pulsing interval curves for contrast enhanced ultrasound 
measurement of microvascular volume and flow velocity. Acoustic index (Al) of the 
region of interest (Figure 32) is plotted as a function of pulsing interval (PI) as 
described in the text. Values are means ± SE for saline, AICAR and contraction. SE 
are indicated by the bars; when not visible these are within the symbols. The 
asymptote of each graph is the A-value and is a determination of the microvascular 
blood volume. The tangent at PI = 0 is the /3-value and is a determination of the 
microvascular blood velocity (see text for equation describing the relationship 
between VI and PI in section 2.1.8.2). 
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5.4 DISCUSSION 
One of the key findings in this study is that the acute administration of AICAR 
in vivo, at a dose below the threshold for causing muscle glucose uptake, stimulates 
microvascular perfusion in muscle. This study also demonstrated that muscle 
contraction and AICAR increase microvascular perfusion (microvascular blood 
volume) in vivo however unlike contraction low dose AICAR did not increase the 
microvascular flow rate or total flow. This study also attempts to determine the 
mechanisms by which AICAR causes microvascular perfusion and this was 
performed using in vitro resistance arteries and endothelial cell culture preparations. 
A second key finding of this study was that AICAR sensitized resistance arteries to 
the NO donor sodium nitroprusside and that vasodilator effects of AICAR were also 
blocked by L-NA treatment. Together these findings provide evidence for 
involvement of NO in AMPK mediated vascular relaxation, suggesting that 
microvascular perfusion in vivo also occurs via nitric oxide release. 
The in vitro findings of this study provide evidence that AICAR and 
subsequent AMPK phosphorylation is associated with vascular function involving 
NO. In muscle resistance arteries AICAR was shown to increases NO activity by 
increasing smooth muscle sensitivity to NO as well as causing vasodilation which 
was inhibited with L-NA. There is also evidence to suggest that AMPK stimulates 
NO activity in endothelial cells. A study by Morrow et al. using human aortic 
endothelial cells found that AMPK activation by AICAR resulted in an increase in 
eNOS Ser1177 phosphorylation and subsequent NO production [308]. This group also 
demonstrated that the stimulation of NOS production is inhibited by infection of 
human aortic endothelial cells with an adenovirus expressing a dominant negative 
AMPK mutant [308]. In another study using cardiac endothelial cells Chen et al. 
showed that AMPK phosphorylated eNOS at Ser 1177 [307]. Together results 
observed by others and results of the present study indicate that AMPK activation in 
the endothelium may contribute to the vasodilatory actions of AICAR by causing 
NO release from the endothelium and inducing the smooth muscle to become more 
sensitive to NO. The AMPK phosphorylation in endothelial cells and vasodilation 
caused by AICAR in resistance arteries was blocked by compound C, suggesting a 
link between AMPK activation and vascular NO activity. 
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In contrast, other research workers have provided evidence against a role for 
AMPK to phosphorylate eNOS. Mount et a/. showed that activation of AMPK in the 
ischemic rat kidney was not associated with any change in phosphorylation of eNOS 
at Ser l "7 or Thr495 [427]. A study by Goirand et a/. [428] also provided evidence 
that AICAR is involved in vascular functioning when they demonstrated that 
AICAR (0.1-3mM) induced vasodilation in mouse aortic rings. In the same study 
AICAR induced vasorelaxation was not affected by treatment with a known NOS 
inhibitor L-NMMA (3011M) or by endothelium removal. This finding suggests that 
AICAR induced vasorelaxation is eNOS and endothelium independent, despite a 
clear demonstration that AMPK was phosphorylated. From their results, the authors 
concluded that AMPK can induce vasorelaxation in an endothelium and NOS 
independent manner by a direct action on the smooth muscle cells. 
The role of AMPK in relation to phosphorylation of eNOS in the vascular 
endothelium appears to be inconsistent. These differences may also reflect 
differences in metabolism of AICAR and accumulation of ZMP between endothelial 
and smooth muscle cells from different vascular sources. The role of AMPK induced 
eNOS phosphorylation may vary between macrovascular (aorta) versus 
microvascular endothelial cells. Species differences also exist between these 
experiments and could have implications on the results. Caution should also be taken 
when extrapolating results from in vitro studies to the in vivo situation. 
Phosphorylation of eNOS in microvascular cells can also be activated by other 
physiological stimuli such as shear-stress [387, 429] however the mechanisms by 
which eNOS is activated by sheer stress are yet to be resolved. A study by Zhang et 
a/. demonstrated that changes in shear-stress activate AMPK in bovine aortic 
endothelial cells (BAECs) which leads to eNOS phosphorylation and NO production 
[430]. The increase in microvascular perfusion in vivo in the present study occurred 
in the absence of any increase in total blood flow measured in the femoral artery; 
hence it is unlikely that in this case microvascular perfusion was induced by shear-
stress. 
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The mechanism by which AMPK activation causes vasodilation in the 
microcirculation has not been fully determined. Our data lacks in vivo evidence for 
the effects of NOS inhibition on the vasculature during AICAR treatment. One way 
to determine whether the effects of AICAR to increase microvascular perfusion in 
vivo are NO dependant would be to infuse L-NAME locally into one leg via the 
epigastric artery. The contra lateral leg could be used as the control. If microvascular 
perfusion in the L-NAME leg is inhibited then this would provide in vivo evidence 
to support our findings in isolated muscle resistance arteries. 
A side effect of AICAR treatment was the profound decrease in heart rate 
which was demonstrated in the in vivo studies. To our knowledge this in vivo effect 
has not been previously reported. This effect on heart rate is probably a direct action 
of AICAR on the heart as it was not observed with isolated perfused hearts in a 
study by Longus et al. [328]. In addition, AICAR is a analogue of adenosine and in 
some studies has been reported to have physiological actions in the heart via 
adenosine receptor stimulation [431]. 
The in vivo protocol for AICAR treatment comprised of a 20mg.kg -1 bolus of 
AICAR followed by constant infusion of 3.75mg.min 1kg-1 . The in vivo plasma 
concentrations of AICAR reached approximately 250[1M. The study demonstrates 
that low dose AICAR infusion increases microvascular perfusion without increasing 
glucose uptake. A study by Bergeron et al. has reported on the use of AICAR in vivo 
at approximately double the dose (40mg.kg -1 initial bolus followed by 
7.5mg.min-l .kg-1 constant infusion) than used in the present study [313]. The 
AICAR dose used in the Bergeron et al. study resulted in a 2 fold increase in glucose 
uptake. It is likely that the low dose of AICAR used in our study, over the duration 
of the experiments, was below the threshold for translocation of GLUT4transporters 
to the plasma membrane. Preliminary studies (data not shown) also revealed that a 
higher dose (approximately 7.5mg.min -l .kg-1 ) of AICAR than used in the current 
study resulted in an increase in glucose uptake and total blood flow. In addition, 
infusion of AICAR (3.75mg.min-l .kg-1 ) for 3 hours resulted in development of 
glucose uptake which commenced after 120 minutes (data not shown). Since there 
was no increase in glucose uptake from the present study this indicates that 
microvascular perfusion is more sensitive than glucose uptake to AICAR. A study 
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by Vincent et al. [27] demonstrated that microvascular perfusion is more sensitive to 
insulin than glucose uptake when it was shown that microvascular perfusion occurs 
before increases in glucose uptake. Similarly Zhang et al. [63] have demonstrated 
that during low dose insulin infusion microvascular perfusion may occur 
independently of glucose uptake. Time course experiments would further define the 
relationship between AICAR induced microvascular perfusion and the subsequent 
development of glucose uptake. 
In the present study AICAR increased microvascular perfusion in vivo and this 
has occurred without a corresponding increase in the total flow rate. One possible 
explanation for this would be that AICAR causes a redistribution of blood flow from 
the non-nutritive route to the nutritive route. As part of this action AICAR may have 
been involved in both vasodilation and vasoconstriction of vascular beds which 
determine microvascular perfusion and thereby re-directing blood to the nutritive 
route. AMPK may play a complex role in vascular function and vascular perfusion 
however the possible involvement of AMPK in a dual role of vasodilation and 
vasoconstriction remains to be tested. 
In conclusion low dose AICAR stimulates microvascular perfusion in 
skeletal muscle in vivo at a dose below that known to increase muscle glucose 
uptake. The increase in microvascular perfusion potentially enhances hormone and 
nutrient delivery to muscle myocytes. Evidence from the high dose studies in vitro 
suggests that AICAR-mediated vasodilation results from AMPK-mediated activation 
of eNOS (but not production) and sensitization of vascular smooth muscle to NO. A 
vascular action may be an important factor for AICAR's potential as a therapeutic 
agent for treating muscle insulin resistance. 
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6.1 INTRODUCTION 
Exercise has beneficial effects in insulin resistant subjects by increasing 
insulin sensitivity [194]. Insulin resistant subjects have normal levels of the glucose 
transporter GLUT4 in skeletal muscle but attenuated GLUT4 translocation to the 
plasma membrane in response to insulin [432]. However, skeletal muscle GLUT4 
translocation and glucose uptake during exercise are normal in insulin resistant 
subjects. Exercise induced glucose uptake, unlike insulin, is not inhibited by the 
PI3K inhibitor wortmannin [2] indicating exercise and insulin have different 
pathways for glucose uptake. Numerous studies have demonstrated that exercise 
increases glucose transport [172, 433] which may involve AMP kinase [177]. Direct 
activation of AMPK by AICAR mimics some of the beneficial effects of exercise by 
enhancing insulin-mediated glucose uptake in muscle and ameliorating insulin 
resistance [339, 434, 435]. 
Because of the beneficial nature of exercise in increasing insulin sensitivity, 
some research groups have explored the use of AICAR as a potential anti diabetic 
agent [419] and AMPK as a target enzyme for treating type 2 diabetes [318]. 
Cuthbertson et al. [436] have examined the effects of AICAR administration 
(10mg.kg-1 .11-1 ) in healthy male humans. There was a 2.1 fold increase in 2-DG 
uptake after 3hrs of AICAR infusion. Iglesias et al. [318] have examined the effect 
of subcutaneous injection of AICAR (250mg.kg -1 ) one day before conducting a 
hyperinsulinemic euglycemic clamp on insulin resistant high-fat fed rats. Whole 
body glucose infusion rate was found to be enhanced during the clamp by 50% in 
the AICAR treated HFF rats compared with the controls. 
Evidence provided in the previous chapter on the effects of AICAR treatment 
in vivo and the NO dependant effects of AICAR to cause vasorelaxation show that 
the muscle microcirculation can be enhanced by AICAR. It was also shown that 
AICAR, at the dose used, caused microvascular perfusion in the absence of glucose 
uptake. The AMPK activator AICAR, at maximal doses acutely activates glucose 
transport in resting rat muscle in vitro and in vivo however it is not known if lower 
doses can sensitize physiologic insulin. There have been few studies examining the 
effect of AMPK activation combined with insulin action. Moreover, there have been 
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no studies examining whether AMPK activation by AICAR improves the ability of 
insulin to increase microvascular perfusion. Since insulin depends upon 
microvascular perfusion and bulk blood flow for optimal insulin mediated glucose 
uptake [437] it was hypothesised that AICAR treatment should enhance insulin 
action. 
6.1.1 Aim of the Study 
The aim of this study was to investigate whether the effects of a low dose 
AICAR infusion, below the dose to cause glucose uptake alone, contributes to 
enhanced insulin mediated glucose uptake in vivo during physiological insulin 
infusion. 
6.2 RESEARCH AND DESIGN METHODS 
6.2.1 Animals 
Male Hooded Wistar rats weighing 245 ± 1 g were raised in the University of 
Tasmania Animal House as described in section 2.1.1. These experiments were 
performed in accordance with the guidelines of the University of Tasmania Animal 
Ethics Committee. 
6.2.2 In Vivo Experiments 
In vivo experiments were carried out using overnight fasted anaesthetized 
rats (16 hour fast from the time the food is removed at 5 p.m. on the day prior to the 
commencement of the experiment) as described in section 2.1.2. Once the surgery 
was completed a period of equilibration of approximately 60 minutes was allowed 
so that blood flow and pressure could become stable and constant. 
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6.2.2.1 	Experimental Protocols 
The experimental protocols are shown in Figure 35, page 147. There were 
two formats of this protocol, protocol a and protocol b. Both protocols a and b 
shared the following details: rats were randomly assigned into four experimental 
groups as shown in Table 5: 
Table 5: Number (n) of experiments per experimental treatment group for 
protocol a and protocol b. Details are given in Figure 35. 
Experimental Treatment Groups 	 Protocol a Protocol b 
(n) 	 (n) 
Saline (control) 	 6 	 6 
Insulin (3mU.min -1 .kg -1 ) 	 10 	6 
AICAR (3.75mg.min -1 .kg-1 ) + saline 	 10 	6 
AICAR (3.75mg.rnin -1 .kg-1 ) + insulin (3mU.min -1 .kg -1 ) 	12 	6 
Rats were infused with saline, AICAR (3.75mg.min -l .kg-1 , Sigma Chemical Co., St. 
Louis, MO, USA), insulin (3mU.min -1 .kg-1 , Human R Eli Lilly, Indianapolis, IN, 
USA) or insulin + AICAR (3mU.min -l .kg-1 and 3.75mg.min-l .kg-1 respectively). 
AICAR infusions were initiated by a bolus injection (20mg.kg -1 in 0.20mL 
saline) at t = 60 minutes followed by a constant infusion (3.75mg.min -1 .kg-1 , via the 
jugular vein) for 1 hour commencing at t = 60 minutes and concluding at t = 120 
minutes for protocol a and t = 145 minutes for protocol b. Infusions for protocols a 
and b are indicated by the bars in Figure 35. 
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6.2.2.1.1 Euglycaemic Hyperinsulinemic Clamp 
Hyperinsulinemic euglycaemic clamps (3mU.miri l .kg-1 , as described in 
section 2.1.2) were performed in the insulin and insulin + AICAR groups to assess 
insulin sensitivity [341]. Insulin infusions commenced at t = 0 minutes and 
concluded at t = 120 minutes for protocol a and t = 145 minutes for protocol b. In 
the experiments where rats received insulin, blood glucose was maintained at the 
initial blood value (euglycaemia) by co-infusion of variable rates of glucose (30% 
w/v solution) which began at t = 2 minutes and continued until the end of the 
experiment. Infusions are indicated by the bars in Figure 35. 
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Figure 35: Animals were subject to a 2 hour euglycaemic clamp of 3mU.kg -l .min-1 
insulin or saline infusion with or without AICAR. Arterial blood samples (6) were 
taken for glucose and lactate analysis. A bolus injection (i.v.) of AICAR (20mg.kg -1 ) 
is indicated by Eiii and preceded AICAR infusion (3.75mg.min-l .kg 1 ) as indicated by 
the bar. Other bolus infusions are indicated by P. In protocol a, arterial and venous 
blood samples were taken (indicated as A-V) for plasma glucose determination as 
well as arterial insulin and AICAR determination. The gastrocnemius group of 
muscles was freeze clamped at 120 minutes for the determination of AICAR and 
ZMP content as well as R'g determination. In protocol b, microbubble infusion 
(40p.L.min -1 ) and periods where ultrasound measurement of microvascular volume 
and flow rate were made are shown by CEU. Muscle contraction (field stimulation, 
2Hz, 0.1msec, 30-50V) is indicated by EX. 
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Protocol a: 
In protocol a, in order to measure the glucose uptake into individual muscles 
at 45 minutes prior to the completion of the experiment, a bolus dose (50iCi) of 
[ I4C] 2-DG was administered via the venous cannula in 0.20 mL saline. The 
clearance of 2-DG from the blood was determined from plasma samples (2511L) 
collected at 5, 10, 15, 30 and 45 minutes after administration of the 2-DG bolus. At 
the conclusion of the experiment individual muscles of the lower left leg were 
removed, freeze clamped in liquid nitrogen and stored at -80 °C until assayed for 2- 
DG radioactivity as described in section 2.1.5.2. 
Femoral blood flow (FBF) was continuously measured and recorded using a 
Transonic® flow probe positioned around the femoral artery. At the end of the 
experiment, arterial (A) and femoral vein (V) blood and plasma samples were 
collected at t = 120 minutes from the carotid artery and femoral vein. A portion of 
the blood plasma was stored at -20°C for subsequent determination of AICAR 
concentration as described in section 2.1.9. The remaining blood plasma was used 
for plasma glucose and lactate analysis (described in section 2.1.3.1.1) and the 
hindleg glucose uptake was calculated from the arterio venous difference (A-V) 
multiplied by the femoral blood flow. The gastrocnemius group of muscles was 
removed from the right leg and freeze clamped in situ at t = 120 minutes and stored 
at -80°C for later determination of AICAR and ZMP content. 
Protocol b: 
Femoral blood flow measurements could not be made in protocol b due to 
microbubble infusion interfering with the signal of the transonic flow probe. 
Femoral blood flow measurements obtained in protocol b were used to confirm the 
presence of microbubbles in the circulation. In protocol b, contrast enhanced 
ultrasound (CEU) measurements of microvascular perfusion were made by 
microbubble (MB) infusion at three different time periods; firstly, immediately 
before the commencement of the insulin clamp or saline infusion (basal, t = -20 to 0 
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minutes), secondly, during the saline (saline or AICAR + saline) or insulin (insulin 
or insulin + AICAR) clamp (t = 100 to 120 miniutes) and thirdly, immediately 
before commencement of electrical stimulation and during electrical stimulation and 
saline (saline or AICAR + saline) or electrical stimulation and insulin (insulin or 
insulin + AICAR, t = 120 to 145 minutes). Microbubble infusion periods are 
indicated in Figure 35. The microbubble infusion period (OptisonTM  microbubbles 
diluted 1:5 with perfluopropane gassed saline and infused at 4011L.min -1 ) consisted 
of a 10 minute equilibration followed by 10 minutes of CEU measurements 
(continuous images and pulsing interval curves). 
6.2.2.2 	Plasma Insulin Assay 
Arterial plasma samples were taken at the beginning (t = -2 minutes) and at 
the conclusion (t = 120 minutes) of the experimental protocol for insulin 
determination (Figure 35, protocol a). Samples were kept frozen at -20 °C until 
subsequent insulin determination using a commercial rat insulin enzyme immuno-
assay kit (ELISA, Mercodia AB, Sweden). A correction factor calculation was 
performed to account for the cross reactivity between rat insulin and the 
exogenously infused human insulin. 
6.2.2.3 Plasma AICAR Assay 
Arterial samples were taken at the end of the experiment (Figure 35, 
protocol a). Plasma AICAR was determined using HPLC analysis as described 
previously (section 2.1.9). 
6.2.2.4 Skeletal Muscle AICAR and ZMP Assay 
In protocol a, the gastrocnemius group of skeletal muscles (taken in situ) 
were removed and freeze clamped with aluminium tongs pre-cooled in liquid 
nitrogen at the end of each experiment and stored at -80 °C for subsequent 
determination of AICAR and ZMP. HPLC analysis was used for determination of 
AICAR and ZMP content as described in section 2.1.9. 
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6.2.2.5 Microvascular Perfusion Measurement In Vivo 
In protocol b, the thigh muscle of the left hind limb was imaged in short axis 
with a linear array transducer which was secured in position for the duration of the 
experiment and connected to an ultrasound system (L7-4 transducer, HDI-5000, 
ATL Ultrasound). A schematic drawing showing the positioning of cannulae, flow 
probe and ultrasound inducer is shown in chapter 2: Figure 5, p42. The muscles in 
the region of interest were essentially the adductor magnus and semimembranosus 
muscles. Intermittent imaging was performed using pulsing intervals (PIs) ranging 
from 0.5 to 15 seconds to allow incremental microvascular replenishment with 
microbubbles between each pulse until the volume within the beam was completely 
refilled. Continuous imaging was also performed (0.05s) and used for background 
subtraction calculations. Details are given in section 2.1.8.2. Several frames were 
obtained at each PI. Data was analysed using QLABTM  Software (Version 2.0, 
Phillips Ultrasound, Bothwell). 
6.2.2.5.1 Microbubbles 
Albumin microbubbles (OptisonTM, GE Healthcare) were diluted 1:5 with 
perfluopropane gassed saline and infused at 4011L.min -1 via the left jugular vein 
using a polyethylene cannula (PE 20, Intramedic® infusion line connected to a PE 
50, Intramedic® infusion line) for the duration of the data acquisition. The infusion 
pump containing the microbubbles was mounted in a hand driven mixing apparatus 
and the microbubbles were mixed continuously for the duration of the microbubble 
infusion period. The infusion tubing between the rat and the microbubble mixing 
apparatus was continuously mixed using a vortex mixer (John Morris Scientific). 
The mixing process was conducted to ensure that the microbubble suspension 
remained homogeneous. 
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6.2.3 Data Analysis 
All data are expressed as means ± SE. Data-analysis was conducted as 
described in section 2.3. 
6.2.4 Statistical Analysis 
Repeated two-way analysis of variance (ANOVA) was used to test the 
hypothesis that there was no difference among treatment groups for blood glucose, 
glucose infusion rate, blood lactate, blood pressure, femoral blood flow, femoral 
vascular resistance and heart rate throughout the time course. One-way ANOVA 
was used to test the hypothesis that there was no difference among treatment groups 
for plasma insulin values, muscle AICAR and ZMP levels, hindleg and 2-deoxy 
glucose uptake (combined muscles and individual muscles) and microvascular 
perfusion measurements at the end point of the experiments. When a significant 
difference (P <0.05) was found between the treatment groups, pair wise 
comparisons by the Student-Newman-Keuls post hoc test was used to determine at 
which individual time points the differences were significant. Statistical difference 
among treatments for plasma AICAR values was determined by an unpaired t-test. 
All tests were performed using the SigmaStatTM statistical program (Jandel 
Software, version 2.03). 
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6.3 RESULTS 
6.3.1 Plasma Insulin and AICAR Content 
Table 6 shows plasma insulin values measured at the end of the experiment 
(t = 120 minutes) for the four protocols: saline, insulin (3mU.min -l .kg-1 ), AICAR 
(3.75mg.min -l .kg1 ) and AICAR + insulin (AICAR: 3.75mg.min -l .kg-1 and insulin: 
3mU.min-l .kg-1 ). The plasma insulin values were significantly increased 
(approximately 2 fold) when insulin was infused. An insulin infusion of 
3mU.min-l .kg1 increased the basal value of 204 ± 13pM to 395 ± 17pM and 425 ± 
12pM (in the presence of AICAR). AICAR treatment alone or in combination with 
insulin had no significant effect on plasma insulin levels (Table 6). 
AICAR content in the plasma samples increased from a basal value of zero 
(Table 6) when AICAR was infused. Plasma AICAR levels were slightly (22%) but 
significantly (P <0.05) lower with insulin treatment than with saline treatment 
(Table 6), suggesting a stimulating effect of insulin on whole body AICAR 
clearance. 
Table 6: Plasma values at the end of the experiment (t = 120 minutes). Details 
are given Figure 35 (protocol a). 
Treatment Saline Insulin Saline + Insulin + 
AICAR AICAR 
Plasma Insulin (pM) 204± 13 395 ± 17# 161 ±43 425 ± 12# 
Plasma AICAR (pM) 0 0 266 ± 12 208 ± 12# 
Values are means ± SE from saline (n = 6), insulin (n = 10), saline + AICAR 
(n = 10) and insulin + AICAR (n = 12) determined at t = 120 minutes. # insulin 
treated significantly different (p <0.05) from corresponding untreated animals. 
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6.3.2 Muscle AICAR and ZMP Content 
Table 7 shows AICAR and ZMP values measured at t = 120 minutes (Figure 
35, protocol a) for experiments with AICAR (3.75mg.min-l .kg-1 ) and AICAR + 
insulin (AICAR: 3.75mg.min-1 .14 1 and insulin: 3mU.min -l .kg-1 ) treatments. AICAR 
and ZMP content in the soleus, plantaris, gastrocnemius red (GR) and gastrocnemius 
white (GW) increased from a basal value of zero (data not shown). The muscle 
content of AICAR and ZMP were not significantly different between insulin and 
saline treated animals. The muscle content of AICAR and ZMP in the GR and GW 
was significantly less than in the soleus muscle in the saline + AICAR group. The 
muscle content of AICAR in the plantaris was significantly less than in the soleus in 
the saline + AICAR group. There was a similar trend in the insulin + AICAR group 
for increased AICAR and ZMP levels in the soleus muscle but statistical 
significance was not reached with the number of experiments used for muscle 
analysis (n = 4). 
Table 7: Muscle content of AICAR and ZMP from AICAR and insulin + 
AICAR treated animals determined at t = 120 minutes. Details are given in 
Figure 35, protocol a. 
Treatment Saline + AICAR 	Insulin + AICAR 
  
AICAR 	ZMP 	AICAR 	ZMP 
(mmol.g -1 wet wt) 
Soleus 	 161 ± 9 	325 ±31 	152 ±22 237 ± 33 
Plantaris 	 116 ± 11 * 252 ±29 	116 ± 17 207 ±43 
Gastrocnemius (White) 	98 ± 16 * 170 ± 27 * 	86 ± 12 	145 ± 25 
Gastrocnemius (Red) 	86 ± 7* 	174 ± 30* 110 ±13 188 ±23 
Values are means ± SE. * AICAR and ZMP values significantly different (P < 
0.05) from soleus values (n = 7 for saline + AICAR and n = 4 for insulin + AICAR). 
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6.3.3 Glucose Metabolism 
Figure 36 shows time courses for blood glucose (BG) and glucose infusion 
rate (GIR) for experiments with or without insulin or AICAR treatment. There were 
no significant differences between blood glucose values for the four treatment 
groups. During experiments which underwent insulin infusions, blood glucose was 
maintained at a constant level (euglycaemia) by variable infusions of glucose (30% 
w/v solution) (Figure 36A). 
The GIR from t = 0 to 120 minutes is shown in Figure 36B. During the 
3mU.min-l .kg-1 insulin clamp, glucose infusion was required in order to maintain 
basal blood glucose levels. The GIR increased during the first hour until a plateau 
was reached at t = 60 minutes. 
The GIR in the insulin + AICAR experiments was significantly lower than 
for insulin alone from t = 90 to 120 minutes (Figure 36B). Values for the GIR at the 
end of the experiment showed that the GIR required to maintain euglycaemia 
decreased by approximately 30 percent from 9.7 ± 0.5mg.min -1 .14 1 at 60 minutes to 
7.0 ± 0.3mg.mitf l .kg-1 at 120 minutes, which was significantly (P < 0.01) lower than 
that required by insulin alone (Figure 36B). 
Glucose infusion was not required in order to maintain the basal blood 
glucose levels during AICAR infusion alone. 
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Figure 36: Time course for the effect of saline (0), insulin (0), AICAR (•) and 
AICAR + insulin (E) treatment on blood glucose (BG, A) and glucose infusion rate 
(GIR, B). AICAR infusion commenced at 60 minutes. Details are given in Figure 
35. Values are given as means ± SE. * AICAR treated significantly different (P < 
0.05) from corresponding untreated animals (n = 6 -12 per group). If error bars are 
not visible they fall within the symbol. 
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Figure 37 shows the effects of AICAR and insulin on hindleg glucose uptake 
and hindleg 2-deoxy glucose uptake (R'g) of the combined muscles of the lower leg. 
Glucose uptake measured by hindleg glucose uptake and lower leg R'g in combined 
muscles was significantly increased during insulin treatment compared with the 
saline control (Figure 37A-B). Glucose uptake (hindleg glucose uptake and lower 
leg R'g combined muscles) was not significantly different during AICAR treatment 
alone compared with the saline control treatment. When combined with insulin, 
AICAR infusion during the last 60 minutes of infusion resulted in a significantly 
greater (P < 0.05) uptake of hindleg glucose (2 fold) and R'g in combined lower leg 
muscles compared with insulin alone treatment (Figure 37A and Figure 37B 
respectively). 
Figure 38 shows the effects of AICAR and insulin on the individual muscles 
of the lower leg. The glucose uptake (R'g) in the insulin alone group was 
significantly increased compared to the saline control group in all muscles of the 
lower leg except the white gastrocnemius. The glucose uptake (R'g) in the AICAR 
alone group was not significantly different to the control group in any of the lower 
leg muscles. The glucose uptake (R'g) in the AICAR + insulin group for the soleus, 
which consists of type I fiber type muscle [438], was significantly (P < 0.05) lower 
compared with the insulin alone group. The glucose uptake (R'g) in the AICAR + 
insulin group for gastrocnemius red was not significantly different from the insulin 
alone group which consists of a mixture of type I and type IIA fibers [438]. The 
glucose uptake (R'g) in the AICAR + insulin group was significantly increased 
compared with insulin alone group in the plantaris, tibialis, EDL and white 
gastrocnemius muscles which are a mixture of type IIA and IIB fibers [438]. Since 
the white fiber type muscles or the IIA and IIB fiber type muscles make up the bulk 
of the muscles in the lower leg, the overall effect of AICAR on muscle glucose 
uptake (R'g) was a significant increase in insulin medicated glucose uptake (Figure 
37B). 
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Figure 37: Effect of saline, insulin, AICAR and AICAR + insulin treatments on 
hind leg glucose uptake (HLGU, A) and 2-deoxyglucose uptake (R'g, B) of lower 
leg muscles. Saline or AICAR treatment (open bars) as indicated and insulin 
treatment (filled bars) as indicated. Details are given in Figure 35. Values were 
determined at the end of the experiment (t = 120min) and are means ± SE. # insulin 
treated significantly different (P < 0.05) from untreated animals. * AICAR treated 
significantly different (P < 0.05) from untreated animals (n = 6 -12 per group). 
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Figure 38: Effect of saline, insulin, AICAR and AICAR + insulin treatments on 
2-deoxyglucose uptake (R'g) of soleus, plantaris (plant.), gastrocnemius red (GR), 
gastrocnemius white (GW), extensor digitorum longus (EDL) and tibialis (Tib.) 
lower leg muscles. Saline or AICAR treatment (open bars) as indicated and insulin 
treatment (filled bars) as indicated. Details are given in Figure 35. Percent (%) fiber 
type is indicated by pie charts; dark grey — slow oxidative; light grey — fast oxidative 
glycolytic; white — fast glycolytic. Values were determined at the end of the 
experiment (t = 120min) and are means ± SE. # insulin treated significantly different 
(P < 0.05) from untreated animals. * AICAR treated significantly different 
(P < 0.05) from untreated animals (n = 6 -12 per group). 
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6.3.4 Lactate Metabolism 
Figure 39 shows the time courses for changes in arterial blood lactate 
concentration during saline, insulin, saline + AICAR and insulin + AICAR 
treatments. The arterial blood lactate concentration in the saline and insulin groups 
remained constant throughout the experiment. The arterial lactate concentration in 
the insulin group increased compared with the saline group but this difference was 
not significant. The arterial blood lactate concentration in the AICAR alone group 
was significantly (P <0.05) greater 30 minutes after the commencement of AICAR 
infusion compared with the saline group and remained significant until the end of 
the experiment. The arterial blood lactate concentration in the AICAR + insulin 
group was significantly (P < 0.05) greater 45 minutes after the commencement of 
AICAR infusion compared to the insulin group and remained significant until the 
end of the experiment (Figure 39). 
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Figure 39: Time course for the effect of saline (0), insulin (0), AICAR (•) and 
AICAR + insulin (11I) treatments on change in blood lactate. AICAR infusion 
commenced at 60 minutes. Details are given in Figure 35. Values are given as means 
± SE. * AICAR treated significantly different (P < 0.05) from corresponding 
untreated animals. # Insulin + AICAR treated significantly different (P < 0.05) from 
insulin treated animals (n = 6 -12 per group). 
3 
2 
1 
-1 
159 
CHAPTER 6 — Effects of AICAR on the Actions of Insulin In Vivo. 
6.3.5 Haemodynamic Measurements 
Figure 40 shows the mean arterial blood pressure (MAP) time course for 
saline, insulin, saline + AICAR and insulin + AICAR treatments. The basal MAP 
remained constant throughout the experiment for all treatment groups. 
Figure 41 shows the time course for change in femoral blood flow and 
change in femoral vascular resistance. The FBF in the insulin alone group tended to 
increase over the duration of the experimental time course compared to the saline 
control group and AICAR alone group. This increase became significant at t = 75 
minutes and continued until the end of the experiment. The FBF in the insulin + 
AICAR group showed a similar trend to the insulin alone group but this was only 
statistically significant compared to the saline control and AICAR alone group at t = 
105 minutes (Figure 41A). The FBF in the AICAR alone group showed no 
significant difference from the saline control. There was a trend for the insulin and 
the insulin + AICAR groups to decrease FVR compared to the saline and AICAR 
alone control groups (Figure 41B), however this was not statistically significant. 
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Figure 40: Time course for the effect of saline (0), insulin (0), AICAR (•) and 
AICAR + insulin (•) treatments on mean arterial pressure (MAP). AICAR infusion 
was commenced at t = 60minutes. Details are given in Figure 35. Values are given 
as means ± SE (n = 6 -12 per group). 
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Figure 41: Time course for the effect of saline (0), insulin (0), AICAR (•) and 
AICAR + insulin (•) treated animals on change femoral blood flow (AFBF, A) and 
change in femoral vascular resistance (AFVR, B). AICAR was commenced at t = 60 
minutes. Details are given in Figure 35. Values are given as means ± SE. * Insulin 
treated significantly different (P < 0.05) from saline treated and AICAR alone 
treated animals. # Insulin + AICAR treated significantly different (P < 0.05) from 
saline treated and AICAR alone treated animals (n = 6 -12 per group). 
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Figure 42 shows the time course for the change in heart rate during saline, 
insulin, saline + AICAR and insulin + AICAR treatments. The HR in the insulin 
group was not significantly different to the saline control group. The HR in the 
AICAR alone and the AICAR + insulin group was significantly (P < 0.05) less after 
the first 15 minutes of AICAR infusion compared with the corresponding control 
group and this decrease continued until the conclusion of the experiment. 
A Heart Rate 
Figure 42: Effect of saline (0), insulin (0), AICAR (D) and AICAR + insulin (•) 
treatment on the time course for change in heart rate (A HR). AICAR infusion 
commenced at 60 minutes. Details are given in Figure 35. Values are given as means 
± SE. * AICAR treated significantly different (P<0.05) from corresponding 
untreated animals. # AICAR + insulin treated significantly different (P<0.05) from 
corresponding untreated animals (n = 6 -12 per group). 
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6.3.6 Microvascular Perfusion 
Figure 43 shows the effect of insulin and insulin + AICAR on microvascular 
volume (MV) and microvascular flow rate (MFR) taken at the commencement (t = 0 
minutes) and prior to the commencement of contraction stimulation (t = 120 
minutes). The effect of contraction for each group is shown at t = 145 minutes. 
Figure 43A shows that insulin significantly increased the MV compared with basal 
which was further significantly increased by contraction. Figure 43B shows that 
insulin + AICAR treatment significantly increased MV compared to basal and this 
was not further significantly increased with contraction treatment. Figure 43C shows 
that insulin infusion had no effect on the MFR compared to basal however MFR 
significantly increased after contraction. Figure 43D shows that insulin + AICAR 
treatment significantly increased MFR compared to basal which was further 
significantly increased with contraction stimulation. 
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Figure 43: Measurements of the microvascular volume (MV) (A -value) for insulin 
(A) and insulin + AICAR (B) groups and microvascular flow rate (MFR) 
(A x # -value) for insulin (C) and insulin + AICAR (D) groups. Values are means ± 
SE (n = 6 in each group). * Significantly different (P <0.05) from basal values; 
# contraction treated significantly different from untreated. 
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Figure 44 shows the changes in microvascular volume (A-value) for saline, 
insulin, saline + AICAR and insulin + AICAR treatments. The MV measurement 
was taken prior to the commencement of contraction stimulation (t = 120 minutes) 
for the four experimental groups and compared with basal values (AMV). The AMV 
in the insulin and the AICAR alone group was significantly increased compared to 
the saline control. The AMV in the AICAR + insulin group was significantly 
increased compared to the insulin alone group, indicating that the effect of AICAR 
alone and insulin alone to increase microvascular perfusion is additive. 
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Figure 44: Changes in the microvascular volume (A-value) for saline, AICAR, 
insulin and insulin + AICAR groups. Saline or AICAR treatment (open bars) and 
insulin treatment (filled bars). Details are given in Figure 35. Values were 
determined at the end of the experiment (t = 130 minutes).Values are means ± SE (n 
= 6). # Insulin treated significantly different (p < 0.05) from untreated. * AICAR 
treated significantly different (p <0.05) from untreated. 
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6.3.7 Additional Experiments: Glycogen Depleted 
A sub-set of insulin + AICAR experiments were performed using protocol a, 
and A-V sampling was omitted. The in vivo experiments were carried out using rats 
which were fasted for 40 hours in order to deplete liver glycogen content (food 
removed at 5pm 40 hours prior to the commencement of the experiment). 
6.3.7.1 	Glucose Metabolism 
Figure 45 shows the effects of insulin and AICAR + insulin on glucose 
infusion rate (GIR) and hindleg 2-deoxyglucose uptake (R'g) of the combined 
muscles of the lower leg for 16 hour and 40 hour fasted groups. During the insulin 
infusions blood glucose was maintained at the initial value (euglycaemia) by a 
variable infusion of glucose (30% w/v solution). There were no significant 
differences between blood glucose values for the three treatment groups at the end of 
the experiment (data not shown). 
The GIR at the end of the experiment (t = 120 minutes) is shown in Figure 
45A. The GIR in the 16 hour fasted insulin + AICAR group was significantly lower 
(30% less) compared with the insulin alone group (time course values shown in 
Figure 36B). The GIR in the 40 hour fasted insulin + AICAR group was 
significantly higher compared with the 16 hour fasted insulin and insulin + AICAR 
groups. Figure 45B shows that there was no significant difference between the R'g 
of the 40 hour fasted insulin + AICAR group compared with the equivalent 16 hour 
fasted group. 
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Figure 45: Effect of insulin (0) and insulin + AICAR (M) [16 hour fasted animals] 
and insulin + AICAR (!4) [40 hour fasted animals] treatment on glucose infusion 
rate (GIR, A) and hindleg 2-deoxyglucose uptake (R'g, B). Details are given in 
Figure 35. Values were determined at the end of the experiment (t = 120) and are 
means ± SE. * AICAR treated significantly different (P <0.05) from corresponding 
untreated animals; # 40 hour fast treated significantly different (P < 0.05) from 
corresponding 16 hour fasted group (n = 12 per group [16 hour fast], n = 6 per group 
[40 hour fast]). 
167 
CHAPTER 6— Effects of AICAR on the Actions of Insulin In Vivo. 
6.4 DISCUSSION 
This study was undertaken to investigate the effects of the AMPK activator 
AICAR on insulin-mediated microvascular perfusion and skeletal muscle glucose 
uptake. The main finding of this study was that acute administration of AICAR in 
vivo, at a dose which does not stimulate glucose uptake by itself, improves insulin 
mediated glucose uptake. A second major finding of this study was that AICAR 
increased microvascular perfusion (microvascular blood volume) in vivo and this 
was further increased with the addition of insulin. This study also demonstrated that 
AICAR induced increases in insulin mediated muscle glucose uptake were greater in 
the white fiber type muscles. 
The effects of insulin to increase total blood flow and microvascular perfusion 
[49] have been established by others and were also observed in the present study. As 
discussed in the previous chapter, at the dose used, AICAR was found to increase 
microvascular perfusion and microvascular flow without a corresponding increase in 
total flow or glucose uptake. Plasma concentrations of AICAR reached 
approximately 0.24mM and although these treatments alone were without effect on 
muscle glucose uptake they were found to markedly potentiate physiological insulin 
mediated glucose uptake. Bergeron et al. [313], demonstrated that the effects of 
AICAR on glucose transport activity are additive with insulin. The results from the 
present study differ from Bergeron as a lower dose of AICAR was used which was 
below the threshold to stimulate glucose uptake however insulin mediated glucose 
uptake was markedly increased. It likely that increased insulin mediated glucose 
uptake in the presence of low dose AICAR is due to increased availability of glucose 
and insulin to muscle through enhancement of nutritive blood flow. It has been 
shown that there is a strong correlation between nutritive blood flow and glucose 
uptake in the presence of insulin [2]. 
In this study AICAR enhanced insulin-mediated increases in skeletal muscle 
glucose uptake which were found to be dependant upon the fiber type composition 
of the muscles. Type I (red) muscles showed a decrease in insulin mediated glucose 
uptake while the type IIA and JIB (white) muscles showed a marked increase in 
insulin-mediated glucose uptake. The fiber type specific effects of AICAR have also 
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been reported by other workers at higher doses than used in the current study. 
Bergeron et al. [313] reported AICAR (0.58 mM, in vivo) to directly stimulate 2-DG 
uptake, in the absence of insulin, in the lateral and medial gastrocnemius and the 
soleus muscle. Iglesias et al. [318], reported that subcutaneous injection of 250 
AICAR to insulin resistant high fat fed rats one day before conducting a 
hyperinsulinemic euglycaemic clamp markedly improved insulin-stimulated glucose 
uptake (2-DG) in white but not red quadriceps muscles. In this study enhancement 
of insulin mediated glucose uptake occurred after the expected time of AMPK 
activation had passed. Follow up studies by Iglesias et al. [318] also revealed that 
significant enhancement of insulin stimulated glucose uptake in white muscle also 
occurred in normal rats. Ai et al. also reported that 0.5 - 4 mM AICAR stimulated 2- 
DG uptake occurred in incubated epitrochlearis, less in flexor digitorum brevis 
(FDB) and not at all in soleus muscle [323]. Of these muscles, the epitrochlearis is 
richest in type JIB, the soleus in type I and the FDB in type IIA fibers [323]. Ai et al. 
also reported AMPKal expression to be highest in the epitrochlearis and lowest in 
the soleus; FDB muscles had the lowest expression of AMPKa2 [323]. In contrast, 
Putman etal. [439] also demonstrated that the al and a2 isoforms of AMPK are 
consistently expressed in a fiber type specific manner. They showed that both the al 
and a2 protein levels were greatest in the slow-twitch oxidative soleus, slightly less 
with in the mixed fast-twitch red gastrocnemius and lowest within the fast-twitch 
white gastrocnemius. 
The in vivo findings of this study provide evidence that AICAR increases 
insulin-mediated hindleg glucose uptake and 2-deoxy-glucose uptake. Despite this 
finding there was no increase in whole body glucose infusion rate (GIR). The GIR 
during the insulin + AICAR infusion was significantly reduced, such that by the end 
of the experiment the rate was approximately 30% less than during infusion of 
insulin alone. This implies that AICAR inhibits the ability of insulin to suppress 
hepatic glucose output (HGO). A number of studies have provided in vivo evidence 
in support of AICAR having the ability to inhibit insulin induced suppression of 
HGO. A study by Peneck et al. [440], using conscious dogs, showed that intra-portal 
AICAR infusion of 1 mg.min-l .ke abolished net hepatic glucose uptake (NHGU) 
and infusion of 2 mg.min-I .14 1 stimulated net hepatic glucose out-put (NHGO). In 
another in vivo study by Camacho etal. [441], 1 mg.mirc 1 .kg-1 AICAR was infused 
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into dogs for 90 minutes during a 2 mU.miri l .kg1 hyperinsulinemic insulin clamp. 
AICAR caused a stimulation of both hepatic glucose output and hepatic 
glycogenolysis even in the presence of physiological insulin. Another similar study 
by Camacho et al. [442] revealed that AICAR is effective in countering the 
suppressive effect of pharmacological insulin on NHGO which occurred even 
though AICAR-stimulated ACC phosphorylation was completely blocked. These 
findings indicate that, when activated, AMPK increases the availability of blood 
glucose to skeletal muscle by countering insulin induced inhibition of hepatic 
glucose production. Thus AICAR induced HGO provides a reasonable explanation 
for the observed decrease in GIR during AICAR + insulin treatment in this study in 
the presence of a net increase in skeletal muscle glucose uptake. 
An additional set of experiments were performed with animals fasted for 40 
hours. It was assumed that liver glycogen content would be markedly depleted in 40 
hour fasted animals compared with the over night fasted animals. A significantly 
increased GIR was required to maintain euglycemia in the 40 hour fasted AICAR + 
insulin treatment compared with the corresponding overnight fasted treatment while 
R'g was unchanged. This finding supports the idea that in over night fasted animals 
AICAR inhibited insulin's suppression of HGO. Similarly, Camacho et al. [441], 
noted that the stimulation of NHGO during AICAR treatment was lost in animals 
subject to a 42 hour fast where liver glycogen was markedly reduced (unpublished 
observation). The use of radio-labelled tracers in the current study for an accurate 
determination of the rates of hepatic glucose appearance and disappearance from the 
liver in the presence of AICAR would clarify this issue. 
An additional finding of this study was that AICAR treatment increased 
lactate production in resting muscle. This finding is in agreement with other reports 
which have also observed an increase in lactate concentration with AICAR treatment 
in vitro [269, 314] and in vivo [313, 336, 441, 443]. Merrill etal., using the perfused 
rat hindlimb, demonstrated that AICAR treatment (2mM) increased lactate 
production by approximately 2 fold over 45 minutes compared with the control 
group [269]. Bergeron etal. [313], using conscious rats, also reported a marked 
increase in plasma lactate to about 13 mM at 90 minutes when the plasma levels of 
AICAR had reached 2.5 mM. Chamacho etal. [441] also reported that AICAR 
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significantly increased net hepatic lactate output in the presence of hypoglycemia. 
The increased blood lactate concentration in AICAR treated animals was also noted 
by W. Winder in a review article [444] who suggested that increased intra-muscular 
glucose concentration in response to AICAR is not all oxidised in resting muscle and 
may be shunted towards lactate production. A number of studies have also 
demonstrated that AMPK phosphorylates phosphofmctokinase and thereby 
stimulates glycolysis [445-447] and this action is likely to account for the observed 
increase in net hepatic lactate production. 
The genetically obese Zucker rat (OZR) displays impaired insulin mediated 
glucose transport in skeletal muscle [448] and insulin mediated microvascular 
perfusion is absent [338]. In contrast, contraction-mediated glucose uptake by 
muscles of the obese Zucker rat appears to be essentially normal as does the increase 
in microvascular perfusion in response to exercise [338]. This suggests that, in the 
OZR, the defects particular to insulin signalling may explain the insulin resistance. It 
has been demonstrated by Bergeron et al. [317] that acute infusion of AICAR in the 
OZR increases glucose transport during a physiological insulin clamp. The 
mechanism for enhanced insulin sensitivity in the Bergeron study may be partly due 
to increased microvascular perfusion allowing greater access of insulin and glucose 
to the myocyte. It is yet to be determined whether AICAR enhances insulin 
mediated microvascular perfusion and thus glucose uptake in models of insulin 
resistance, such as the OZR and this area needs further investigation. 
In conclusion low dose AICAR stimulates microvascular perfusion in 
skeletal muscle in vivo at a dose which does not stimulate glucose uptake by itself 
and enhances insulin stimulated glucose uptake and microvascular perfusion. The 
increase in microvascular perfusion caused by AICAR is likely to enhance hormone 
and nutrient delivery to the muscle myocytes which in turn increases glucose uptake 
in skeletal muscle when insulin is present. The AICAR enhanced insulin-stimulated 
glucose uptake occurred predominantly in the white fiber type muscles. AICAR 
inhibited insulin's ability to increase whole body glucose uptake which is likely to 
be due to inhibition of insulin's suppression of hepatic glucose output. The 
stimulation of lactate accumulation and the suppression of heart rate detract from the 
use of AICAR for the treatment of insulin resistance. 
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7.1 Major Findings 
The work presented in this thesis explores the links between insulin and 
AMPK activated microvascular perfusion and glucose uptake in muscle in vivo. The 
mechanisms relating to insulin were examined by infusing the PI3K inhibitor 
wortmannin systemically and the NOS inhibitor L-NAME locally during a 
hyperinsulinemic euglycaemic clamp in anesthetised rats. The mechanisms relating 
to AMPK activation were examined using muscle resistance arteries in vitro and 
with AICAR infusion alone or combined with a euglycaemic hyperinsulinemic 
clamp in vivo. 
The experiments resulted in new previously unpublished findings that; (i) 
inhibiting the insulin signalling step at PI3K, using the PI3K inhibitor wortmannin, 
blocked insulin-mediated glucose uptake and microvascular perfusion, (ii) local 
infusion of L-NAME blocked insulin-mediated microvascular perfusion and blunted 
glucose uptake in the treated leg, (iii) in isolated resistance arteries, AICAR induced 
vasodilation, which was abolished by NOS or AMPK inhibition and sensitised 
resistance arteries to sodium nitroprusside (SNP), (iv) in vivo, infusion of low dose 
AICAR increased microvascular perfusion in the absence of increased glucose 
uptake. When combined with insulin, low dose AICAR enhanced insulin-mediated 
glucose uptake, possibly by allowing greater access of insulin and glucose via 
increased microvascular perfusion. 
Collectively these findings suggest that insulin activation of NOS via PI3K 
and AMPK activation can enhance glucose uptake through increased microvascular 
perfusion. These results further strengthen the previous reports regarding the 
important contribution of microvascular blood flow to glucose uptake. 
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7.2 Insulin Mediated Microvascular Perfusion and its 
Effects on Glucose Uptake 
Previous studies in our laboratory have provided considerable evidence for 
the existence of two vascular routes in skeletal muscle which have been termed 
nutritive and non-nutritive vascular flow routes (reviewed in [2]). Experiments using 
the vasodilator ephinepherine demonstrated that total blood flow can be increased 
without affecting microvascular perfusion or glucose uptake [49]. The exact 
anatomical arrangement of the nutritive and non-nutritive vascular routes is 
unknown; however it is thought that the nutritive route consists of long tortuous 
capillaries which allow extensive microvascular perfusion of the muscle. The non-
nutritive route is thought to be made up of shorter slightly larger and wider vessels 
[449]. The 1-MX and more recently CEU techniques were developed for specifically 
measuring skeletal muscle microvascular perfusion in vivo. Using these techniques it 
was possible to clearly demonstrate the ability of insulin to increase microvascular 
perfusion [49, 57, 58] either with or without a corresponding increase in total blood 
flow. Insulin may act via the insulin receptors on the endothelium at key flow 
controlling points in the muscle microvasculature relaxing the arterioles supplying 
the nutritive flow route. This action of insulin thus facilitates the delivery of glucose 
and itself to the muscle and contributes to the action of insulin to increase glucose 
uptake [5]. 
In individuals who have a normal response to insulin, a significant and 
positive correlation can be observed between microvascular perfusion and glucose 
uptake in skeletal muscle. This relationship can be observed using a number of 
interventions in rats demonstrating that impairment of microvascular perfusion can 
cause impairment in muscle glucose uptake. For example; a-methyl serotonin, TNF-
a or intralipid + heparin infusions acutely block the ability of insulin to induce 
microvascular perfusion and impair insulin-mediated glucose disposal. The same 
correlation was observed in chapter 4 of this thesis with local L-NAME infusion. 
Also, AICAR caused an increase in microvascular perfusion, which when combined 
with insulin, potentiated insulin-mediated microvascular perfusion and glucose 
uptake (see chapter 6). 
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Evidence for a role for the endothelium involvement in the vasoactive action 
of insulin is supported by results from the eNOS knockout mouse which are 
hypertensive and display a 40% reduction in muscle blood flow and glucose uptake 
compared with wild type (WT) mice [403]. Similarly Shankar et al. [402] 
demonstrated, using euglycaemic hyperinsulinemic clamps in eN0S -/- mice, that 
glucose infusion and glucose turnover rates were decreased. In addition the 
endothelial-specific IRS-2 knockout mouse displayed insulin resistance and 
impaired glucose tolerance compared with the wild type mouse as assessed by the 
hyperinsulinemic-euglycaemic clamp [450]. Together these studies strongly support 
an important role for a vascular component in maintaining normal responses to 
glucose disposal. 
In contrast, some studies using gene knockout and transgenic mouse models 
present evidence against a role for the endothelium in microvascular perfusion for 
regulation of glucose disposal. The vascular endothelial cell insulin receptor knock-
out (VENIRKO) mouse displays no major abnormality in vascular development or 
glucose homeostasis [451]. However, VENIRKO mice placed on a low salt diet 
display altered eNOS expression and insulin resistance, suggesting that eNOS is 
required to maintain insulin sensitivity. 
The transgenic mouse with an endothelium specific mutant insulin receptor 
over expression (ESMIRO) retains intact insulin receptor binding but signal 
transduction is absent [452]. This transgenic model displays normal glucose 
homeostasis despite significant endothelial dysfunction evidenced by blunted aortic 
vasorelaxation responses to acetylcholine and calcium ionophore. Glucose and 
insulin tolerance testing demonstrated that there was no attenuation of insulin 
sensitivity in the ESMIRO mouse compared with the WT mouse. This result is 
despite a loss of insulin stimulated vascular function and blunted insulin induced 
eNOS phosphorylation. 
Evidence from the ESMIRO and VENIRKO mice seem to indicate that 
endothelial dependant vascular actions of insuln lack importance however an 
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assessment of insulin-mediated microvascular perfusion has not been made in these 
models. Results from the VENIRKO and ESMIRO studies should be interpreted 
with caution as compensatory changes may occur in knockout or transgenic models. 
One possible explanation may be that the loss of endothelial insulin receptors may 
be compensated by signalling via the IGF-1 pathway. There are substantially more 
IGF-1 receptors on endothelial cells than insuln receptors and insulin is able to bind 
and activate IGF-1 receptors [453]. IGF-1 signalling shares the same downstram 
pathway so when this pathway is impaired such as in the eNOS knockout or IRS-2 
knockout, the vascular contribution to insulin resistance becomes evident. 
The hyperinsulemic euglycaemic clamp would also provide a more accurate 
measure of insulin sensitivity compared with tolerance tests performed in the 
ESMIRO mouse studies [452]. A significant and positive correlation exists between 
microvascular perfusion and glucose uptake so that in normal individuals 
microvascular perfusion can account for up to 50% of glucose uptake [2]. If insulin 
interacts with insulin receptors on the endothelium to enhance perfusion and 
therefore glucose uptake then it would be expected that the VENIRKO and ESMIRO 
mouse models would display some degree of insulin resistance. The development of 
the VENIRKO and ESMIRO has opened up some new and interesting areas for 
research. A detailed examination of insulin-mediated microvascular perfusion and 
glucose metabolism in these models has not been assessed and needs to be 
determined to resolve this issue. 
Alternatively, it is possible that insulin can act directly on the VSMC leading 
to vasodilation in an endothelium independent mechanism. Studies using VSMC 
have demonstrated that insulin can directly activate a constitutive Ca2+ dependant 
NOS (cNOS) and increase cGMP and cAMP levels thereby causing vasorelaxation 
[72, 73]. This finding suggests that insulin-induced vasodilation is not entirely 
endothelium-mediated but does not exclude an insulin-induced endothelium 
mediated process in vivo. 
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7.3 Involvement of NO in Insulin Action 
There is substantial evidence suggesting that NO is involved in the action of 
insulin to increase limb blood flow [41, 89, 397, 399, 454]. Within muscle, NO is 
produced by NOS located in the vascular endothelium [400] and myocytes [401]. It 
has been demonstrated that endothelial and vascular smooth muscle cells have 
insulin receptors and that insulin stimulates phosphorylation and activation of Akt, 
which can in turn phosphorylate and activate eNOS [37, 38, 455]. 
Previous studies provided evidence that insulin interacts with the vasculature 
when it was demonstrated that inhibition of NO production can fully abolish the 
effect of insulin to increase total flow [5, 41, 89, 399] and glucose uptake [399]. 
Insulin induced vasodilation in the rat cremaster muscle has been abolished with the 
addition of a NOS inhibitor or endothelium removal [397]. It has also been reported 
by Vincent et al. that systemic NO inhibition abolishes insulin-stimulated 
microvascular perfusion and inhibits glucose uptake by approximately 50% [88]. 
The results presented in chapter 4 are in agreement with these findings. 
7.4 Microvascular Perfusion: Dependant on PI3K 
Results from chapter 3 demonstrated that the PI3K inhibitor wortmannin 
abolished insulin mediated increases in total flow and microvascular perfusion. The 
main finding of this chapter indicates that the PI3K pathway is involved in 
downstream signalling resulting in modulation of vascular function in vivo. This 
finding is in agreement with previous studies (section 7.3) that insulin mediated 
increases in blood flow are nitric oxide dependant [41, 89] and that insulin mediated 
NO production involves Akt mediated activation of eNOS [84]. 
Wortmannin treatment completely abolished microvascular perfusion and 
attenuated insulin-mediated glucose uptake by approximately 50%. Inhibition of 
PI3K by wortmannin would be expected to completely block muscle glucose uptake. 
Although wortmannin administration caused unexpected increases in plasma insulin, 
177 
CHAPTER 7 — Discussion. 
Akt phosphorylation in the liver and aorta was completely blocked whereas there 
was no significant inhibition in skeletal muscle. It is likely that wortmannin did not 
reach the myocyte due to it's insolubility and thus passage across the microvascular 
endothelial barrier may have been restricted. The 50% inhibition of insulin mediated 
glucose uptake may be the result of reduced delivery of insulin and glucose because 
of the total inhibition of microvascular perfusion. 
7.5 Local NOS Inhibition: Blocks Insulin Action 
Impairment of vascular endothelial function is a feature of type 2 diabetes 
[456] and this feature may contribute to reduced substrate delivery for insulin-
stimulated glucose uptake. Results from chapter 4 indicate that local NOS inhibition 
blocks insulin mediated increases in total blood flow and microvascular perfusion 
and well as partially inhibiting skeletal muscle glucose uptake. This finding suggests 
that NOS activation in the vasculature plays an important role in insulin action. 
It has been shown that ICV administration of NOS inhibitors during systemic 
insulin infusion caused a reduction in insulin mediated glucose disposal [90, 91] and 
microvascular perfusion [91]. Due to these reported effects, a key question is 
whether the effects of systemically administered NOS inhibitors to block insulin-
mediated increases in microvascular perfusion [88] are due to the NOS inhibitor 
accessing central sites. In the present study L-NAME was administered locally thus 
eliminating systemic and central effects. 
7.6 AMPK Activation Stimulates Microvascular 
Perfusion by Association with NO 
Studies which involved AICAR activation of AMPK were made for two 
main reasons. AMPK is known to increase NO and is involved in exercise effects. 
The hypothesis to be tested is whether AMPK activation to increase NO effects 
microcirculation and enhances the action of insulin. 
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Previously AMPK has been shown to regulate endothelial function. In 
conduit arteries AMPK enhances endothelium-dependant vasodilation [235] and 
increases eNOS phosphorylation at Ser 1177 [308]. In addition to previous studies, the 
findings in chapter 5 demonstrate an important role for the vascular smooth muscle 
sensitisation to NO. AMPK activation by AICAR directly caused vasodilation of 
skeletal muscle resistance arteries by enhancing NO activity and enhanced 
microvascular perfusion in skeletal muscle in vivo. These findings indicate a link 
between AMPK activation and vascular NO activity. These findings also highlight 
an important link between vascular function and metabolism as greater 
microvascular perfusion, to increase capillary surface area, potentially enhances 
hormone and nutrient delivery to skeletal muscle. 
In summary, AICAR administration in vivo, at a dose that did not stimulate 
glucose uptake by itself, significantly enhanced insulin-stimulated glucose uptake. 
Low dose AICAR infusion increased microvascular perfusion and further increased 
insulin-mediated microvascular perfusion. It is likely that increased microvascular 
perfusion is responsible for the observed potentiation of insulin mediated glucose 
uptake through increased access of insulin and glucose to myocytes. The ability 
AICAR to potenitate insulin mediated glucose uptake was greater in white rather 
that red fiber type skeletal muscle. The present study suggests that AMPK activators 
such as AICAR may have potential for the treatment of insulin resistance and type 2 
diabetes. However the effect of AICAR to stimulate lactate accumulation and the 
effects on heart rate pose challenges to be overcome before AMPK activates such as 
AICAR are used as therapeutic agents. 
7.7 Other Future Directions 
The results outlined in the present thesis confirm microvascular involvement 
in skeletal muscle glucose metabolism. The stimulation of NO production leading to 
increases in microvascular perfusion is common to both insulin and AMPK 
mediated pathways for increased glucose uptake. Previously it has been 
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demonstrated that insulin-mediated glucose uptake and microvascular perfusions is 
impaired in insulin resistance, obesity, hypertension and diabetes. Exercise enhances 
insulin action and part of this mechanism involves AMPK activation. A major 
finding of this study is that phosphorylation and activation of AMPK enhances 
microvascular perfusion. A key question which needs to be addressed is can 
increasing microvascular perfusion reverse impairments in insulin resistance? 
The effect of AMPK activation by acute AICAR administration in models of 
insulin resistance have been investigated using lean and oblob mice [457] and in 
dbldb diabetic mice [458] which resulted in increased glucose disposal. It has also 
been demonstrated that a single dose of AICAR leads to an improvement in whole 
body, muscle and liver insulin action in high rat fed rats [318]. In the latter study, it 
is possible that part of the action of AICAR to improve the insulin response was 
through increased microvascular perfusion which would be otherwise unresponsive 
to insulin. The effects of AICAR and insulin on microvascular perfusion and glucose 
uptake in an insulin resistant model such as the high fat red rat or the obese Zucker 
rat should be further investigated. Also the effect of chronic AICAR treatment in 
relation to improved microvascular perfusion and insulin stimulated glucose uptake 
could be examined. 
A recent study demonstrated that NOS inhibition attenuated increases in 
skeletal muscle glucose uptake during contraction without affecting microvascular 
perfusion, suggesting that NO is critical for part of the normal increase in skeletal 
muscle glucose uptake during contraction [409] however AMPK is not the only 
signalling process involved during exercise. The effects of local NOS inhibition 
during AICAR infusion in vivo should be investigated which may further 
consolidate the results reported in chapter 5. 
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7.8 Conclusions 
In conclusion, the work presented in this thesis explored a number of 
possible mechanisms of insulin and AMPK activation extending previous findings of 
our laboratory. Insulin mediated increases in total flow, microvascular perfusion and 
glucose uptake were attenuated with both PI3K and NOS inhibition. These results 
highlight the importance of the haemodynamic effect of insulin for enhancing 
glucose uptake. The AMPK activator AICAR enhanced NO activity in muscle 
resistance arteries and markedly increased microvascular perfusion which could 
enhance hormone and nutrient delivery to the myocyte. AICAR treatment combined 
with insulin had an additive effect on microvascular perfusion. Insulin-mediated 
glucose uptake, which predominantly occurred in the white fiber types muscles, was 
markedly enhanced with AICAR treatment. These results identify AMPK as a 
potential target for pharmacological interventions for the treatment of impaired 
vascular function in insulin resistance. Collectively these findings demonstrate an 
important relationship between microvascular perfusion and glucose uptake. 
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